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Abstract 
Pharmaceutical excipients are usually considered as “inert” ingredients according 
to pharmaceutical regulations and standards. The solubilizing excipient 
polyethylene glycol 400 (PEG 400), however, unexpectedly alters the oral 
bioavailability of the BCS class III drug, ranitidine, in a sex-dependent manner. A 
63% increase in bioavailability was exhibited in male rats, however, no increase 
was identified in female counterparts. This finding has significant implications for 
the use of supposedly “inactive” excipients and additionally highlight distinct 
differences, simply due to the sex of the animal. The aim of this thesis was to clarify 
the mechanism underlying this sex-associated phenomenon, alongside the 
discovery of a variety of “active” excipients that potentially exhibit sex-related 
behavior. The work involved an assessment on the influence of PEG 400 on the 
bioavailability of a number of BCS class III drugs in male and female rats. The 
presence of PEG 400 only showed sex-based enhancement on the absorption of 
drugs (ranitidine and ampicillin) which are substrates for efflux transporter, P-
glycoprotein (P-gp). A step-by-step investigation then revealed that PEG 400 was 
capable of decreasing the overall P-gp activity, protein abundance and mRNA 
expression. This, however, was only observed in male rats and not in females. 
Besides PEG 400, a number of pharmaceutical excipients including Cremophor RH 
40, Poloxamer 188 and Tween 80 also demonstrated a sex-specific reduction on the 
function of P-gp to increase the bioavailability of P-gp-mediated drugs. Overall, the 
results are promising and demonstrate that excipients and sex of the organism have 
a major influence on drug bioavailability. The results of the investigation 
contributed to establish a small database of excipients, commonly selected in oral 
formulation design that researchers should acknowledge and avoid to ensure 
therapeutic efficacy and to limit side effects between males and females. 
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1.1 Overview 
Our cells are innately infused with differences that cannot be ignored. The phrase 
“every cell has a sex’’ captures the essence of how fundamentally different men and 
women are when it comes to health and disease. However, our sex differences have 
vastly been ignored when it comes to health research. Female subjects have 
historically been excluded from toxicology or biomedical research for several 
reasons, especially given the complexity of their menstrual cycles and risks of 
teratogenicity. Ignoring female participants from clinical trials have somehow 
backfired and results to the deaths of at least one in five women, directly related to 
drug use (Vadam, 2014). The U.S. General Accounting Office (GAO) also reviewed 
that eight of the ten drugs withdrawn from the market were due to greater risks of 
adverse effects in women (GAO, 2001). 
Progress has finally been made since then when the U.S Food and Drug 
Administration (FDA) outlined that both sexes should be represented in all phases 
in clinical trials to avoid undetected sex differences in drug efficacy and side effects 
(Kando., 1995, Beierle et al., 1999, Soldin et al., 2011). However, there is still a 
long way to go. In a 2014 study, researchers reported that only 39% of the 
participants involved in the medical studies were women. More recently, formerly 
regarded ‘inert’ excipients reportedly have a sex-related influence on the 
bioavailability of BCS Class III drugs, a number of which have been proposed to 
be eligible for biowaivers (waivers from in vivo bioequivalence testing) by The 
World Health Organization (WHO).  
Based on the aforementioned data, sex equality has been warranted in clinical as 
well as pre-clinical research. Better understanding of the reasons behind the sex 
difference in drug response can provide beneficial information in drug design and 
formulation strategy. This can also can be considered in the context of personalized 
medicine.  
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1.2 Sex Differences in Physiology  
John Gray’s best seller “Men Are from Mars, Women Are from Venus” stated that 
most common relationship problems between men and women are the result of 
fundamental psychological differences between the sexes. It is true there are 
significant physiological differences between men and women, such as body weight, 
percentage of body fat, body water volume, plasma volume and organ blood flow. 
These can be implicated in a differing response to medication (Beierle et al., 1999). 
1.2.1 Body Composition  
The differences between the men and women in body composition are well known 
(showed in Table 1.1): males typically have proportionately more muscle mass, a 
higher bone mass and a lower percentage of body fat than women (Brown, 2008).  
Body mass is a visible example of a distinction between the sexes. Physical size 
plays a vital role, but differences go beyond size. Namely, a woman is not a small 
man. Endocrinological events, such as the onset of puberty in boys and girls, occur 
at various ages, resulting to variations in body fat, height and growth. Each factor 
can influence the usage of drugs. For example, the differences in percentage of fat 
and water between men and women mainly cause the sex-related differences in drug 
distribution, especially for the highly water-soluble or lipid-soluble medicine. On 
the other hand, various factors come together to create the anatomic, physiologic, 
biochemical and endocrine differences between men and women that can influence 
drug disposition and response. 
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Table 1.1 Select physiological parameters and their values for men and women. 
Parameter Adult Male Adult Female 
Mass (kg) 73 60 
Height (cm) 176 163 
Body Surface Area (m2) 1.90 1.66 
Fat (kg) 14.6 18.0 
Ventilation Rate 
(m3/day) 
22.9 18.5 
Cardiac Output (L/min) 6.5 5.9 
Tissue Mass (g, varies with age) 
Liver 1,800 1,400 
Lung 500 420 
Kidneys 310 275 
Fat (storage fat) 14,600 18,000 
Blood Flow Rate (% Cardiac Output) 
Liver 25.5 27 
Kidneys 19 17 
Fat 5.0 8.5 
Skeletal muscle 17 12 
(Extracted from ICRP, 2002. Basic Anatomical and Physiological Data for Use in 
Radiological Protection Reference Values. ICRP Publication 89. Ann ICRP. 32:3-
4), (Brown, 2008). 
1.2.2 Cardiac Output 
Cardiac output, also known as regional blood flow, is similar for both sexes between 
18 and 44 years of age. The distribution of regional blood flow, is similar for men 
and women for some organs, such as adrenal, bone, brain, lung and skin, but 
different for others. For example, the percent of cardiac output in liver was 25% in 
men but 27% in females, reflecting sex-based differences in body composition 
(ILSI, 1994). 
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1.2.3 Sex-specific Condition: Sex Hormones 
There have been numerous evidences that support the argument that female sex 
hormones influence drug-metabolizing pathways, increase drug accumulation 
and/or decrease elimination of some drugs. For instance, estrogen can bind the 
membrane ion channels and receptors alongside modulate CYP1B1 expression 
(Nicolson et al., 2010, Tsuchiya et al., 2004). It is further exhibited that female 
steroid hormones and prolactin can result in a two- to ten-fold increase of 
inflammatory diseases in women than men (Ostrom, 2006).  
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1.3 Sex Variations in Drug Pharmacokinetics 
All the sex variations mentioned above in physiological parameters could result to 
sex-related differences in drug response or pharmacokinetics. The basic stages of 
pharmacokinetics, namely absorption, distribution, metabolism and elimination 
(ADME), were described in Figure 1.1. 
During the period from 1977 to 1995, 26 studies were submitted to U.S. FDA 
because of the sex-dependent differences in bioequivalence (Chen et al., 2000, 
Coker, 2008, Nicolas et al., 2009). The number of studies and available sample sizes 
in these studies were limited, however, the understanding of sex differences in 
medicinal drug toxicology and pharmacology was expanding (shown in Table 1.2). 
FDA regulations and guidance were then placed to ensure that both sexes are 
represented in all phases of clinical trials, and that medical products are labelled to 
alert physicians and patients to any differences in the way in which men and women 
respond to a drug.  
Figure 1.1 The process of absorption, distribution, metabolism and elimination 
(ADME), (Undevia et al., 2005).
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Table 1.2 Sex-specific differences in the pharmacokinetics of drugs. 
Drug Sex Differences Reasons Reference 
nimodipine higher AUC0-480 and Cmax in female rats lower oral clearance in female rats (Liu et al., 2005) 
glucose 
lower absorption during the first hour and higher absorption  
in the last hour of a three-hour OGTT in female  
different body sizes and plasma glucose 
levels, and β-cell fuction from OGTTs 
should be taken into account 
(Anderwald et al., 2011) 
early glucose absorption was lower in females with i-IGT (Faerch et al., 2013) 
metronidazole higher distribution in males compared with females 
water-soluble drugs; lower total body 
clearance(TBC) and volume of distribution 
in girls as higher content of water in men 
(Carcas et al., 2001) 
flouroquinolones 
significantly higher AUC0-480 in girls(44.8±39.8) than in 
boys(16.9±5.00) 
(Zulfiqar et al., 2008) 
pantoprazole 
higher AUC in women(8015.4±1056.8) than men(5787.6
±401.2) (Miriam et al., 2011) 
losartan larger AUC in females than in males 
rocuronium 
longer duration in women compared with men 
lipid-soluble drugs; higher content of fat in 
women 
(Xue et al., 1997) 
vecuronium (Houghton et al., 1992) 
diazepam 
1.67% free fraction found in females while 1.46% shown in 
men volunteers; larger distribution found in females 
plasma binding was similar among men and 
women, however, concentration of sex 
hormones impacted the protein systems 
responsible for drug binding, protein 
binding contribute to sex-specific 
differences during the menstrual cycle 
(Ochs et al., 1981) 
lidocaine 
higher distribution was shown in females when compared  
with males 
(Walle et al., 1994) 
(Soldin and Mattison, 2009) 
warfarin 
testosterone 
phenytoin (Ueno, 2009) 
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Table 1.2 (Continued) 
Drug Sex Differences Reasons Reference 
metoprolol 
lower distribution, higher clearences and shorter t1/2 were 
shown in men than in women 
plasma binding was similar among men and 
women, however, concentration of sex 
hormones impacted the protein systems 
responsible for drug binding, protein 
binding contribute to sex-specific 
differences during the menstrual cycle 
(Luzier et al., 1999) 
quinine (Terrell et al., 2010) 
methylprednisolone (Silvaggio and Mattison, 1994) 
propranolol 
clearence was smaller in women, and t1/2 was decreased in 
women compared to men but does not appear to be altered 
during pregnancy 
(Nicolson et al., 2010) 
zolmitriptan 
higher bioavailability in women after both 5mg oral dosing  
and intravenous dosing 
sex differences in first-pass metabolite, as 
the plasma concentration in women was 
higher with relatively higher levels of  
active metabolite 183C91 in men 
(Seaber et al., 1998) 
diltiazem higher Cmax and longer tmax in female rats than males 
10-fold higher concentration of DAD and 
10-fold lower concentration of DMD in 
females 
(Los et al., 1996) 
schizandrin higher Cmax and AUC0-480 were found in female rats  
compared with male rats 
sex differences in the level of metabolism 
(CYP3A and CYP2C11) 
(Xu et al., 2008) 
γ-schizandrin (Zhao, 2010) 
letrozole 
AUC and t1/2 in females were 3-fold and 4-fold higher  
than in males 
letrozole metabolized more extensively in 
male rats 
(Liu et al., 2000) 
heparin 
longer duration in women compared with men lower clearance in females 
(Campbell et al., 1998) 
cefotaxime (Terrell et al., 2010) 
ciprofloxacin (Waxman and Holloway, 2009) 
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Table 1.2 (Continued) 
Drug Sex Differences Reasons Reference 
aspirin higher clearance and shorter t1/2 in women cleared more rapidly in women (Aarons et al., 1989) 
chlordiazepoxide higher AUC was found in men than in women sex differences in metabolism (Greenblatt et al., 1977) 
midazolam lower AUC in women compared with men lower level of CYP3A expression in males (Gorski et al., 1998) 
atenolol lower oral clearance and volume of distribution in women 
not clear, due to the pharmacokinetcis but 
not pharmacodynamic differences 
(Custodio et al., 2008) 
flurazepam 
higher AUC of its major blood metabolites namely N-1-
hydroxyethylfurazepam and N-1-desalkylflurazepam in 
women 
sex differences in metabolism transporters 
or proteins 
(Cooper et al., 1984) 
ranolazine 
plasma concentrations in female rats were significantly  
higher than those in male rats. Drug exposures based on  
Cmax and AUC in female rats were roughly 2-to 3-fold of 
those in male rats. t1/2 and MRT in male rats were shorter  
than those in female rats. The recoveries in urine and bile  
of female rats were also markedly higher than those in  
male rats. Tissue concentrations in female rats were also 
markedly higher than those in male rats. 
marked sex difference in ranolazine 
pharmacokinetics in rats, the main reason 
may be due to sex-related differences in 
metabolism. 
(Liu et al., 2003) 
levofloxacin 
higher Cmax was found in females while larger AUC0-480 was 
shown in males 
differences in body sizes by sexes (Almeida et al., 2005) 
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Table 1.2 (Continued) 
Drug Sex Differences Reasons Reference 
daidzein 
higher AUC0-480 was attained in women, but no differences 
between premenopausal and postmenopausal women in t1/2, 
tmax and AUC 
——— (Cassidy et al., 2006) 
genstein 
2-fold higher oral bioavailability of total genstein in females 
with 4-fold higher plasma geinstein glucuronide  
concentrations and higher biliary exretion 
not because of the sex differences in 
hormonal changes 
(Kulkarni, 2010) 
fentanyl lower urinary excretion in women than in men 
higher glomerular filtration rat(GFR) in 
males compared to female groups  
(Berg, 2006) 
taurocholate renal clearance was markedly decreased in male rats  (Schlattjan et al., 2005) 
torasemide lower clearance in females with higher AUC and Cmax (Werner et al., 2010) 
celastrol 
higher absolute bioavailability in female rats after oral 
administration  
mechanism for absorption and metabolism (Zhang et al., 2012) 
ofloxacin 
higher AUC and Cmax, and lower total body clearance(TBC) 
and volume of distribution in girls 
——— (Hassan, 2008) 
fluconazole 
higher plasma levels in women than in men 
sex differences in the level of CYP3A4, 
CYP2C9, CYP2C19 
(Carrasco-Portugal Mdel and 
Flores-Murrieta, 2007) 
clindamycin (Lujan and Dicarlo, 2008) 
acebutolol larger AUC was found in females ——— (In et al., 1990) 
ethanol 
smaller distribution was found in women while lower AUC 
was shown in men 
as the ethanol is ingested and men 
metabolize more in first pass metabolism 
(Gaudry et al., 1993) 
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1.3.1 Absorption 
The first step for a drug to reach its site of action is its absorption (for drugs not 
administered intravenously). The factors influencing absorption are drug- and 
route-specific but also sex-dependent. 
The cases that illustrate sex differences in drug absorption include aspirin and 
naratriptan. To be specific, the oral administration of aspirin to healthy adult male 
and female young volunteers resulted in quicker absorption in females than in males 
(mean absorption times of 16.4 and 21.3 min, respectively) (Aarons et al., 1989, Ho 
et al., 1985). Sex differences were also found in the oral bioavailability of 
naratriptan, with higher peak concentrations in females than in males (Mattison and 
Zajicek, 2006). There are several possible reasons behind these sex-related 
differences in drug absorption, one being the role of physiological parameters 
(shown in Table 1.3).  
Moreover, iron and alcohol are two important chemicals that exhibit significant 
differences in gastrointestinal absorption between males and females. Gastric 
alcohol dehydrogenase activity is higher in males than in females. Decreased gastric 
alcohol dehydrogenase has been shown to result in a higher percentage of absorbed 
alcohol concentrations (Parlesak et al., 2002). On the other hand, in preadolescent 
males and females, it has been shown that 45% of ingested iron is incorporated into 
erythrocytes by females compared with 35.2% in males (Arthur et al., 1984, Jacobs, 
1976). 
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In general, oral drug administration is the route of choice in the daily practice of 
pharmacotherapy, especially in outpatient settings. It is therefore important to 
consider that the ingestion of food, food interactions (e.g. grapefruit juice) (Lilja et 
al., 2005), gut motility and transit time, gut pH, biliary secretion and gut flora 
(enterohepatic circulation and the impact of oral contraceptives) can have major 
influences on drug absorption (Soldin and Mattison, 2009). 
 
Table 1.3 Sex differences in physiological parameters which influence absorption, 
(Soldin and Mattison, 2009). 
Parameter Physiologic Difference Pharmacokinetic Impact 
Gastric pH Acidity M>F>pregnant F Altered absorption of acid/bases 
depending on specific drug ionization. 
In pregnancy decreased absorption of 
weak acid. 
Gastric Fluid Flow M>F Higher absorption in males 
Intestinal Motility M>F>pregnant F Absorption increased in males 
Gastric Emptying M>F>pregnant F Absorption, gastric hydrolysis 
increased 
Dermal Hydration Increased in pregnant F Altered absorption in pregnant F 
Dermal Thickness M>F Absorption decreased in males 
Body Surface Area M>pregnant F>F Absorption increased when surface 
area larger 
Skin Blood Flow Increased in pregnant F Absorption increased 
Pulmonary Function* M>pregnant F>F Pulmonary exposure increased in 
males 
Cardiac Output* M>pregnant F>F Absorption increased in males 
M = male; F = female  
*normalized for body surface area 
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1.3.2 Distribution 
Once absorbed, most drugs bind to plasma proteins that are specific for some aspect 
or structural feature of the drug. The distribution of a drug is affected by multiple 
body composition parameters (shown in Table 1.4). Sex differences in these 
parameters may account for differences in the concentration of a drug at the target 
site and result in varying responses. 
Table 1.4 Sex differences in physiological parameters which influence distribution, 
(Soldin and Mattison, 2009). 
Parameter Physiologic Difference Pharmacokinetic Impact 
Plasma Volume Pregnant F>M>F Decreased concentration in pregnancy 
Body Mass Index (BMI) M>F Higher in men 
Average Organ Blood 
Flow 
Pregnant F>M>F Higher in pregnant women 
Total Body Water M>Pregnant F>F Decreased concentration 
Plasma Proteins M,F>pregnant F Free concentration increases in 
pregnancy 
Body Fat pregnant F>F>M Increased body burden of lipid-
soluble drug in women 
Cardiac Output M>pregnant F>F Increased rate of distribution in men 
 
On average, men have higher total body water, extracellular water, intracellular 
water, total blood volume, plasma volume and red blood cell volume than women. 
The larger proportions of body fat in women, especially in pregnant women, may 
increase the body burden of lipid-soluble, slowly metabolized toxicants. 
Differences in body fat and organ blood flow in women have been implicated in the 
faster onset of action and prolonged duration of neuromuscular blockade in women 
(e.g. vecuronium and rocuronium bromide) (Houghton et al., 1992, Xue et al., 1997). 
Differences in body fat content and in protein binding are responsible for sex-
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related pharmacokinetic differences in the distribution of diazepam, where females 
have been shown to have larger volumes of distribution than males due to higher 
free fraction (Ochs et al., 1981). 
Using a previous human study as an example, women exhibited a significantly 
lower peripheral volume of distribution (Vp/F) (3.33±0.38 L/kg for women; 5.49
±0.31 L/kg for men) after the oral administration of (S)-metoprolol and (R)-
metoprolol, respectively (Luzier et al., 1999). Furthermore, women were shown to 
have significantly higher Cmax values compared with men. A greater drug exposure 
was observed in women as evident by greater AUC in women than in men as well 
(shown in Figure 1.2).  
Figure 1.2 Fitted plasma concentration versus time profile for (R)-metoprolol (open 
symbols) and (S)-metoprolol (solid symbols) in male (circles) and female 
(diamonds) subjects (Mean±S.D, n=10), (Luzier et al., 1999). 
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1.3.3 Metabolism 
Drug metabolism (biotransformation) occurs predominantly in the liver, as well as 
in extra hepatic sites such as the intestinal tract, lung, kidney and skin. Despite large 
variations in drug metabolism in individuals, correction for height, bodyweight, 
body surface area and body composition eliminates most ‘sex-dependent’ 
differences. Sex-dependent differences in drug metabolism, however, have been 
observed mainly due to transporters and enzymes expressed on the hepatocytes. It 
was reported that drugs metabolized by phase I, phase II (conjugative) and by 
combined oxidative and conjugation processes are usually cleared faster in men 
compared to women (Schwartz, 2007, Schwartz, 2003). 
Sex-specific difference in hepatic metabolism was first observed in the case of 
antipyrine in 1971 (Omalley et al., 1971). After that, some other studies have also 
reported sex-based differences in the bioavailability of drugs due to drug 
metabolism, such as heparin (Campbell et al., 1998), chlordiazepoxide (Greenblatt 
et al., 1977), midazolam (Gorski et al., 1998), flurazepam (Cooper et al., 1984) and 
nimodipine (Liu et al., 2003). 
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Interestingly, dose-related sex differences were found in some drug metabolisms. 
Using zolmitriptan as an example (summarized in Figure 1.3), the bioavailability 
of zolmitriptan was significantly higher in women than men after both 5mg oral 
dosing and intravenous dosing. However there were no reported sex differences in 
oral bioavailability with a dose of 2.5mg (Seaber et al., 1998). This sex-related 
variation was smaller than the finding in the previous report which also 
demonstrated sex difference in the bioavailability of zolmitriptan after 10mg oral 
administration (Seaber et al., 1997). It therefore stands a dose-related manner in the 
bioavailability of zolmitriptan. The reason for this sex-dependent difference was 
assumed to be most likely explained by a difference in first-pass metabolism 
(Seaber et al., 1996), as the plasma concentrations of zolmitriptan in women were 
higher than in men with relatively higher levels of the active metabolite 183C91 in 
men.  
Figure 1.3 Mean AUC0-∞ after 2.5mg, 5mg and 10mg zolmitriptan in men and 
women (Mean±S.D., n=10), (Seaber et al., 1998, Seaber et al., 1997). * Values are 
statistically different between the male and female groups at p<0.05. 
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1.3.4 Elimination 
The kidney is the major organ of drug excretion of either the parent drug compound 
or the drug metabolites. There are known sex differences in all three major renal 
functions (namely glomerular filtration, tubular secretion and tubular reabsorption) 
resulting in generally higher renal clearance in men than in women (Gaudry et al., 
1993, Berg, 2006). 
For example, the clearance of acetaminophen was noted being slower in females 
than in males (Slattery et al., 1987). It is possibly due to the increases in renal blood 
flow and glomerular filtration increase the elimination rate of drugs cleared by the 
kidneys.  
Renal blood flow, glomerular filtration, tubular secretion and tubular reabsorption 
are all greater in men than in non-pregnant women, however, changes in renal blood 
flow, the glomerular filtration rate, hepatic blood flow, bile flow and pulmonary 
function may alter maternal elimination of a drug in women during gestation. 
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1.4 Sex-specific Influence of Excipients on Drug 
Bioavailability 
This issue regarding sex inequality in drug response becomes more complicated 
when excipients are co-formulated in the medicine.  
Celastrol, a chemical compound isolated from the root extracts of tripterygium 
wilfordii (Thunder god vine) and celastrus regelii, exhibits anti-inflammatory (Kim 
et al., 2009) and anti-cancer (Lee et al., 2001, Byun et al., 2009) ability. The 
bioavailability of celastrol was the same in male and female rats. However, the 
presence of carboxymethylcellulose sodium (CMC-Na) three-fold increased the 
celastrol bioavailability in female rats, while there was no change in male rats 
(summarized in Figure 1.4) (Zhang et al., 2012). 
 
Figure 1.4 The bioavailability of celastrol in male and female rats after 
administration with two celastrol formulations (Mean±S.D). * Values are 
statistically different between pure solution and TVG table groups. 
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In another study, the area under the curve (AUC) of the drug γ-schizandrin 
following oral administration of pure γ-schizandrin solution (dissolved in water) 
was twenty-times higher in male rats compared to females. Unexpectedly, an 
opposite trend was observed when γ-schizandrin was administered as a solid 
dispersion with polyvinylpyrrolidone K30 (PVP K30) or in a capsule prepared in-
house, where AUC in female rats was six-fold higher than in male ones from both 
γ-schizandrin formulations (shown in Figure 1.5). Although the mechanism of this 
sex-based difference has not been identified, the surprising influence on γ-
schizandrin bioavailability could have been caused by the excipients in the 
formulations, such as PVP K30 in the solid dispersion or starch in the capsule 
formulation (Xu et al., 2008, Zhao, 2010). 
 
Figure 1.5 AUC0-∞ of γ-schizandrin after administered pure γ-schizandrin solution 
and twoγ-schizandrin formulations in male and female rats. 
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In our laboratories, we have investigated the influences of polyethylene glycol 400 
(PEG 400) on oral ranitidine bioavailability in both men and women. Men and 
women had similar ranitidine bioavailability when they took the pure ranitidine 
water solution, however, orally addition of PEG 400 increased the bioavailability 
of ranitidine in men but not in women (human data was described in Figure 1.6) 
(Ashiru et al., 2008). This unexpected sex-dependent influence of PEG 400 on 
ranitidine was also revealed in the animal model using Wistar rats (Afonso-Pereira 
et al., 2016). Moreover, intravenous PEG 400 administration could not induce the 
bioavailability of ranitidine in both male and female rats. This may provide the 
reason behind the sex-related impact of PEG on ranitidine in the gastrointestinal 
(GI) tract (unpublished data).  
PEG 400 is a widely used excipient which is typically employed as a solubility 
enhancer to improve the dissolution and subsequent bioavailability of poorly-
soluble drugs. Other aforementioned excipients such as CMC-Na, PVP K30 and 
starch are also commonly co-formulated in the products widely used in the market. 
These excipients are added to formulations to aid in further processing of the 
materials into its final dosage form and to achieve an optimum absorption and 
therapeutic effect (Badawy et al., 2006). Most “inert” materials commonly used in 
the design of oral dosage forms are assumed to not influence drug absorption. It has, 
however, recently been reported that these inert excipients are able to affect drug 
bioavailability via the alteration on the physiological characteristics and membrane 
transporters in GI tract (more information shown in section 1.4.1 and 1.4.2). This 
may possibly have a sex-dependent manner (more information shown in section 
1.5), and thus, further contribute to the fact that excipients have a sex-specific effect 
on the bioavailability of the drug.
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Figure 1.6 Change in ranitidine bioavailability in the presence of different doses of polyethylene glycol 400 in male and female volunteers, 
n=6 (Ashiru et al., 2008). * Values are statistically different between the control and PEG 400 groups at p<0.05.
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1.4.1 Physiological Characteristics 
Pharmaceutical excipients can influence the absorption, distribution and clearance 
of the drugs due to their effects on a variety of physiological characteristics of GI 
tract or blood fluid rate. For example, the emulsifying agent, cholesterol, increases 
the fluidity of cancer cell membranes (Baggetto and Testa-Parussini, 1990). The 
suspending agent, carrageenan, induces inflammatory reactions in rats and mice 
(Halici et al., 2007, Farges et al., 2006), whilst the filler, mannitol, reduces small 
intestine transit time in a dose-dependent manner (Adkin et al., 1995b, Adkin et al., 
1995a). 
1.4.2 Membrane Transporters 
Transporter proteins are integral proteins that function via either facilitated 
diffusion, or active, energy-dependent mechanisms to mediate transcellular flux of 
xenobiotics and nutrients (Amidon et al., 1995). These transporters were reportedly 
modified by some active pharmaceutical excipients.  
For instance, surfactants have been found to reduce membrane viscosity and 
increase elasticity (Martin et al., 1978). This results to an enhanced absorption of 
compounds by both the paracellular and the transcellular pathways (Tomita et al., 
1988). In addition, changes in membrane fluidity can alter the microenvironment 
of the apically oriented transmembrane domains, and subsequently, alter substrate 
recognition, substrate binding and/or ATPase activity of efflux of transporters (P-
gp) or the function of influx transporters (PEPT-1) (Ferte, 2000). 
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1.5 Sex Differences in Gastrointestinal Tract  
The gastrointestinal tract is comprised of the stomach and intestines, and is divided 
into the upper and lower gastrointestinal tracts. Sex variations were reported in 
some human and animal studies in terms of its physiological characteristics and 
membrane transporters.  
5.1.1 Gastrointestinal Anatomy  
The mucosal surface area of the stomach from 222 volunteers revealed that women 
(783 cm2) have smaller stomachs than men (850 cm2) in a post-mortem study (Cox, 
1952). The anatomical features have been reviewed in Figure 1.7. 
Figure 1.7 Key sex differences at the level of gastrointestinal tract affecting oral 
drug delivery and bioavailability (M=Male, F=Female), (Freire et al., 2011).  
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1.5.2 pH of Gastrointestinal Lumen  
The fasting gastric pH was reportedly higher in women when compared with men, 
and researchers purposed it was due to the two-fold increase of basal acid output in 
men without taking meals (Feldman and Barnett, 1991). The secretion of acid was 
also substantially higher in males in the fed state (Prewett et al., 1991). Interestingly, 
there were no sex differences shown in the pH of duodenum and jejunum, although 
these studies were conducted among a small number of subjects (Lindahl et al., 
1997, Perez de la Cruz Moreno et al., 2006). The prevalence of duodenal ulcers was 
further identified to be lower in women than in men (Johnson et al., 1992).  
There were few studies on the sex-related differences in the pH of colon, and the 
majority of the studies did not exhibit any statistically significant differences 
(McDougall et al., 1993). However, faecal pH is higher in women than in men 
owing to a higher incidence of methane producing bacteria in women (49%) than 
men (33%) (Stephen et al., 1986, Pitt et al., 1980). 
1.5.3 Volume of Fluid 
Sex-associated variations could not only be found in the pH values of 
gastrointestinal lumen, but also the volumes of lumen fluid. In a study involving 8 
men and 5 women, post-mortem fluid volumes were measured in the stomach, small 
intestine and proximal colon. It stands that the fluid volume in stomach and intestine 
were higher in males than in females, whereas there no differences in the volume 
of fluid in colon were identified between the sexes (Gotch et al., 1957). Since then, 
it has been noted that postprandial changes in gastric volumes were higher in males 
than females (Bouras et al., 2002). 
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1.5.4 Composition of Fluid 
Considerable attention has been paid to the characterization of the luminal fluids in 
last decade (Kalantzi et al., 2006, Clarysse et al., 2009). However, there were 
previously limited knowledge regarding the composition of the gastric and 
intestinal fluids by sex, except in saliva. The composition of saliva has been shown 
to vary between men and women (Bales et al., 1990, Laine et al., 1991). Female sex 
hormones may be responsible for such differences as salivary composition has been 
shown to fluctuate during pregnancy (Laine et al., 1988). This phenomenon was 
also identified in women who take oral contraceptives (Laine et al., 1991).  
In addition, the differences in bile acid composition and secretion between male and 
females is well documented. The ratio of primary to secondary bile acids in the 
gallbladder is lower in young adult women when compared with men (Fisher and 
Yousef, 1973). Moreover, the composition of bile fluid also appears to change 
during the menstrual cycle and pregnancy in women (McMichael and Potter, 1980). 
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1.5.5 Gastrointestinal Motility 
A number of studies have highlighted differences in gastrointestinal motility 
(usually represented with transit time) by sexes, and these differences have been 
well reviewed in previous reports (Freire et al., 2011). Higher total gastrointestinal 
transit time has been shown in females (91.7±12.8h) than in males (44.8±4.3h), with 
clear differences seen mainly in gastric emptying time and colonic remain time 
(Stephen et al., 1986). When it comes to the variability in the small intestine transit 
times between sexes, the results are controversial. No differences have been 
reported in some studies (Isner et al., 1992), whist other reports showed longer small 
intestine transit time in females (Graff et al., 2001, Sadik et al., 2003). In contrast, 
it has been concluded that there is a markedly slower colon transit in women 
compared to the men (Jung et al., 2003). More data on values for transit in the right, 
left and sigmoidal colon have been exposed; longer transit times in right and left 
colon was found in female volunteers compared to male groups (Metcalf et al., 
1987). A lower pressure activity in women was also demonstrated when compared 
with their male counterparts. In addition, there were variations in the transverse and 
descending colon between the sexes (Rao et al., 2011). 
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1.5.6 Membrane Transporters 
Apart from physiological characteristics, membrane transporters have also been 
shown to play an essential role in drug absorption (Zhang et al., 1998). A number 
of these membrane transporters have been reported of their sex-associated manners, 
leading to sex-related differences in drug bioavailability. 
Extraction of chemicals from the intestinal lumen is achieved by passive diffusion, 
also accomplished by a variety of transporters, including OCT-1, OCT-3, OCTN-1, 
OCTN-2, PEPT-1, PEPT-2 and OATPs. Likewise, there are apical efflux 
transporters on enterocytes (BCRP, P-gp and MRPs) that prevent the entry of 
chemicals into the systemic circulation and are often responsible for the poor oral 
bioavailability of pharmaceuticals (shown in Figure 1.8). 
Figure 1.8 Diagram of major drug transporters on the intestinal epithelia, (derived 
from XenoTech). 
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There were a few studies that reported sex-related differences in the expression of 
uptake transporters in the intestine (shown in Table 1.5). One of the best studied 
influx transporters in the intestine was OATPs. Of the OATPs, only OATP2B1 has 
relatively high expression in intestine. It is generally believed that most xenobiotics 
are mainly absorbed from the intestine by simple diffusion. However, OATP2B1 is 
still a vital uptake transporter in the intestine and has demonstrated a higher 
expression in the jejunum in males compared with female rats (Cheng et al., 2005). 
On the other hand, compared to the influx transporters, the influence of sex on the 
efflux transporters in the intestine has been better investigated via both indirect and 
direct methods. Ballent et al (2011) studied the transport of P-gp substrate 
ivermectin in the presence or absence of P-gp inhibitor PSC833 across the intestinal 
sacs of male and female Wistar rats. The results demonstrated ivermectin 
accumulation in the everted gut sacs was higher in female compared with male 
intestine, hereby suggesting higher P-gp expression in the intestine of male rats than 
females (Mariana et al., 2011). This finding was in line with some previous reports 
indicated men may have a significantly higher level of P-gp in the jejunum 
compared with women (Schuetz et al., 1995a).  
For another two efflux transporters, namely MRPs and BCRP, similar protein 
expression was found between males and females in the small intestine. However, 
the pharmacokinetics of nitrofurantoin, a specific BCRP substrate, was examined 
after oral or intravenous administration in rats and mice treated with chrysin (a 
typical BCRP inhibitor), following BCRP, mRNA levels in the intestine were 
measured. The results validated lower expression of BCRP in female rats and mice 
(Atsushi et al., 2009), which supported a study conducted by Yuji et al. that outlined 
the different sex-related BCRP mRNA expressions in rat and mouse intestinal 
tissues (Yuji et al., 2005) 
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Table 1.5 Sex-based differences in typical transporters in the gastrointestinal tract. 
Location Transporters Sex Differences Content Reference 
Intestine 
PEPTs M=F 
the thyroid hormone regulation of PEPT1 and PEPT2 mRNA in 
rodents has been studied, and showed PEPTs have no 
significant difference between sexes (rodents) 
(Lu and Klaassen, 
2006) 
OATP2B1 M>F higher DNA expression in jejunum in males (mice) (Cheng et al., 2005) 
P-gp unclear 
higher absorption of Rhodamine 123 was measured in the 
intestine of females and higher P-gp expression was shown in 
females; but higher enterocyte P-gp content in men has been 
reported; while no differences between the sexes in P-gp 
expression in the upper duodenum (rats)  
(Schuetz et al., 1995a) 
(Potter et al., 2004) 
(Paine et al., 2005a) 
(Mariana et al., 2011) 
BCRP M>F lower mRNA expression of BCRP in females (rats and mice) (Atsushi et al., 2009) 
MRP M=F 
no significant differences in MRP2 between males and females 
in the quantitative real-timepolymerase chain reaction and 
Western blot studies (rats) 
(Caroline et al., 2008) 
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1.6 Rationale for the Study 
Based on the interest in the previous finding regarding sex-specific influence of 
PEG 400 on ranitidine bioavailability, the aim of this research project was to clarify 
the reason behind the unexpected sex-associated phenomenon and to identify more 
excipients that would express a sex-based effect on the overall drug bioavailability.  
In view of the aforementioned findings on the sex differences in the physiological 
characteristics in GI tract and membrane transporters, alongside the interaction 
between these factors and “inert” pharmaceutical excipients, we hypothesize the 
reason behind this sex-associated phenomenon could be related to the mechanisms 
of ranitidine absorption.  
Ranitidine is predominantly absorbed via the paracellular pathway and membrane 
transporters of which both influx and efflux transporters are involved, (Bourdet and 
Thakker, 2006). Therefore, the bioavailability-enhancing effect of PEG 400 in 
males could be due to the opening of tight junctions by PEG 400 and/or its 
interactions with membrane transporters. It is known that ranitidine is a substrate 
for the organic cation uptake transporters (OCTs) (Ming et al., 2009, Han et al., 
2013), as well as the efflux transporter P-glycoprotein (P-gp) (Cook and Hirst, 1994, 
Collett et al., 1999). Meanwhile, PEGs are known to inhibit P-gp in a concentration-
dependent manner from 0.1 to 20% (w/v) (Hugger et al., 2002, Shen et al., 2006b). 
Additionally, the activity and expression of P-gp has been reported to be different 
in males and females (Mariana et al., 2011). Consequently, we contemplated that 
the observed sex-related influence of PEG 400 on the bioavailability of ranitidine 
could be due to its interaction with the efflux membrane transporter P-gp. Therefore, 
a step-by-step investigation was conducted in this study.
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The current thesis summarized the following parts of the research project: 
 Determination of the influence of PEG 400 on the bioavailability of another 
two P-gp substrates (fexofenadine and ampicillin) and a non-P-gp substrate 
(metformin) in male and female rats (Chapter 2: Phase I). 
 Assessment of the effect of PEG 400 on drug bioavailability in the presence 
of a P-gp inhibitor (the immunosuppressive agent cyclosporine A) (Chapter 
2: Phase II).  
 Extensive investigation into the influence of PEG 400 on the permeation of 
ranitidine and P-gp activity in four intestinal divisions of male and female 
rats, with an in vitro method (Chapter 3). 
 Evaluation of the sex differences on the P-gp protein content and mRNA 
expression, alongside the influence of PEG 400 on the intestinal P-gp 
expression in male and female rats (Chapter 4). 
 Mechanism investigation into the influence of other commonly-used 
excipients on the absorption of ranitidine in both male and female rats 
(Chapter 5: Phase I). 
 Exploration the sex-related effect of the aforementioned excipients in Phase 
I (commonly-used doses in the commercial products) on the in vivo 
bioavailability of ranitidine (Chapter 5: Phase II). 
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CHAPTER 2: Innate Influences: Do efflux 
transporters contribute to sex-specific 
differences of PEG 400 on drug bioavailability? 
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2.1 INTROUDCTION 
The formerly regarded “inert” pharmaceutical excipient, polyethylene glycol 400 
(PEG 400) unexpectedly alters the bioavailability of the BCS class III drug, 
ranitidine, in a sex-dependent manner. We hypothesized that the sex-related 
influence could be due to interactions between PEG 400 and the efflux transporter 
P-glycoprotein (P-gp). The investigation was completed in two phases to test this 
hypothesis. 
Phase I: The determination on the influence of PEG 400 on the bioavailability of 
another two P-gp substrates (fexofenadine and ampicillin) and a non-P-gp substrate 
(metformin) in male and female rats. 
Ampicillin and fexofenadine have been reported to be mediated by the same efflux 
transporter, P-gp, but differential influx transporter peptide transporters (PEPTs) 
and organic anion-transporting polypeptide (OATP) transporter respectively 
(Glaeser et al., 2007, MacLean et al., 2010). Metformin was chosen as it is a non-
P-gp substrate and is also transported via the same uptake transporter and organic 
cation transporters (OCTs) as ranitidine (Chen et al., 2010). Furthermore, all drugs 
tested in this study are transported via the paracellular pathway. Thus, any possible 
influence of PEG 400 on the paracellular pathway would be observed, if applicable. 
(Lafforgue et al., 2008, Alvi and Chatterjee, 2014) (Details of absorption 
mechanisms and the model drugs are shown in Table 2.1 and Table 2.2). 
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OATPs, OCTs and PEPTs are the three main families of uptake transporters in the 
GI tract. In details, OATPs are responsible for the uptake of a wide range of 
substrates contain steroidal or peptide structural backbones and/or anionic or 
cationic chemicals (Abe et al., 1999, Hsiang et al., 1999, Cui et al., 2001). OCT 
transporters mediate the uptake of organic cations that are positively charged at 
physiological pH, with relatively low molecular weights and also with widely 
diverse molecular structures (Koepsell and Endou, 2004). PEPTs transports di- and 
tripeptides into cells, which were first identified as key peptide carriers in the small 
intestine and kidneys, respectively (Fei et al., 1994, Liu et al., 1995). 
If the sex-related influence of PEG 400 occurred only for drugs whose absorption 
is controlled by the efflux transporter P-gp (fexofenadine and ampicillin in this 
study), we will then proceed to Phase II. If not, the results will be analyzed and the 
transporter responsible for those drugs that showed sex differences in the presence 
of PEG 400 will be regarded as the determining factor behind this sex-related 
phenomenon. Then, this transporter will be blocked in the following study. 
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Table 2.1 The substrates and inhibitors for various transporters on the intestinal epithelial membrane. 
BCS Class III 
Drugs 
Influx Transporter Efflux Transporter 
PEPT OATP OCT P-gp BCRP MRP2 
Ranitidine ×[1][2][3]  √[4] √[5][6] ×[6] ×[6] 
Metformin ×[1][2][3]  √[7] ×[8] ×[1]  
Ampicillin √[9]  ×[1][10][11] √[12]   
Fexofenadine ×[1][2][3] √[13]  √[14][15] ×[15] ×[15] 
√ stands for the substrates. × stands for this drug is neither inhibitor nor substrates for the transporter. 
 
[1](Konig et al., 2013)  [2](Leibach and Ganapathy, 1996)  [3](Liang et al., 1995)  [4](Muller et al., 2005)  [5](Bourdet et al., 2006)  [6](Collett et al., 1999)    
[7](Chen et al., 2010)    [8](Song et al., 2006)   [9](Sala-Rabanal et al., 2008)  [10](Muller et al., 2012)  [11](Tsuji et al., 1981)  [12](Siarheyeva et al., 2006)    
[13](Bailey et al., 2000)  [14](Chen, 2007)  [15](Tahara et al., 2006)  
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Table 2.2 Physicochemical properties of fexofenadine, ampicillin and metformin. 
Model Drugs Molecular Weight pKa Solubility  
in Water 
Molecular Formula Structure 
Fexofenadine 538.13 pKa1=4.25 
pKa2=9.53 
2.44mg/mL C32H39NO4 
 
Ampicillin 349.41 pKa1=2.5 
pKa2=7.3 
50mg/mL C16H19N3O4Na 
 
Metformin 165.62 pKa1=2.8 
pKa2=11.5 
>300mg/mL C4H11N5 
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Phase II: The investigation of the influence of PEG 400 on drug bioavailability in 
the P-gp ‘knock-out’ model. 
So far, the P-gp blocking animal models were conducted in two methods: 1) using 
a genetically modified mouse or rats (whose existing specific gene was replaced or 
disrupted with an artificial piece of DNA); 2) blocking the target protein or mRNA 
with its inhibitors. In our study, the rats modified with method 2 (blocking P-gp 
with inhibitors) were used, as the P-gp gene “knock-out” rodent forms were too 
expensive.  
P-gp inhibitors have been intensively studied as potential multidrug resistance 
(MDR) reversers (shown in Table 2.3 and Table 2.4). Initially, drugs to reverse 
MDR were not specifically developed for inhibiting P-gp; in reality, they had other 
pharmacological properties, as well as a relatively low affinity for MDR 
transporters. An example of this first-generation P-gp inhibitors is verapamil. The 
second generation included more specific inhibitors that presented lower side-
effects such as dexverapamil or dexniguldipine. A third generation of P-gp 
inhibitors comprises of compounds such as tariquidar with high affinity to P-gp at 
nanomolar concentrations (Palmeira et al., 2012). 
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Table 2.3 Classification of P-gp inhibitors. 
Generations Samples Specificity Limitations 
First 
Generation 
verapamil, cyclosporin A, 
reserpine, quinidine, yohimbine, 
tamoxifen, toremifena 
Non-selective and low 
binding affinities. 
They are substrates to other transporters and 
enzyme systems. They are pharmacologically 
active. They themselves are transported by P-gp. 
Second 
Generation 
dexverapamil, dexniguldipine, 
valspodar (PSC 833), dofequidar 
fumarate (MS-209) 
Higher specificity then 
first generation inhibitors 
but interact with other 
systems. 
They are substrates to CYP 3A4 enzyme and 
other ABC transporters. 
Third 
Generation 
cyclopropyldibenzosuberane 
zosuquidar (LY335979),  
laniquidar (R101933),  
mitotane (NSC-38721),  
biricodar (VX-710),  
elacridar (GF120918/GG918),  
ONT-093, tariquidar (XR9576), 
HM30181 
Highest specificity that 
specifically and potently 
inhibit P-gp function. 
No limitations like the first and the second 
generation inhibitors. 
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Table 2.4 Characterization of Typical P-gp Inhibitors. 
P-gp 
Inhibitors 
Structure 
Therapeutic 
Drugs 
Inhibitor of 
Representative P-gp Assays 
P-gp BCRP MRP 
F
ir
st
 G
en
er
at
io
n
 
V
er
ap
am
il
 
 
Cardiac / 
circulation 
Drugs 
√[1] √[1] x[2] 
Increased Rho123 accumulation in K562Dox cell line [3] 
Increased ATPase activity (Competitive P-gp inhibitor) [3] 
5.9-fold decrease in doxorubicin GI50 K562Dox cell line [3] 
Q
u
in
id
in
e 
 
Antimalarial 
Drugs 
√[4] √[4]  
Weak effect on doxorubicin accumulation in a resistant human 
erythroleukemia cell line [5] 
Completely restored doxorubicin sensitivity in the resistant human 
erythroleukemia cell line [6] 
 
C
y
cl
o
sp
o
ri
n
e 
A
 
 
Immunossu-
ressant 
Drugs 
√[7] √[8] √[8] 
Combination with doxorubicin on K562/A02 cells: MDR partially 
reversed [9] 
Combination with doxorubicin on hepatocellular carcinoma cell 
lines: decreased doxorubicin IC50 [10] 
Photo affinity labelling with [3H]azidopine: P-gp competitive 
inhibition [11] 
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Table 2.4 Continued 
P-gp 
Inhibitors 
Structure 
Derivative/ 
Stereo -
isomer of 
Inhibitor of 
Representative P-gp Assays P-gp BCRP MRP 
S
ec
o
n
d
 G
en
er
at
io
n
 
D
ex
v
er
ap
am
il
 
 
verapamil √[1] x[1]  
Increased [3H]vimblastine accumulation in theF4-6RADR cell line 
[12] 
Combination of dexverapamil with DINIB, a P-gp substrate, in the 
colon cancer cell line, HCT-15, and renal cell line, UO-31: reversed 
P-gp-mediated resistance in both cell lines, increasing DINIB 
cytotoxicity [13] 
D
ex
n
ig
u
ld
ip
in
e 
 
niguldipine √[12]   
Reversed vinblastin resistance in F4-6RADR cells [12]. 
Decreased adriamycin GI50 in adriamycin resistant 
erythroleukemia F4-6RADR cells [14] 
V
al
sp
o
d
ar
 (
P
S
C
 8
3
3
) 
 
cyclosporine √[15] x[15] √[15] 
Decreased doxorubicin GI50 in SK-MES-1/DX1000 resistant cells, 
but also downregulated P-gp expression by activating JNK/c-
Jun/AP-1 and suppressing NF-қB [16] 
Administration of valspodar to rats before mitoxantrone treatment: 
increased the accumulation of mitoxantrone in the MDR tumors to 
94% of that in the wild-type tumors [17] 
 
 
  Chapter 2 
59 
 
Table 2.4 Continued 
P-gp 
Inhibitors 
Structure 
Inhibitor of 
Representative P-gp Assays 
P-gp BCRP MRP 
T
h
ir
d
 G
en
er
at
io
n
 
E
la
cr
id
ar
 (
G
F
1
2
0
9
1
8
) 
 
√[18] x[19] √[19] 
Increase verapamil distribution in rat brain (which expresses P-gp) up to 11-fold 
over baseline at maximum effective doses, with elacridar being about three times 
more potent than tariquidar [20] 
Combination with etoposide, doxorubicin, vinblastine, docetaxel and paclitaxel in 
MDR sarcoma MES-Dx5 cells: reversal of resistance [21] 
Significant increase of the systemic exposure of topotecan, leading to an increase 
of oral bioavailability [22] 
Z
o
su
q
u
id
ar
 
(L
Y
3
3
5
9
7
9
) 
 
√[23] x[23] x[23] 
Increased paclitaxel levels in plasma and tissues in mice to levels similar to those 
observed in P-gp knockout mice [24] 
Combination with imatinib in mice: improved the delivery of imatinib to the brain, 
making it potentially more effective against malignant gliomas [25] 
√ stands for the substrates. × stands for this drug is neither inhibitor nor substrates for the transporter. 
[1] (Perrotton et al., 2007)  [2] (Leibach and Ganapathy, 1996) (Leibach and Ganapathy, 1996) (Leibach and Ganapathy, 1996) (Leibach and Ganapathy, 1996) (Leibach 
and Ganapathy, 1996) (Leibach and Ganapathy, 1996) (Leibach and Ganapathy, 1996)  [3] (Palmeira et al., 2012)  [4] (Vezmar and Georges, 2000)  [5] (Lehnert et al., 
1991)  [6] (Bennis et al., 1995)  [7] (Pawarode et al., 2007)  [8] (Gupta et al., 2006)  [9] (Chen et al., 2008)  [10] (Shiraga et al., 2001)  [11] (Ueda et al., 1994)  [12] 
(Hollt et al., 1992)  [13] (Bates et al., 2004)  [14] (Dietel et al., 1996)  [15] (Breedveld et al., 2006)  [16] (Bark and Choi, 2010)  [17] (Shen et al., 2009)  [18] (Stokvis et 
al., 2004)  [19] (Lagas et al., 2009)  [20] (Kuntner et al., 2010)  [21] (Traunecker et al., 1999)  [22] (Kruijtzer et al., 2002)  [23] (Shepard et al., 2003)  [24] (Kemper et al., 
2004)  [25] (Bihorel et al., 2007)
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2.1.1 First Generation 
2.1.1.1 Verapamil 
In 1981, the first description of verapamil was made as a potential MDR reversing 
agent, indicating the possibility of identifying clinically useful reversing agents of 
MDR (Tsuruo and Fidler, 1981). The calcium channel blocker, verapamil, was the 
first compound ever found which was able to enhance the intracellular 
accumulation of many anticancer drugs such as vincristine, and doxorubicin 
(Bellamy et al., 1988, Yusa and Tsuruo, 1989). Indeed, it was demonstrated that 
verapamil inhibited the efflux of anticancer drugs from tumor cells that over-
expressed P-gp, causing an increase in the intracellular concentration of the 
chemotherapeutic drug. Some authors suggest that verapamil inhibits P-gp activity 
by direct competition with P-gp substrates (Futscher et al., 1996).  
2.1.1.2 Cyclosporine A 
In 1986, an immunosuppressive drug, cyclosporine A (CsA), demonstrated that it 
also had the capacity to reverse resistance to anticancer drugs in vitro (Slater et al., 
1986). CsA was reported to interfere with the P-gp mediated reaction. The truth is, 
it has been demonstrated that CsA competed with the substrates of P-gp to bind to 
the drug-binding site of P-gp (Sakata et al., 1994). At the beginning of the 90s, the 
first clinical trial with CsA and anticancer drugs were initiated in patients with 
multiple myeloma and acute leukemia (Bartlett et al., 1994, List et al., 1993, 
Yahanda et al., 1992). Subsequently, several other clinical trials were performed. 
However, CsA showed no selectivity towards P-gp. It is able to increase cellular 
drug uptake in cells overexpressing P-gp, MRP-1 or BCRP and nuclear drug uptake 
in cells overexpressing LRP (Gupta et al., 2006, Pawarode et al., 2007). 
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2.1.2 Second Generation 
Owing to the experience with the first-generation compounds, the approach 
subsequently followed was to identify analogues that were devoid of the 
pharmacological properties of the original molecule but could specifically inhibit 
P-gp, with less toxicity and a greater potency (Krishna and Mayer, 2000).  
2.1.2.1 Valspodar (PSC 833) 
Valspodar was developed by Novartis and derives from CsA due to a methylation 
in a lateral chain of an amino acid and an oxidation of an alcohol to a carbonyl. It 
is a nonimmunosuppressive cyclosporine analog which is a potent MDR modifier 
(5- to 20-fold more potent than CsA) (Boesch et al., 1991, Kusunoki et al., 1998). 
The main problem associated with this compound is the interaction with the 
pharmacokinetics of the associate chemotherapeutic drugs, which resulted to an 
increase in the chemotherapeutic drug toxicity, sequentially requiring a reduction 
of its dose (Chico et al., 2001). 
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2.1.3 Third Generation 
To overcome the limitations of the second generation P-gp modulators, a third-
generation of P-gp inhibitors, which specifically and potently inhibit P-gp, has been 
developed by using quantitative structure-activity relationships (QSAR) and 
combinatorial chemistry (Krishna and Mayer, 2000). 
2.1.3.1 Tariquidar (XR9576) 
Tariquidar (XR9576) is an anthranilamide derivative and an example of a third 
generation P-gp inhibitor (Fox and Bates, 2007) and has long been described as a 
specific P-gp inhibitor. However, it is now accepted that tariquidar (Kelly et al., 
2011) and elacridar (Lagas et al., 2009) also bind with breast cancer resistance 
protein (BCRP). Tariquidar binds P-gp through a noncompetitive mechanism and 
with an affinity that greatly exceeds that of the transported substrates (Bauer et al., 
2013). It inhibits the ATPase activity of P-gp, however, it is not clear whether the 
binding of tariquidar on P-gp is directed to the ATP binding site or to an allosteric 
location, thus, indirectly blocking the P-gp catalytic cycle (Martin and Baxter, 
1999).  
Various types of compounds and techniques for the reversal of P-gp-mediated MDR 
have been developed and the strategy has been mainly to inhibit the function of the 
pump. It has been 35 years since the discovery of the first P-gp inhibitor and 48 
years since the isolation of the first MDR cells. However, some defeatism still 
remains on the possibility of finding a “perfect” P-gp inhibitor that can efficiently 
modulate the pump and restore the efficacy of chemotherapy. Considering the 
purpose of this study and the cost of P-gp inhibitors into account, the first generation 
P-gp inhibitor, cyclosporine A (CsA), was chosen to start a comprehensive analysis 
of the efficacy of P-gp inhibitors in this sex-based phenomenon in Phase II.
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Phase I 
2.2 MATERIALS AND METHODS 
2.2.1 Materials  
Fexofenadine hydrochloride was purchased from Cambridge Bioscience Ltd. 
(Cambridge, UK). Metformin hydrochloride and ampicillin sodium was obtained 
from USV Ltd. (Mumbai, India) and VWR International (Lutterworth, UK), 
respectively. Polyethylene glycol 400, sodium dodecyl sulfonate and HPLC-grade 
water were supplied by Sigma-Aldrich (Dorset, UK). HPLC-grade reagents such as 
acetonitrile, methanol and glacial acetic acid were obtained from Fisher Scientific 
(Loughborough, UK). Analytical grade reagents such as ammomium acetate and 
sodium dihydrogen phosphate were procured from VWR International (Lutterworth, 
UK).  
2.2.2 Animals 
All the animal work was approved by the UCL School of Pharmacy’s ethical review 
committee and was conducted in accordance with the home office standards under 
the Animals (Scientific Procedures) Act, 1986. Healthy male and female, 8-13 week 
old Wistar rats (Harlan UK Ltd, Oxfordshire, UK) weighing 150-250 g were used. 
The rats were housed at controlled temperatures (25℃) and humidity (50-60%) 
with a constant light-dark cycle of 12h. Food and water were provided and the rats 
were acclimatized for 7 days before being studied. 
 
  Chapter 2 
64 
 
2.2.3 Dose studies on the model drugs 
Fexofenadine, ampicillin and metformin were weighed accurately and dissolved 
with water, prepared in 10mg/mL, 15mg/mL and 25mg/mL. Only male Wistar rats 
were used for these dose studies.  
Rats were divided into three groups and administered with 0.5mL solutions in 
different concentrations. After dosing, approximately 250μL-300μL of blood was 
collected from the tail vein of rats into anticoagulant centrifuge tubes (BD 
Microtainer® K2E Becton, Dickinson and Company, USA) at 0.5, 1.25, 2, 3, 4 and 
6h. At 8h post-administration, the rats were sacrificed in a CO2 euthanasia chamber 
and about 1mL of blood was taken via cardiac puncture immediately. 
2.2.4 Effect of PEG 400 on drug bioavailability  
The day before the experiment, all the rats were fasted overnight and individually 
housed in metabolic cages. 
On the day of the experiment, each rat was weighed and administered an aqueous 
solution, corresponding to a dose of fexofenadine, ampicillin or metformin 
(selected based on the results from section 2.3.3) with or without 26mg/kg PEG 400 
by oral gavage. PEG 400 was used at a dose of 26mg/kg as this caused the greatest 
enhancement in ranitidine bioavailability in rats (Afonso-Pereira et al., 2016). 
Subsequently, approximately 250μL-300μL of blood was collected from the rats’ 
tail vein into anticoagulant centrifuge tubes (BD Microtainer® K2E Becton, 
Dickinson and Company, USA) at 0.5, 1.25, 2, 3, 4 and 6h. At 8h post-
administration, the rats were killed in a CO2 euthanasia chamber and about 1mL of 
blood was taken by cardiac puncture.  
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2.2.5 Samples preparation 
Blood samples were centrifuged at 10,000rpm for 10min, and the supernatants 
(plasma samples) were collected into 1.5mL Eppendorf tubes. 
Fexofenadine was extracted from a 100μL plasma sample by protein precipitation 
with 300μL acetonitrile. The mixture was vortex-mixed for 6s and centrifuged at 
13,000rpm for 15min. The supernatant was then collected and evaporated to 
dryness in a Savant SPD2010 SpeedVac Concentrator system (Thermofisher, 55303 
Minnesota, USA). The dried residue was dissolved in a 100μL diluent (a mixture 
of methanol-acetate buffer in the ratio of 50:50) and vortex-mixed for 30s. An 
aliquot of 50μL of each sample was then processed on the HPLC apparatus. 
For ampicillin and metformin, 100μL of acetonitrile or methanol was added to 
100μL of plasma samples respectively, to precipitate the protein. The mixtures were 
vortex-mixed for 6s and centrifuged in a Centrifuge 5804R (Eppendorf AG, 22331 
Hamburg, Germany) at 13,000rpm for 10min. The supernatant was then collected 
and a 50μL aliquot of each sample was analysed by HPLC.  
2.2.6 Chromatographic analysis 
The amount of drug in the withdrawn samples was quantified using a high 
performance liquid chromatography (HPLC) system (Agilent Technologies, 1260 
Infinity) equipped with a pump (model G1311C), autosampler (model G1329B) and 
a diode-array UV detector (model G1314B). All the peaks of model drugs can be 
achieved with a Luna C18(2) 100A (250mm×4.6mm I.D./5μm particle size, 
Phenomenex, Torrance, USA). The best suited HPLC conditions for quantification 
of four model drugs in rat plasma were shown in Table 2.5
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Table 2.5 Chromatographic conditions and parameters for quantification of fexofenadine, ampicillin and metformin in rat plasma. 
Model Drugs Column Column 
Temperature 
Detector Wavelength Mobile Phase Flow Rate Injection 
Volume 
Fexofenadine C18 
(250mm×4.6mm 
I.D./5μm) 
25℃ Fluorescence Excitation: 230nm  
Emission: 310nm 
0.1M Ammonium 
Acetate Buffer (pH 
4.0, 63%); 
Acetonitrile (37%) 
1mL/min 50μL 
Ampicillin C18 
(250mm×4.6mm 
I.D./5μm) 
25℃ Ultraviolet 220nm 10mM Sodium 
Dihydrogen 
Phosphate Buffer (pH 
7.0, 60%); Methanol 
(40%) 
0.6mL/min 50μL 
Metformin C18 
(250mm×4.6mm 
I.D./5μm) 
25℃ Ultraviolet 234nm 10mM Sodium 
Dihydrogen 
Phosphate Buffer 
with 10mM Sodium 
Dodecyl Sulfonate 
(pH 7.0, 60%); 
Acetonitrile (40%) 
1mL/min 50μL 
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2.2.7 HPLC method validation 
Quality control standards of low, medium and high concentrations of the molecules 
were prepared in control rat plasma to evaluate the precision and accuracy of the 
method. Separate standards of low concentrations were prepared to investigate the 
limit of detection and quantification. 
2.2.7.1 Linearity 
Calibration curves are constructed daily, for five consecutive days. The linearity of 
the methods was evaluated with a total of seven calibration standards over the 
concentration range 20-1000ng/mL for fexofenadine, 0.2-20μg/mL for ampicillin 
and 50-5000ng/mL for metformin. Coefficients of calibration equation and the 
correlation coefficient were expressed. 
2.2.7.2 Detection and quantification limits (sensitivity) 
According to the visual evaluation method, limit of detection (LOD) is determined 
by establishing the minimum level at which the analyte can be reliably detected. 
Limit of quantitation (LOQ) is considered as the lowest concentration of analyte in 
standards that can be reproducibly measured with an acceptable accuracy of 80-120% 
and precision ≦20%. 
2.2.7.3 Assay precision and accuracy 
Accuracy, intra- and inter-day precisions of the method were determined for three 
model drugs according to FDA guidance. The quality control samples (low, medium 
and high) were investigated using five determinations on the same day. The inter-
day variation was also evaluated at these three different concentrations on five 
different non-consecutive days.  
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The accuracy was calculated from the mean value of observed concentration (Ca) 
and the nominal concentration (Cb) as follows: Accuracy(%)=[(Ca-Cb)/Cb]×100.  
The precision coefficient of variation, C.V. (%) was calculated from observed 
concentrations as follows: Precision, C.V.(%)=[standard deviation(S.D.)/Ca]×100. 
2.2.7.4 Recovery 
Three quality control samples were prepared in diluents and blank rat plasma. The 
mean peak areas were then collected. Recovery was calculated by comparing the 
mean peak area of an extracted sample (n=5) to the one obtained after the direct 
injection of a solution with the same drug concentration. 
2.2.7.5 Stability tests  
2.2.7.5.1 Untreated plasma short-term stability 
The quality control samples were maintained at ambient temperature for 2h. The 
model drugs in the samples were then processed following the HPLC method. The 
stability was calculated by comparing the mean peak area of samples treated 
immediately and the untreated samples. 
2.2.7.5.2 Post-preparative short-term stability 
Six plasma samples in three different concentrations were prepared. Three of them 
were investigated with HPLC immediately, whist the other three were processed 
24h later. The stability was calculated as follows:  
Stability (%) = 
Peak area response of samples at 0h
peak area response of samples at 24h
 x 100 
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2.2.7.5.3 Repetitive freeze-thaw stability 
Repetitive freeze-thaw stability of the quality control samples of model drugs in rat 
plasma samples was determined for three freeze-thaw cycles. The samples were 
thawed at room temperature, and then kept in the freezer at -20℃ for 24h before 
the next thawing. 
2.2.7.5.4 Long-term stability 
The quality control samples were assessed by performing the experiment after 30 
days of storage at -20℃. The stability was calculated from the relative recovery as 
follows:  
Recovery (%) = 
Peak area response of samples on 0 day
Peak area response of samples on 30 days
 x 100 
2.2.8 Pharmacokinetic analysis 
Pharmacokinetic parameters, (Cmax, tmax, AUC0-480, AUC∞, CL, Vd and t1/2) were 
calculated by non-compartmental analyses using a free Microsoft Excel add-in, 
“PKSolver.” (Zhang et al., 2010).  
2.2.9 Statistical analysis 
All results are expressed as mean ± SD (n = 6). The control and test group data were 
analysed by one-way ANOVA, followed by post-hoc Tukey analysis with a 95 % 
confidence interval using IBM SPSS Statistics 16 (SPSS Inc., Illinois, USA). 
Repeated measures ANOVA was conducted to assess any statistically significant 
differences along the absorption profiles.  
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2.3 RESULTS AND DISCUSSION 
2.3.1 HPLC method validation 
2.3.1.1 Optimization of chromatographic conditions 
Chromatographic conditions were optimized by changing the mobile phase 
composition and buffers used in the mobile phase.  
For fexofenadine, the mixture of 0.05M phosphate buffer and methanol in the ratio 
65:35(v/v) was used as mobile phase in the beginning, however, the peak area of 
fexofenadine was small and the limit of detection (LOD) was high. The mobile 
phase consisted of 63% 0.1M acetate buffer. 37% acetonitrile was then use which 
achieved optimized results. By altering the pH of mobile phase, better separation of 
target drug from plasma was accomplished. Various excitation and emission 
wavelengths have also been used to determine fexofenadine in rat plasma, to be 
specific, a 52 factorial design was supplied to obtain the best peak area. The 
selection of levels for the optimization was based on the wavelengths have been 
used in other experiments, and the largest peak area have been found when the 
fluorescence measurements for fexofenadine were done at 230nm excitation and 
310nm emission wavelengths. Typical chromatograms using the HPLC method 
with fluorescence detection for blank rat plasma and fexofenadine in plasma at the 
medium are shown in Figure 2.1. The retention time of fexofenadine was 8.6min. 
For ampicillin, the LOD was 5μg/mL in rat plasma when 60% 0.1M sodium 
dihydrogen phosphate and 40% acetonitrile was used as the mobile phase, which 
was not suitable in rat plasma. Following this procedure, the organic phase was 
changed to acetonitrile instead of methanol where the LOD decreased to 0.1μg/mL. 
However, the column pressure was increases from 220bar to 240bar. To modify the 
method, the flow rate was reduced from 1mL/min to 0.6mL/min which helped ease 
the column pressure to 190bar. Chromatogram profiles of ampicillin were obtained 
in Figure 2.2. 
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For metformin, the retention time was too early to detect the drug in rat plasma 
when 60% 10mM phosphate buffer and 40% acetonitrile was used as mobile phase. 
As it is reported that there are complex reactions between sodium dodecyl sulfonate 
and phosphate radical, the retention time was successfully delayed to 12 min by 
adding 10mM sodium dodecyl sulfonate in the phosphate buffer. However, when 
the sodium dodecyl sulfonate and potassium dihydrogen phosphate buffer were 
mixed, potassium precipitated out from the mixture and white floccule could be 
found in the solution. Therefore, 10mM sodium dihydrogen phosphate was used 
instead of potassium dihydrogen phosphate buffer. Typical chromatograms of blank 
rat plasma and metformin in plasma at the medium were shown in Figure 2.3. 
2.3.1.2 Linearity 
Calibration curves for fexofenadine, ampicillin and metformin in rat plasma were 
linear over the concentration range of 20-1000ng/mL, 0.2-20μg/mL and 50-
5000ng/mL, respectively. Typical calibration curves, which were analyzed for five 
different days respectively, could be expressed for plasma samples as 
y=(0.0041±0.0003)x+(0.1653±0.0836), y=(36.2490±1.2347)x-(0.2516±1.9454) 
and y=(0.1263±0.0033)x-(0.5374±1.8189), where y is the peak area and x is the 
concentration in ng/mL with a mean correlation coefficient of 0.9977, 0.9999 and 
0.9998. 
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Figure 2.1 Representative chromatograms of (A) blank rat plasma and (B) blank 
rat plasma spiked with 150ng/mL fexofenadine. 
 
 
 
Fexofenadine 
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Figure 2.2 Representative chromatograms of (A) blank rat plasma and (B) blank 
rat plasma spiked with 2μg/mL ampicillin. 
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Figure 2.3 Representative chromatograms of (A) blank rat plasma and (B) blank 
rat plasma spiked with 2μg/mL metformin. 
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2.3.1.3 Limit of detection and limit of quantitation (sensitivity) 
The lower limit of quantification (LOQ) of fexofenadine, ampicillin and metformin 
were found to be 10ng/mL, 200ng/mL and 20ng/mL, respectively. While the 
accuracy (%bias) for these three model drugs were round 92.34%, 90.15% and 
98.23%, with a precision (C.V.) not exceeding 20%. The limit of detection (LOD) 
considering a signal-to-noise ratio 3:1 were estimated to be 5ng/mL, 100ng/mL and 
20ng/mL for fexofenadine, ampicillin and metformin respectively.   
2.3.1.4 Accuracy and precision 
The accuracy and precision of the method were evaluated with the samples at three 
different concentrations. The intra- and inter-day accuracy and precision values of 
the assay method are shown in Table 2.6.  
The intra-day C.V. (%) for fexofenadine was below 19.03%, while they were below 
1.48% and 1.63% for ampicillin and metformin respectively. All inter-day C.V. (%) 
for drugs were below 6.17%. The intra-day and inter-day accuracies for 
fexofenadine were found to be within 96.55% and 112.33%, while these two 
parameters for ampicillin were not above 98.56% and 105.59%, of the target values. 
For metformin, the accuracies were observed between 96.16% and 109.97%. 
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Table 2.6 Intra- and inter-day accuracy and precision of fexofenadine, ampicillin 
and metformin determination at three concentration levels (n = 5). 
Samples 
(ng/mL) 
Measured 
Concentration 
(ng/mL) 
Accuracy 
(%) 
Intra- 
Precision 
C.V. (%) 
Inter- 
Precision 
C.V. (%) 
Fexofenadine 
20 22.47±4.27 112.33 19.03 4.06 
150 158.02±4.27 105.35 2.71 2.30 
1000 979.80±12.17 97.98 1.24 1.50 
 
Ampicillin 
500 527.96±4.21 105.59 0.80 6.17 
2,000 2045.30±26.77 102.26 1.31 1.84 
20,000 20659.61±306.48 103.30 1.48 0.94 
 
Metformin 
100 109.97±1.31 109.97 1.19 2.43 
2000 1923.12±27.93 96.16 1.45 2.81 
5000 5007.15±76.99 101.25 1.63 1.54 
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2.3.1.5 Recovery  
The mean extraction recovery of fexofenadine at the three different concentrations 
were 92.52%, 98.35% and 99.19% respectively, whilst metformin showed a better 
recovery (96.88%, 97.43% and 99.46%). The ampicillin recovery from rat plasma 
were not as high as those of fexofenadine and metformin, shown in Table 2.7.  
 
Table 2.7 Recovery of fexofenadine, ampicillin and metformin in plasma. 
Sample 
(ng/mL) 
Concentration(ng/mL) 
Mean S.D. 
Recovery 
(%) Add Found 
Fexofenadine 
20 19.80  17.58  19.80  17.58  18.32  1.28  92.52  
150 147.49  142.61  145.05  147.49  145.05  2.44  98.35  
1000 1008.46  984.07  1032.85  984.07  1000.33  28.16  99.19  
        
Ampicillin 
500 537.61 490.51 484.84 504.70 494.35 10.23 91.77 
2,000 2051.82 1909.11 1954.51 1920.46 1928.03 23.62 93.97 
20,000 20830.41 18909.62 18248.56 18745.07 18634.42 344.14 89.46 
 
Metformin 
100 113.73  111.22  109.66  109.66  110.18  0.90  96.88  
2000 1989.39  1953.94  1942.21  1918.73  1938.29  17.93  97.43  
5000 4956.14  4978.98  4874.91  4933.60  4929.17  52.18  99.46  
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2.3.1.6 Stability  
The stability of fexofenadine, ampicillin and metformin in plasma were investigated 
in four different studies using samples at three concentration levels. The results 
were showed in Table 2.8.  
For fexofenadine and metformin, the stability of plasma samples at room 
temperature was examined by comparing the data of the samples analyzed 
immediately with those at 2h after sample preparation, and the results showed no 
significant change in the concentration of all the model drugs. The 24h autosampler 
stability results of fexofenadine in plasma ranged from 91.67% to 98.13%, which 
showed a good stability. Better stability was found for metformin with the recovery 
from 92.13% to 101.56%. The freeze and thaw cycles did not change the 
concentration levels of analyte significantly, whereas the long-term data showed 
that both fexofenadine and metformin were stable for 30 days in rat plasma too.   
For ampicillin, the stability of the samples during room temperature and during their 
storage at 4°C was also analyzed. No significant change in peak area was observed 
if the samples were stored at 4°C, where at least 94.79% and 89.86% recovery was 
observed in short-term and long-term stability studies. However, if the samples 
were allowed to sit at room temperature, there was, at least, a 10% increase in the 
peak area after 2h, as determined by the HPLC assay. Lowest stability was found 
after freeze and thaw cycles, which was only 81.23% recovery for the low 
concentration sample.
  Chapter 2 
79 
 
 
Table 2.8 Stability of fexofenadine, ampicillin and metformin in rat plasma at three concentration levels (n=3). 
Samples (ng/mL) 
Stability (%) 
Untreated Plasma 
Short-Term Test 
Post-Preparative 
Short-Term Test 
Freeze-Thaw 
Test 
Long-Term 
Test 
Fexofenadine 
20 93.55 91.67 92.00 96.43 
150 95.56 98.73 85.43 84.55 
1000 91.30 95.24 93.62 92.00 
     
Ampicillin 
500 82.83 94.79 81.23 91.03 
2,000 87.27 97.60 82.66 90.96 
20,000 88.07 96.05 85.74 89.86 
 
Metformin 
100 105.79 92.13 92.40 98.80 
2000 99.76 97.89 91.68 98.21 
5000 99.32 101.56 100.03 99.78 
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2.3.2 Dose studies  
2.3.2.1 Fexofenadine 
From the data shown in Figure 2.4, no extreme differences were identified in the 
drug plasma concentration when fexofenadine was administered at 10mg/kg, 
20mg/kg and 50mg/kg. However, in the 10mg/kg administration group, the detected 
fexofenadine concentration was only 3ng/mL at 8h, which was below 5ng/mL 
(LOD). Therefore, 20mg/kg or 50mg/kg fexofenadine could be given to the rats in 
the bioavailability studies. 
It was previously reported that 10mg/kg fexofenadine was used in the rat studies. 
However, the pharmacokinetic studies of fexofenadine in rats have shown a 
relatively low bioavailability when administered orally. For example, a single oral 
dose of 10 mg/kg yielded the highest plasma level of 20-25ng/mL. Although a 
HPLC method with fluorescence detection has been developed, and the LOD is 
5ng/mL, it would be better to attempt a high dose in the pharmacokinetic studies.  
Figure 2.4 Concentration-time curve of fexofenadine in male rat plasma in dose 
study (Mean ± S.D., n=3). 
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2.3.2.2 Ampicillin 
Three different concentrations of ampicillin (20mg/kg, 30mg/kg and 50mg/kg) 
were prepared in water and administered to rats. However, the ampicillin plasma 
concentration was too low to be detected with our HPLC method at some time 
points, for example, when the rats were given 20mg/kg or 30mg/kg ampicillin 
(shown in Figure 2.5). 50mg/kg ampicillin was therefore administered during the 
rat experiments.  
Figure 2.5 Concentration-time curve of ampicillin in male rat plasma in dose 
study (Mean ± S.D., n=3). 
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2.3.2.3 Metformin 
High doses (50mg/kg, 100mg/kg, 200mg/kg) were used in the former 
pharmacokinetic studies of metformin in rats. However, the last blood sample was 
collected on 48h. In our studies, we collected seven samples over 8 hours, therefore, 
lower concentrations of metformin were utilized in the dose studies. Concentrations 
of metformin in rat plasma were significantly different when this compound was 
administered in different concentrations, outlined in Figure 2.6. 
 
 
Figure 2.6 Concentration-time curve of metformin in male rat plasma in dose 
study (Mean ± S.D., n=3). 
In short, considering 50mg/kg ranitidine was used in the previous study and 
50mg/kg ampicillin was selected to be given to the rats in this study, same dose of 
fexofenadine and metformin were utilized in the bioavailability study with the aim 
of minimizing the variable factors. 
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2.3.3 Effect of PEG 400 on drug bioavailability  
2.3.3.1 Fexofenadine 
The bioavailability of fexofenadine in the absence and presence of PEG 400 are 
observed in Figure 2.7, Figure 2.8 and Table 2.9. It stands that the effect of PEG 
400 on the pharmacokinetic parameters of fexofenadine were significant in both 
male and female rats (p<0.05 for Cmax and AUC), however, a greater impact was 
found in male rats compared with females.  
To be specific, the fexofenadine AUC0-480 for both male and female control group 
was 13.8±3.1µg.min/mL and 22.6±7.3µg.min/mL respectively. The presence of 
PEG 400 enhanced the bioavailability of fexofenadine to 55.6±13.5µg.min/mL and 
62.48±10.0µg.min/mL in males and females, (p<0.05). However, a greater response 
was found in the effect of PEG 400 on the bioavailability of fexofenadine in males 
(an increase with 150%) when compared with female rats in which the induction 
was only approximately 93%.    
Figure 2.7 Plasma concentration-time profile of fexofenadine in the absence and 
presence of PEG 400 over 8 hours in male and female Wistar rats (Mean ± S.D., 
n=6).* Value is statistically different at p<0.05. 
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Figure 2.8 Mean AUC0-480 of fexofenadine in the presence and absence of PEG 400 
in male and female Wistar rats (Mean ± S.D., n=6). * Values are statistically 
different between the control and PEG groups at p<0.05. 
 
 
Table 2.9 Influence of 26mg/kg PEG 400 on the pharmacokinetic parameters of 
fexofenadine in male and female rats (Mean±S.D., n=6). 
Pharmacokinetic 
Parameters 
Male Female 
Control PEG 400 Control PEG 400 
AUC0-480 
(μg.min/mL) 
88.62±12.30 221.78±9.11 * 118.45±12.62 228.83±29.19* 
AUC∞ (μg.min/mL) 132±18.40 234.64±11.18* 135.24±20.59 244.97±30.57* 
cmax (μg/mL) 0.34±0.06 1.14±0.07* 0.58±0.07 1.08±0.09* 
tmax (min) 67.50±33.88 75.00±28.46* 60.00±23.23 67.50±44.24 
CL (mL/min) 0.07±0.04 0.05±0.003 0.09±0.01 0.05±0.006 
Vd (mL) 50.69±18.51 8.64±0.95* 21.04±2.84 9.84±2.08* 
t1/2 (min) 299.22±76.35 112.74±16.12* 156.94±27.45 133.91±36.06 
* Values are statistically different between the control and PEG groups at p<0.05.  
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The findings in the case of fexofenadine was partly in conflict with our hypothesis 
which stated that PEG 400 showed sex-related impact on the bioavailability of P-
gp substrates, since fexofenadine was confirmed as a typical substrate for the efflux 
transporter P-gp alongside the influx transporter OATP1A2. However, a recent 
study demonstrated that PEG 400 was not only a selective modulator of P-gp but 
also OATP1A2 (Engel et al., 2012), which may make the result too complicated to 
be analyzed. Therefore, the bioavailability of another P-gp substrate, ampicillin 
with PEG 400, need to be investigated in male and female rats, as followed.  
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2.3.3.2 Ampicillin 
The influences of PEG 400 on ampicillin absorption in male and female rats are 
shown in Figure 2.9, Figure 2.10 and Table 2.10. It can be seen that ampicillin 
absorption profiles and pharmacokinetic parameters were similar for males and 
females in the absence of PEG 400 (p>0.05). The presence of PEG 400 caused no 
changes in the drug absorption in females (p>0.05). In contrast, PEG 400 had a 
considerable influence on ampicillin absorption in male rats (p<0.05 for tmax, Cmax 
and AUC), where ampicillin absorption was more rapid and more extensive 
compared to the control, such that tmax occurred earlier at 38min compared to 
120min, Cmax was almost doubled and the AUC increased by 58%.  
 
 
Figure 2.9 Plasma concentration-time profile of ampicillin in the absence and 
presence of PEG 400 over 8 hours in male and female Wistar rats (Mean ± S.D., 
n=6).* Value is statistically different at p<0.05. 
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Figure 2.10 Mean AUC0-480 of ampicillin in the presence and absence of PEG 400 
in male and female Wistar rats (Mean ± S.D., n=6). *Values are statistically 
different between the control and PEG groups at p<0.05. 
 
Table 2.10 Influence of 26mg/kg PEG 400 on the pharmacokinetic parameters of 
ampicillin in male and female rats (mean±S.D., n=6). 
Pharmacokinetic 
Parameters 
Male Female 
Control PEG 400 Control PEG 400 
AUC0-480 
(μg.min/mL) 
527.93±52.34 807.47±29.81* 639.87±42.86 687.22±27.96 
AUC∞ 
(μg.min/mL) 
577.39±74.46 939.49±57.86* 733.55±30.97 896.59±71.83 
cmax (μg/mL) 2.99±0.30 5.17±0.69* 3.28±0.63 2.63±0.22 
tmax (min) 108.75±22.50 37.50±18.37* 122.50±33.43 144.00±32.86 
CL (mL/min) 0.02±0.003 0.01±0.0008 0.02±0.0007 0.01±0.003 
Vd (mL) 4.84±1.01 3.07±0.35 3.64±0.70 5.20±2.25 
t1/2 (min) 156.05±43.29 160.50±26.68 147.86±28.30 209.93±33.74 
* Values are statistically different between the control and PEG groups at p<0.05.  
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This sex-based influence of PEG 400 on ampicillin absorption was the same as that 
seen with ranitidine, where the bioavailability of the latter was increased by 49% in 
male rats but was unchanged in female (Afonso-Pereira et al., 2016). The similar 
increase in drug bioavailability in male rats for ranitidine and ampicillin indicate 
that the mechanisms responsible for the sex-specific influence of PEG 400 may be 
the same. The absorption of ranitidine and ampicillin are known to be controlled by 
the intestinal efflux transporter, P-gp (Collett et al., 1999, Siarheyeva, 2006), while 
PEG 400 is also known to influence the P-gp efflux transporter (Cook and Hirst, 
1994). From this knowledge, we hypothesize that the sex-specific influence of PEG 
400 on the absorption of ampicillin and ranitidine is mediated by the influence of 
PEG 400 on the efflux transporter P-gp. To test this hypothesis, we investigated the 
sex-based influence of PEG 400 on the absorption of a drug whose absorption is 
not controlled by P-gp. Metformin (a non-Pgp substrate) was consequently chosen 
as a model drug and its absorption in the absence and presence of PEG 400 is 
discussed in the following section. 
 
 
 
 
 
 
 
 
  Chapter 2 
89 
 
2.3.3.3 Metformin 
The influences of PEG 400 on metformin are shown in Figures 2.11, Figure 2.12 
and Table 2.11. It can be seen that the presence of PEG 400 caused no change in 
metformin bioavailability in either males or females (p>0.05). As expected, any 
influence of PEG 400 on P-gp had no resulting effect on the absorption of 
metformin, which is not a substrate for P-gp. 
Figure 2.11 Plasma concentration-time profile of metformin in the absence and 
presence of PEG 400 over 8 hours in male and female Wistar rats (Mean ± S.D., 
n=6).* Value is statistically different at p<0.05. 
 
Briefly, the metformin AUC0-480 for the male and female rats was 
31.2±5.22µg.min/mL and 39.7±11.2µg.min/mL, respectively. The bioavailability 
of metformin was decreased by 5.38% in the presence of PEG 400 in the male group. 
However, the metformin AUC0-480 in the female group noted a different trend 
compared to the male partners. It increased to 47.5±8.1µg.min/mL (19.7%) with no 
statistical significance obtained in both male and female PEG 400 groups.  
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Figure 2.12 Mean AUC0-480 of metformin in the presence and absence of PEG 400 
in male and female Wistar rats (Mean ± S.D., n=6). *Values are statistically 
different between the control and PEG groups at p<0.05. 
 
 
Table 2.11 Influence of 26mg/kg PEG 400 on the pharmacokinetic parameters of 
metformin in male and female rats (mean±S.D., n=6). 
Pharmacokinetic 
Parameters 
Male Female 
Control PEG 400 Control PEG 400 
AUC0-480 
(μg.min/mL) 
125.68±12.03 114.30±19.17 118.53±11.93 121.16±12.95 
AUC∞ (μg.min/mL) 130.02±12.00 117.47±20.04 128.79±13.97 125.35±14.00 
cmax (μg/mL) 0.61±0.13 0.49±0.14 0.45±0.06 0.51±0.07 
tmax (min) 97.50±24.65 125.00±47.12 135.00±59.25 75.00±31.82 
CL (mL/min) 0.09±0.008 0.11±0.02 0.10±0.01 0.10±0.01 
Vd (mL) 13.30±1.98 18.88±5.63 18.24±3.09 14.95±3.52 
t1/2 (min) 100.08±14.80 118.80±22.83 129.28±17.81 102.03±14.04 
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Our data on ampicillin and metformin perfectly support the hypothesis that the sex 
differences in the effect of PEG 400 on the bioavailability of ranitidine was 
attributed to the sex-associated interaction between PEG 400 and P-gp. However, 
the presence of PEG 400 did not show sex-dependent impact on the bioavailability 
of P-gp-mediated fexofenadine.  
Moreover, the tested drugs are also substrates for other transporters in liver or 
kidney. Briefly, metformin was reportedly modified by PMAT which is expressed 
in human intestine; OCT-2 in kidney and OCT-1 in liver (Kimura et al., 2005a, 
Kimura et al., 2005b, Terada et al., 2006). Ampicillin was also reported to 
upregulate xCT and GLT-1 isoforms expression (Alasmari et al., 2015). Therefore, 
our hypothesis is needed to be further confirmed, and proceeded to Phase II. 
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Phase II 
2.4 MATERIALS AND METHODS 
2.4.1 Materials  
Ampicillin sodium and cyclosporine A was obtained from VWR International 
(Lutterworth, UK) and Cambridge Bioscience (Cambridge, UK) respectively. 
Ranitidine hydrochloride and polyethylene glycol 400 were supplied by Sigma-
Aldrich (Dorset, UK). HPLC-grade reagents such as acetonitrile, methanol and 
glacial acetic acid were purchased from Fisher Scientific (Loughborough, UK). 
Analytical grade reagents such as ammomium acetate and sodium dihydrogen 
phosphate were procured from VWR International (Lutterworth, UK).  
 
2.4.2 Animals 
All the animal work was approved by the UCL School of Pharmacy’s ethical review 
committee and was conducted in accordance with the home office standards under 
the Animals (Scientific Procedures) Act, 1986. Healthy male and female, 8 to 13 
weeks old Wistar rats (Harlan UK Ltd, Oxfordshire, UK) weighing 150-250 g were 
used. The rats were housed at controlled temperatures (25℃) and humidity (50-
60%) with a constant light-dark cycle of 12h, provided with food and water, and 
were acclimatized for 7 days before being studied. 
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2.4.3 Time-dependent inhibition study in ranitidine 
The day before the experiment, all the rats were fasted overnight and individually 
housed in metabolic cages. 
Each rat was weighed on the day of the experiment and administered orally with 
50mg/kg CsA solution. 0min, 15min, 30min or 60min later, they were administered 
50mg/kg ranitidine using an oral gavage syringe. Then, the rats were placed 
individually in a metabolic cage and were allowed to move freely until blood 
collections. 
The appropriate period of CsA administration prior to drug treatment (which was 
used in the following ampicillin and metformin study) was chosen based on the CsA 
pre-treatment timing which could result to the greatest enhancement in ranitidine 
bioavailability in this section.  
 
2.4.4 Effect of CsA on the ampicillin and metformin 
bioavailability 
The rats were orally administered an appropriate volume of cyclosporine A 
suspension for a dose of 50mg/kg. 15 minutes later, a solution of ampicillin, 
metformin or ranitidine at a dose of 50mg/kg in the absence or presence of PEG 
400 (at 26mg/kg) was administered via oral gavage. After dosing, approximately 
250μL-300μL of blood was collected from the tail vein of rats into anticoagulant 
centrifuge tubes (BD Microtainer® K2E Becton, Dickinson and Company, USA) 
at 0.5, 1.25, 2, 3, 4 and 6h. At 8h post-administration, the rats were sacrificed with 
a CO2 euthanasia chamber and about 1mL of blood was taken via cardiac puncture 
immediately. 
15 minutes before drug administration was chosen as the appropriate time to give 
the P-gp inhibitor, according to the study on the influence of timing using ranitidine 
as the drug in Section 2.4.3. 
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2.4.5 Sample preparation 
Blood samples were centrifuged at 10,000rpm for 10min, and the supernatants 
(plasma samples) were collected into 1.5mL Eppendorf tubes.  
For ranitidine, the samples were prepared using a reported method (Afonso-Pereira 
et al., 2016). 50µL of the supernatant was placed into a 1.5mL Eppendorf tube, and 
the same volume of acetonitrile was added to precipitate the plasma proteins. After 
1 min of vortex-mixing, 100µL HPLC grade water was added to the mixture, which 
was vortex-mixed again for 30s, and centrifuged at 4ºC for 10 min at 10000rpm. 
The supernatant was collected and 40µL aqueous was analyzed by HPLC. For the 
ampicillin and metformin samples, the methods were described in phase I. 
2.4.6 Chromatographic analysis 
The amount of drug in the withdrawn samples was quantified using a high 
performance liquid chromatography (HPLC) system (Agilent Technologies, 1260 
Infinity) equipped with a pump (model G1311C), autosampler (model G1329B) and 
a diode-array UV detector (model G1314B).  
The ranitidine sample was subjected to HPLC-UV analysis using a previously 
validated method (Ashiru et al., 2007). The column used was a 5µm Luna SCX 
(Phenomenex, UK); the mobile phase was a mixture of 20:80 (acetonitrile):(0.1M 
sodium acetate pH=5.0) with a flow rate of 2ml/min and 40µL of injection volume. 
Methods for ampicillin and metformin samples were described in phase I. 
2.4.7 Pharmacokinetic analysis 
Pharmacokinetic parameters, (Cmax, tmax, AUC0-480, AUC∞, CL, Vd and t1/2) were 
calculated by non-compartmental analyses using a free Microsoft Excel add-in, 
“PKSolver.” (Zhang et al., 2010).  
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2.4.8 Statistical analysis 
All results are expressed as mean ± SD (n = 6). The control and test group data were 
analyzed by one-way ANOVA, followed by post-hoc Tukey analysis with a 95% 
confidence interval using IBM SPSS Statistics 16 (SPSS Inc., Illinois, USA). 
Repeated measures ANOVA was conducted to assess any statistically significant 
differences along the absorption profiles.  
 
2.5 RESULTS AND DISCUSSION 
2.5.1 Time-dependent inhibition study in ranitidine  
A greater response to the effect of CsA on the ranitidine bioavailability was 
observed in males compared with female ones (shown in Table 2.12 and Figure 
2.13). When the male rats were pre-treated with CsA 0, 15, 30 and 60min before 
being given ranitidine, the ranitidine AUC0-480 was enhanced by 84%, 113%, 103% 
and 88% compared with the control (which only received ranitidine). Pronounced 
bioavailability enhancement was obtained with the 15min earlier treatment of CsA 
before ranitidine administered, a 113% increase (p<0.05).  
For the females, significant increases in mean ranitidine AUC0-480 by CsA were also 
observed, where increases of 38%, 42%, 46% and 50% over the control were found 
in the presence of 0, 15, 30 and 60min CsA pre-treatment. Most significant increase 
was found in 60min pre-treatment with CsA, which was not consistent with that in 
males (shown in Figure 2.14). 
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A 
 
           B 
Figure 2.13 Plasma concentration-time curve of ranitidine over 8 hours in male (A) 
and female (B) rats that untreated (control), 0min, 15min, 30min and 60min pre-
treated with CsA (Mean ± S.D., n=5). * Value is statistically different at p<0.05.
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Table 2.12 The pharmacokinetic parameters of ranitidine in the male and female CsA pre-treated Wistar rats (Mean±S.D., n=5). 
Pharmacokinetic 
Parameters 
     Control 
   (in the absence of CsA) 
CsA Administered Time before Given Ranitidine (min) 
0# 15 30 60 
Male 
AUC0-480 (μg.min/mL) 350.24 ± 32.82 646.15 ± 93.88 * 746.91 ± 39.45 * 711.11 ± 60.03 * 660.14 ± 33.34 * 
AUC∞ (μg.min/mL) 569.72 ± 164.76 875.44 ± 175.70* 947.89 ± 70.99 * 888.52 ± 112.68 * 809.98 ± 62.42 * 
cmax (μg/mL) 1.59 ± 0.75 2.57 ± 0.89 * 2.89 ± 0.58 * 3.31 ± 0.48 * 2.77 ± 0.21 * 
tmax (min) 116.25 ± 90.31 126.00 ± 52.61 168.00 ± 50.20 114.00 ± 53.67 135.00 ± 45.00 
CL (mL/min) 0.02 ± 0.005 0.01 ± 0.003 0.01 ± 0.001 0.01 ± 0.002 0.02 ± 0.001 
Vd (mL) 11.83 ± 5.13 5.63 ± 1.29 * 5.45 ± 1.13 * 4.67 ± 0.60 * 5.02 ± 1.39 * 
t1/2 (min) 406.56 ± 37.35 276.02 ± 100.84* 288.27 ± 70.05 * 231.61 ± 46.91 * 228.57 ± 83.04 * 
 
Female 
AUC0-480 (μg.min/mL) 421.26 ± 49.15 581.65 ± 66.75 * 599.27 ± 39.06 * 616.04 ± 46.17 * 631.51 ± 26.55 * 
AUC∞ (μg.min/mL) 526.07 ± 64.79 723.87 ± 46.88 * 702.80 ± 60.89 * 735.66 ± 47.23 * 736.63 ± 29.89 * 
cmax (μg/mL) 1.88 ± 0.27 2.93 ± 0.68 * 2.56 ± 0.33 * 2.38 ± 0.13 2.84 ± 0.48 * 
tmax (min) 117.00 ± 78.23 156.00 ± 32.86 123.00 ± 37.35 138.00 ± 71.47 93.00 ± 24.65 
CL (mL/min) 0.02 ± 0.003 0.02 ± 0.001 0.02 ± 0.002 0.02 ± 0.001 0.02 ± 0.0007 
Vd (mL) 7.85 ± 1.21 6.52 ± 2.10 4.92 ± 0.95 5.24 ± 1.00 4.29 ± 0.58 
t1/2 (min) 230.60 ± 53.60 261.15 ± 84.76 193.31 ± 51.18 214.69 ± 47.71 175.56 ± 29.20 
# Administer the same time with ranitidine 
* Values are statistically different between the control and CsA groups at p<0.05. 
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Figure 2.14 Mean AUC0-480 of ranitidine in the absence and presence of CsA with 0, 15, 30 and 60min pre-treatment (Mean±S.D., n=5).  
* Values are statistically different between the control and CsA groups at p<0.05.
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2.5.2 Influence of CsA on the bioavailability of ranitidine, 
ampicillin and metformin 
We hypothesized that if the sex-related influence of PEG 400 on the bioavailability 
of certain drugs was a result of its influence on P-gp, blocking the latter with a P-
gp inhibitor would remove the effect of PEG 400 on the bioavailability of the P-gp 
substrates (ampicillin and ranitidine), but would have no influence on the 
absorption of the non-P-gp substrate (metformin). To test this hypothesis, male and 
female rats were pre-treated with the P-gp blocker CsA at 15min prior to 
administration of ampicillin, ranitidine or metformin in the absence or presence of 
PEG 400.  
As expected, pre-treatment with CsA did not change the bioavailability of 
metformin in either male or female rats (p>0.05) (shown in Table 2.13 and Figure 
2.15). In contrast, pre-treatment with CsA increased ampicillin bioavailability in 
both males and females (p<0.05), with the percentage increase in bioavailability 
being higher in males than in females (132% vs 42%). Addition of PEG 400 in CsA 
pre-treated rats had no significant effect on the drug bioavailability in either male 
or female rats, compared to the CsA pre-treated rats (p>0.05) (Table 2.13 and Figure 
2.16), i.e. once P-gp have been blocked by CsA, PEG 400 had no influence as its 
site of action was not available. The results are in a good agreement with our 
hypothesis that sex-specific influence of PEG 400 on drug bioavailability are 
mediated via the action of PEG 400 on the efflux transporter P-gp.  
Similar results were observed for ranitidine (Table 2.13 and Figure 2.17). When the 
rats were pre-treated with CsA 15min before being given ranitidine, the ranitidine 
AUC0-480 was increased by 113% in males and 42% in females, respectively, 
compared with the controls (which only received ranitidine). Meanwhile, in the CsA 
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pre-treated rats, no effect of PEG 400 on ranitidine bioavailability was observed in 
either male or female rats. 
 
Table 2.13 Effect of CsA on the pharmacokinetic parameters of ampicillin, 
ranitidine and metformin in male and female Wistar rats (Mean±S.D., n=5). * 
Values are statistically different between the control and CsA groups at p<0.05. 
Pharmacokinetic 
Parameters 
Male Female 
Control 50mg/kg CsA Control 50mg/kg CsA 
Ampicillin     
AUC0-480 
(μg.min/mL) 
528±52 1209±186 * 640±43 892±89 * 
AUC∞ (μg.min/mL) 577±74 1287±185 * 734±31 1003±57 * 
cmax (μg/mL) 3±0.3 6±1 * 3±0.6 4±1 
tmax (min) 109±23 105±56  122±33 123±37 
CL (mL/min) 0.02±0.003 0.01±0.001 0.02±0.0007 0.013±0.0008 
Vd (mL) 5±1 2±0.4 4±0.7 4±1 
t1/2 (min) 156±43 137±17 148±28 196±60 
     
Ranitidine 
AUC0-480 
(μg.min/mL) 
350±33 747±39 * 421±49 599±39 * 
AUC∞ (μg.min/mL) 570±165 948±71 * 526±65 703±61 * 
cmax (μg/mL) 2±0.8 3±0.6 * 2±0.3 3±0.3 * 
tmax (min) 116±90 168±50 117±78 123±37 
CL (mL/min) 0.02±0.005 0.01±0.001 0.02±0.003 0.02±0.002 
Vd (mL) 12±5 5±1 * 8±1 5±1 
t1/2 (min) 407±37 288±70 * 231±54 193±51 
     
Metformin     
AUC0-480 
(μg.min/mL) 
126±12 127±18 119±12 106±20 
AUC∞ (μg.min/mL) 130±12 136±18 129±14 147±29 
cmax (μg/mL) 0.6±0.1 0.6±0.06 0.5±0.06 0.5± 0.1 
tmax (min) 98±25 105±46 135±59 138±58 
CL (mL/min) 0.09±0.008 0.09±0.01 0.1±0.01 0.09±0.01 
Vd (mL) 13±2 19±3 18±3 16±4 
t1/2 (min) 100±15 142±16 129±18 150±39 
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Figure 2.15 Mean AUC0-480 of metformin in the presence or absence of PEG 400 in 
male and female cyclosporine A pre-treated rats (Mean ± S.D., n=6). 
 
Figure 2.16 Mean AUC0-480 of ampicillin in the presence or absence of PEG 400 in 
male and female pre-treated rats with cyclosporine A (Mean ± S.D., n=6). *Values 
are statistically different from those in the control and tested groups at p<0.05. 
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Figure 2.17 Mean AUC0-480 of ranitidine in the presence or absence of PEG 400 in 
male and female pre-treated rats with cyclosporine A (Mean ± S.D., n=6). *Values 
are statistically different from those in the control and tested groups at p<0.05. 
As seen in the results, the influence of PEG 400 and CsA on the bioavailability of 
P-gp substrates depends on the sex of the animals, i.e. a greater response was 
observed in male rats compared to female ones, suggesting higher P-gp activity 
and/or expression in male rats than female ones. 
Higher P-gp activity in males compared to females has previously been suggested 
in a study, where the effect of PSC833 (a P-gp inhibitor) on the intestinal transport 
of two P-gp-mediated drugs, ivermectin and Rho 123, was investigated using 
tissues from male and female rats (Ballent et al., 2012, Mariana et al., 2011). Greater 
ivermectin accumulation was observed in male intestines (by 141%) compared to 
female ones (by 14%). Similar results were observed for Rho 123, in which its 
efflux ratio significantly decreased from 4.33 to 1.51 in males (p<0.05) but not in 
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females. While the reasons for greater P-gp activity in males compared to females 
have not been established, we speculate that the differential P-gp activity is 
modulated by P-gp modifying-mechanisms which may themselves be influenced 
by the sex of organism. For example, CsA alters the P-gp activity by inhibiting both 
the substrate stimulated- and the basal- P-gp ATPase (Watanabe et al., 1997), while 
PEG influences the function of P-gp by producing mitochondrial toxicity and 
depleting the amount of intracellular ATP (Johnson et al., 2002). Sex-related 
differences in the variations in P-gp ATPase or ATP level in cells could cause sex 
differences in the interaction between CsA/PEG and P-gp. Further work is needed 
to clarify the mechanisms underlying this phenomenon.   
In addition to P-gp activity, sex-related differences in P-gp expression could also 
explain our results. Sex difference in the expression of P-gp was first proposed in 
liver (Schuetz et al., 1995b) and later reported in the intestine (Gerrard et al., 2004), 
where men were reported to have higher hepatic and enterocyte P-gp content than 
women. However, no sex-based difference in P-gp expression have been proposed 
in the upper duodenum (Paine et al., 2005b). Meanwhile, no sex-related differences 
in the intestinal P-gp protein content and mRNA expression were found (MacLean 
et al., 2008). The fact that rats were fed in this study (while fasted rats were used in 
our in vivo studies) shows that the possibility of sex-based differences arising in the 
intestines of fasted rats cannot be excluded, given that the fed/fasted states have 
been shown an impact on P-gp and other membrane transporters (Deferme and 
Augustijns, 2003, Deferme et al., 2003, Furumiya and Mizutani, 2008). 
P-gp activity has been found to be largely similar in rats and humans (Li et al., 2015, 
Li et al., 2017). Based on this, the observed influence of PEG 400 (in this paper) on 
the bioavailability of P-gp substrates has implications for drug usage in humans. 
Indeed, we have already shown differential effects of PEG 400 on the oral 
bioavailability of ranitidine in men and women (Ashiru et al., 2008). It suggested 
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that the bioavailability of a drug which is a P-gp substrate and which is formulated 
with PEG 400 as an excipient will be higher in men compared to women, with the 
possibility that the therapeutic level will not be reached in women.  
 
2.6 CONCLUSION 
The work reported in this chapter further enhances our understanding of the 
influence of the supposedly inactive excipient PEG 400 on drug bioavailability, 
specifically its different action depending on the sex of the organism. We confirmed 
that PEG 400 had a greater drug bioavailability-enhancing influence in males 
compared to females, such as ranitidine and ampicillin. Importantly, the sex-related 
influence of PEG 400 occurred only for drugs whose absorption is controlled by the 
efflux transporter P-gp. Thus, blocking of P-gp by cyclosporine A (a P-gp inhibitor) 
eliminated the effect of PEG 400 on the bioavailability of ampicillin and ranitidine. 
Cyclosporine A blocking of P-gp had its own sex-related effect on drug 
bioavailability. This differential sex-based influence on drug bioavailability could 
be due to greater P-gp activity and/or expression in males compared to females, as 
suggested by some existing literature. Given that many compounds are P-gp 
substrates and/or modulate P-gp activity, increasing attention to this topic is needed 
for an optimal usage of excipients. 
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CHAPTER 3: Predictive Techniques: Is in 
vitro data sufficient to correlate PEG 400 in 
vivo effects on drug absorption? 
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3.1 INTRODUCTION 
The hypothesis in chapter 2 (the reason behind PEG’s sex-specific impact on the 
ranitidine bioavailability was attributed to a greater P-gp function in males 
compared to females) was suggested according to the previous in vivo studies. In 
light of countless physiological factors involved in oral drug absorption in vivo 
(namely, GI transmit time as well as the activity and composition of intestinal 
bacteria), an in vitro study was required in order to further explore the reason behind 
the sex-related effect of PEG 400 on ranitidine absorption. Similarly, such an in 
vitro method could also be used to investigate the sex-dependent influence of other 
excipients on drug transport in animal models or even humans. Consequently, the 
aim of the study in this chapter was to explore the impact of PEG 400 on the 
permeation of ranitidine in the absence and presence of P-gp inhibitor and 
cyclosporine A (CsA) in four intestinal divisions of male and female rats with the 
Ussing chamber system, which has been widely used in evaluating intestinal drug 
permeation. 
Current approaches characterizing drug absorption via the intestine have been 
conduction on a variety of models: in vitro (tissue- or cultured cell-based), in situ 
and in vivo intestinal perfusion, and in silico methods (Hillgren et al., 1995, Le 
Ferrec et al., 2001, Reis et al., 2013). For many reasons, although particularly due 
to financial and ethical considerations, in vitro approaches have been pursued in 
this area for decades due to the good agreement between intestinal permeability 
results in specific animals and human subjects (Luo et al., 2013, Antunes et al., 
2013).  
The purpose of any in vitro model is to perform various studies under well-
controlled and easily accessed conditions without using living animals (Roeselers 
et al., 2013). Moreover, for mechanistic studies aiming to elucidate cellular 
processes, a simple cell-line model may be accurate. However, feedback 
mechanisms are lost in most in vitro cell culture models. Additionally, cell culture 
models cannot reflect sex-related characters, which is a necessity in our studies. 
Therefore, if extrapolating in vitro data to the in vivo situation is required, the model 
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must reflect the complexity of the questions being asked. In this context, functional 
organs or tissue ex vivo show extensive interaction and crosstalk with different cell 
lines.  
In in vitro tissue-based models, also called ex vivo models, experiments include 
procedures with living functional tissues or organs isolated from an organism and 
cultivated outside the organism in an artificial environment under highly controlled 
conditions (Agu et al., 2008).  
3.1.1 Ussing Camber 
The Ussing chamber technique was first developed by Ussing and Zerahn (1951) 
to study transepithelial ion transport across frog skin, then later adapted by Grass 
and Sweetana (1988) (Sweetana-Grass diffusion chamber) to evaluate the intestinal 
permeability of drugs. So far, several modifications of the classical Ussing chamber 
were made to improve the performance of this model. Currently, several variants of 
the Ussing chamber are available for permeability studies across epithelial tissues. 
They can vary in size, volume and area of exposed tissue (Clarke, 2009).  
In this model, a section of intestinal tissue is excised, cut in small segments of an 
appropriate size and opened to form a flat epithelial sheet that is placed between the 
two halves of the chamber. The chambers are filled with a physiological buffer, 
continuously gassed with O2/CO2 (95%/5%) and warmed up to 37 °C (Antunes et 
al., 2013). The O2/CO2 mixture not only ensures adequate oxygenation of the tissue 
but also provide a layer that jeopardizes the permeability of poorly soluble 
compounds (Buckley et al., 2012). A schematic representation of the classical 
Ussing chamber is presented in Figure 3.1.  
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Figure 3.1 A presentation of the Ussing chamber system used for the permeation 
study in this chapter. 
The EVOMX voltohmmeter and Ag/AgCl electrodes were used to measure the 
transepithelial electrical resistance (TEER) of the tissue samples. TEER monitors 
the presence of functional tight junction, which are responsible for the barrier 
function and which limit paracellular permeation of water and solutes. The 
resistance is measured by applying a voltage and measuring the change in current 
across the tissue by Ohm's law. Any duodenum, jejunum, ileum and colon segments 
that presented a value of TEER lower than 20Ω•cm2, 40Ω•cm2, 50Ω•cm2 and 
70Ω•cm2 respectively, at the beginning of experiment was regarded poorly viable 
and excluded immediately (Polentarutti et al., 1999). Whenever TEER values 
decreased more than 15% from the value measured at the end of equilibration period, 
the tissue was considered not viable. 
Ussing chamber experiments including tissue preparation, the choice of an adequate 
incubation buffer, and the motorization of tissue viability and integrity. All these 
factors could influence the permeability of drugs.  
 
O2/CO2 (95%/5%) O2/CO2 (95%/5%) 
Tissue Sample 
Ag/AgCl Eletrodes 
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3.1.2 Everted Intestinal Sac 
The everted gut technique was another popular ex vivo method, first introduced by 
Wilson and Wiseman (1954) to study absorption of compounds along the intestine 
of rat and golden hamster (Balimane et al., 2000, van de Kerkhof et al., 2007). 
Currently, this technique can be used as in vitro tool to study the mechanisms and 
kinetics of drug absorption. It has also been extensively explored to carry out 
pharmacokinetic investigations such as drug absorption, drug metabolism, 
multidrug resistance, drug interactions and the impact of efflux transport 
modulators on the absorption of drugs (Alam et al., 2013). In the everted gut model, 
a section of the intestine (about 2-4cm) is quickly removed from the anesthetized 
animal, flushed with buffer or a saline solution and everted over a rod or tube 
(Bohets et al., 2001, Volpe, 2010). The serosa becomes the inside of the sac and the 
mucosa faces the outer buffer solution (Lennernas et al., 1997). Each end of the sac 
is tied and filled with oxygenated buffer and placed in a container with the test drug; 
accumulation in the inner compartment is measured after a specified time period. 
The everted intestinal sac system is observed in Figure 3.2.  
 
Figure 3.2 Design of the device used for the everted gut sac intestinal permeation 
assay, (Quevedo and Brinon, 2009). 
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3.1.3 Comparison 
The various experimental protocols for predicting the fraction absorbed in humans 
or rats from permeability coefficients have their own advantages and limitations 
(shown in Table 3.1). Comparing with other ex vivo methodologies, the Ussing 
chamber system lends itself to fast and reproducible intestinal absorption studies, 
which is very useful for interspecies comparison and position specific transport, 
suitable in vitro methods in our study (Acra and Ghishan, 1991, Fortuna et al., 2012).  
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Table 3.1 Advantages and limitations of various in vitro models. 
Techniques Advantages Limitations 
Everted Intestinal Sac/Rings 
(Rats)  
 All cell types and the mucous layer are present. 
 A relatively fast and inexpensive technique. 
 Can be used for mechanism of absorption or formulation studies. 
 Not a perfused model. 
 The drug must cross the whole intestinal wall. 
 It is an animal model. 
 
Ussing Camber 
(Human and Rats) 
 Drug absorption and passage at specific intestinal sites (human, rat) 
are possible.      
 The test drug can be added on either the apical or the basolateral 
side. 
 Metabolism studies are possible. 
 A human and animal model. 
 Measurement techniques must be sensitive, 
since the drugs are diluted in the diffusion 
chambers. 
 Cell viability is limited. 
 Availability of human tissue is limited. 
 Not used for screening. 
Intestinal Perfusion  
(Human and Rats) 
 It is a reference model. 
 All physiological factors that influence passage are present. 
 Allows studies in humans. 
 Good correlation with pharmacokinetic studies. 
 A difficult technique with local anaesthesia at 
the time of catheter introduction. 
 Not used either in development or routinely. 
 
In situ Techniques  
(Rats) 
 Integrates passage and metabolism aspects. 
 All physiological factors that influence passage are present. 
 Studies of absorption in particular sites of the intestine are possible. 
 Studies of direct effects of the drug on intestinal absorption are 
possible. 
 Used in development, but not routinely. 
 The increase of luminal hydrostatic pressure 
during the experiment can influence intestinal 
permeability. 
 It is an animal model. 
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3.2 MATERIALS AND METHODS 
3.2.1 Materials  
Ranitidine hydrochloride and polyethylene glycol 400 (PEG 400) were purchased 
from Sigma-Aldrich (Poole, UK). Cyclosporine A (CsA) was purchased from 
Cambridge Bioscience (Cambridge, UK). HPLC-grade reagents such as acetonitrile 
and glacial acetic acid were supplied by Fisher Scientific (Loughborough, UK). 
Krebs-Bicarbonate Ringer’s solution (KBR) was prepared with 10mM D-glucose, 
1.2mM CaCl2, 1.2mM MgCl2, 115mM NaCl, 25mM NaHCO3, 0.4Mm KH2PO4, 
2.4mM K2HPO4, and pH was adjusted to 7.4 with NaOH/HCl (Clarke, 2009). 
3.2.2 Animals 
All the animal work was approved by the UCL School of Pharmacy’s ethical review 
committee and was conducted in accordance with the home office standards under 
the Animals (Scientific Procedures) Act, 1986. Healthy male and female, 8-13 week 
old Wistar rats (Harlan UK Ltd, Oxfordshire, UK) weighing 150-25g were used for 
excised rat intestine. The rats were housed at controlled temperatures (25℃) and 
humidity (50-60%) with a constant light-dark cycle of 12h, provided with food and 
water, and were acclimatized for 7 days before being studied. One day before the 
experiments, the rats were fasted overnight and housed individually in the 
metabolic cages. 
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3.2.3 Compound stability in an Ussing chamber system 
Ranitidine solution containing 3mM drug in the absence and/or presence of PEG 
400 were prepared in KBR solution. CsA was suspended in KBR buffer at 8 μM. 
The stability of ranitidine and CsA in KBR solution was assessed by incubating the 
drug in KBR buffer at 37℃ for 180 mins, following quantifying the drugs with 
HPLC methods. The dose of sample withdrawn at 180 mins was compared with the 
drug concentration obtained at the beginning of the assay. 
3.2.4 Mucosal tissue preparation 
On the day of experiment, rats were sacrificed in a CO2 euthanasia chamber and 
their intestines were rapidly removed. The intestine was cut into 4 segments: 
duodenum, jejunum, ileum and colon, which were added to beakers containing ice-
cold KBR solution. The intestinal segments were allowed to rest for approximately 
20 mins after lowering the tissue temperature to minimize tissue damage during 
preparation. Approximately 2-3cm long pieces from the mid part of the duodenum, 
proximal part of the jejunum, the distal to mid part of ileum and ascending colon 
were opened along their mesenteric border. The tissues were washed gently with 
KBR solution to remove the intestinal contents. To obtain the mucosal tissue, 
sections were placed on an ice-cold glass plate and the serosa was gently squeezed 
out. 
3.2.5 Ussing chamber set-up 
Once the mucosal tissues were well prepared, they were mounted in the vertical 
Ussing Chamber (Harvard Apparatus Inc., Holliston, MA, U.S.A) as flat sheets on 
a 0.28 cm2 segment holder with needles to stabilize it. The mucosal surface of the 
tissue was facing the apical chamber, and the endothelial surface of the tissue was 
facing the basolateral chamber. 5 mL blank KBR solution was added to both apical 
and basolateral chambers, gassed with an O2/CO2 (95%/5%) gas mixture. The 
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chambers were tightly screwed with high spring-tension retaining rings and the 
entire assembly was kept at 37℃ with a circulating water bath for an equilibrium 
period. 
To evaluate tissue integrity during experiments, tissue transepithelial electrical 
resistance (TEER) was measured using an EVOMX meter (World Precision 
Instruments Inc., WPI, Hertfordshire, United Kingdom) every 30min during the 
experiment. Any duodenum, jejunum, ileum and colon segments that presented a 
value of TEER lower than 20Ω•cm2, 40Ω•cm2, 50Ω•cm2 and 70Ω•cm2, respectively, 
at the beginning of experiment was regarded as poorly viable and excluded 
immediately. Whenever TEER values decreased more than 15% from the value 
measured at the end of equilibration period, the tissue was considered not viable. 
3.2.6 Bidirectional transport 
After an equilibrium period of 20-30 mins, the experiment was started by replacing 
the blank KBR solution with pre-warmed 3mM ranitidine solution in the donor 
compartment. For the absorptive transport (mucosa to serosa, M-S), the donor was 
the apical chamber, while for the excretive transport (serosa to mucosa, S-M), the 
donor was the basolateral chamber. The permeation experiment lasted 3h, and 
100μL of receiver solution was withdrawn every 30min in order to measure the drug 
amount. An equal volume of heated blank KBR solution was added immediately 
after each sample was withdrawn.  
3.2.6.1 Effect of PEG 400 on ranitidine permeability in the absence 
of CsA 
This study is processed with ranitidine in the absence or presence of 0.25%, 0.5%, 
1%, 1.5%, 2% or 3% PEG 400 in the apical chamber. The dose of PEG 400 that 
caused a pronounced ranitidine permeability enhancement was used to assay its 
effect on the secretive transport of ranitidine, and also to assess the influence of 
PEG 400 on ranitidine intestinal transport in the presence of P-gp inhibitor, CsA. 
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3.2.6.2 The effect of PEG 400 on ranitidine permeability in the 
presence of CsA 
The effect of a validated P-gp inhibitor (CsA) on the bidirectional transport of 
ranitidine was investigated. CsA was added to the apical chamber at a final 
concentration of 8μM. 15min later, ranitidine was added into the apical camber 
(absorptive) or basolateral chamber (secretive) in the absence and/or presence of 
PEG 400. 
15min pre-incubation with CsA before addition of drug solution was chosen as the 
appropriate time to give the P-gp inhibitor following a study on the influence of 
timing. In this study, P-gp inhibition was conducted by incubation intestinal tissue 
with CsA at the same time or 15min, 30min or 60min before adding 3mM ranitidine. 
The results showed the greatest inhibitory influence of CsA on ranitidine 
permeatability, when intestinal tissue was 15min pre-incubation with CsA prior to 
the addition of ranitidine in donor chamber. 
3.2.7 Chromatographic analysis 
The amount of drug in the withdrawn samples was quantified using a high 
performance liquid chromatography (HPLC) system (Agilent Technologies, 1260 
Infinity) equipped with a pump (model G1311C), autosampler (model G1329B) and 
a diode-array UV detector (model G1314B).  
For the analysis of ranitidine, a 5µm Luna SCX column (Phenomenex, UK) was 
used for sample separation using a mixture of 20:80 (acetonitrile):(0.1M sodium 
acetate pH=5.0) as mobile phase for elution, with a flow rate of 2mL/min (Ashiru 
et al., 2008, Xu et al., 2013).  
In the case of CsA, separation was achieved on a 3μm Luna C8(2) column 
(Phenomenex, UK). The elution was isocratic at 1mL/min with a mobile phase of 
acetonitrile–water–phosphoric acid (750:250:1,v/v/v). 
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3.2.8 Calculation 
The apparent permeability coefficient (Papp) of each experiment, in cm/s, was 
calculated using the equation followed: 
𝑃𝑎𝑝𝑝 =
𝑄
𝐶 ▪ 𝐴 ▪ 𝑡
 
where Q (μmol) is the total amount of drug that permeated to the receiver 
compartment throughout the incubation time, C (μmol/mL) is the initial drug 
concentration in the donor side, A (cm2) is the diffusion area of the Ussing Chamber, 
and t (s) is the time of experiment. 
To study ranitidine efflux, an efflux ratio is calculated from the mean serosal-to-
mucosal (S-M) Papp and mucosal-to-serosal (M-S) Papp data, as followed: 
Efflux Ratio =  
𝑃𝑎𝑝𝑝 (𝑆 − 𝑀)
𝑃𝑎𝑝𝑝 (𝑀 − 𝑆)
 
3.2.9 Statistical analysis 
The experiments were performed at least six times and data were expressed as Mean 
± standard deviation (S.D.). Significant differences between groups were analysed 
by one-way ANOVA and three-way ANOVA using IBM SPSS Statistics 19 (SPSS 
Inc., Illinois, USA). A minimum p value of 0.05 was used as a significance level 
for the tests. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 Influence of animal’s sex on the transport of 
ranitidine 
The absorptive and secretive permeability of ranitidine in different intestinal 
segments of male and female rats, presented as the apparent permeability coefficient 
(Papp), are shown in Figure 3.3. 
Sex differences were observed for both absorption and secretion of ranitidine. 
Ranitidine intestinal absorption (Papp mucosa-serosa, M-S) for jejunum, ileum and 
colon was higher in female rats compared to male rats, while its secretion (Papp 
serosa-mucosa, S-M) was larger in males (p<0.05). Contrary to the other intestinal 
segments, no differences was observed between male and female duodenum.  
Greater ranitidine absorption but lower secretion in females (Figure 1) would be 
expected to lead to higher bioavailability of ranitidine in females compared to males 
in vivo. Surprisingly, this was not the case, which reported no sex-based differences 
in the ranitidine bioavailability in rats. We speculated the contrast between in vitro 
and the in vivo data (Afonso-Pereira et al., 2016) is due to higher ranitidine 
metabolism in females compared to males. Ranitidine is metabolised by CYP3A 
(Penston and Wormsley, 1986), and women reportedly have higher CYP3A 
metabolism than men (Wolbold et al., 2003).  
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A 
B 
Figure 3.3 Absorptive (A) and secretive (B) transport of ranitidine across the 
intestine of male and female Wistar rats (Mean ± S.D., n=6). * Values are 
statistically different between the male and female groups at p<0.05. 
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3.3.2 Influence of intestinal region on the transport of 
ranitidine 
Figure 3.4 and Figure 3.5 represent the time course of transport of ranitidine in 
different intestinal segments of male and female rats. It can be seen that the 
absorptive and secretive transport of ranitidine in small intestine (duodenum, 
jejunum and ileum) were higher than in colon (p<0.05). When it comes to three 
divisions in small intestine, the absorption of ranitidine did not exhibit a regional 
difference (it was similar in the duodenum, jejunum and ileum). In contrast, 
ranitidine secretion was found to differ between intestinal segments, which was 
greatest in the jejunum and ileum, and lowest in the duodenum. 
Our data about the absorptive transport of ranitidine in the intestine of male and 
female rats supported the previous study, where ranitidine was reported to be 
primarily absorbed in the ileum as compared to the duodenum and jejunum 
(Mummaneni and Dressman, 1994).  
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A 
B 
Figure 3.4 Time course of the apparent permeability coefficients considering 
absorption (mucosal-to-serosal, M-S) of ranitidine in the male (A) and female (B) 
Wistar rats (Mean ± S.D., n=6). 
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A 
B 
Figure 3.5 Time course of the apparent permeability coefficients considering 
secretion (serosal-to-mucosal, S-M) of ranitidine in the male (A) and female (B) 
Wistar rats (Mean ± S.D., n=6). 
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3.3.3 Dose-dependent influence of PEG 400 on ranitidine 
absorption 
The presence of PEG 400 increased the intestinal absorption of ranitidine in males 
but not in females, which show a sex-specific manner. The effect of this ‘inert’ 
excipient PEG 400 in male rats was also dose-dependent and region-related. As 
shown in Figure 3.7 for the jejunum and Figure 3.6 and Figure 3.8 for the duodenum 
and ileum, increasing the dose of PEG 400 led to increasing and then decreasing 
ranitidine absorption in male rats, such that a bell-shaped effect (in relation to PEG 
concentration) was observed. However, a rising curve was found for male colon, as 
shown in Figure 3.9.  
High doses of PEG 400 (>1g) reportedly reduced transit time in the small intestinal 
and the oral absorption of ranitidine, while a low dose of PEG 400 could increase 
ranitidine bioavailability in males (Schulze et al., 2003). However, our results 
demonstrated that the reduction of oral absorption of ranitidine with a high dose of 
PEG 400 may not only be due to the longer transit time in the small intestine, but 
also due to a reduction in the absorptive permeability of ranitidine. Its modulation 
of the intestinal permeability of ranitidine may be via the alteration of membrane 
fluidity and/or inhibition of some membrane uptake transporters. For example, it 
was reported that the commonly used excipients mannitol and sorbitol reduce the 
intestinal uptake of ranitidine and cimetidine due to high pressure on the membrane 
(Adkin et al., 1995a, Adkin et al., 1995b, Chen et al., 2007). Further, the inhibition 
of OATPs by PEG 400 in the absorption process of estrone-3-sulfate and 
taurocholate from the gut lumen proposed that PEG 400 might be a selective 
modulator of other intestinal uptake transporters (Engel et al., 2012). Likewise, a 
low dose of PEG 400 (such as 0.5%) resulted in the enhanced transport of ranitidine 
in male rats, which was in strong agreement with the human data (Ashiru et al., 
2008). Therefore, the increase in the bioavailability of ranitidine with a low dose of 
PEG 400 in humans may potentially be because of an enhanced intestinal 
permeation.  
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Figure 3.6 Absorptive transport of ranitidine across the duodenum of male (blue) and female (pink) Wistar rats (Mean ± S.D., n=6) in the 
presence of PEG 400. * Values are statistically different between the control and tested groups at p<0.05. 
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Figure 3.7 Absorptive transport of ranitidine across the jejunum of male (blue) and female (pink) Wistar rats (Mean ± S.D., n=6) in the 
presence of PEG 400. * Values are statistically different between the control and tested groups at p<0.05 
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Figure 3.8 Absorptive transport of ranitidine across the ileum of male (blue) and female (pink) Wistar rats (Mean ± S.D., n=6) in the 
presence of PEG 400. * Values are statistically different between the control and tested groups at p<0.05. 
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Figure 3.9 Absorptive transport of ranitidine across the colon of male (blue) and female (pink) Wistar rats (Mean ± S.D., n=6) in the 
presence of PEG 400. * Values are statistically different between the control and tested groups at p<0.05. 
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Furthermore, while PEG 400 enhanced the ranitidine intestinal absorption in male 
rats, it did not increase in females. In accordance with the data from the previous 
studies on humans and animals (summarized in Table 3.2), sex-related differences 
in the jejunal permeability of ranitidine were well matched. It stands that the 
jejunum should therefore be the subject of further study on this sex-based 
phenomenon, as compared with other intestinal segments. Moreover, in the jejunum, 
the differences in ranitidine permeability in males decreased with the amount of 
PEG 400. The largest differences observed were 49% for doses of 0.5% PEG 400 
in the jejunum. Therefore, 0.5% PEG 400 was selected in the following studies. 
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Table 3.2 Sex differences in the effect of PEG 400 on ranitidine bioavailability in rat study and Ussing chamber study.  
Dose of PEG 400 in 
Ussing chamber Study 
(%) 
Sex Differences in the Segments of Intestine Sex Differences in 
Wistar rats study 
Dose of PEG 400 in 
Wistar rats study 
(mg/kg) duodenum jejunum Ileum colon 
0.25      12.9 
0.5  √ √ √ √ 25.7 
0.1  √ √ √ √ 51.4 
1.5  √ √ √ √ 77.1 
2    √  102.8 
3 √ √  √ √ 154.2 
(‘√’=obvious sex differences; blank=no sex differences) 
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3.3.4 The influence of PEG 400 on ranitidine secretion 
As shown in Figure 3.10, the presence of 0.5% PEG 400 decreased the secretion of 
ranitidine in the jejunum, ileum, and colon by 19%, 24% and 31% in male rats 
(p<0.05). However, there were no significant differences found in the secretive 
transport of ranitidine in the presence of PEG 400 in female rats.  
The secretion results, as complementary evidences, strongly indicated that a low 
dose of PEG 400 could demonstrate a sex-based influence on the efflux of ranitidine 
in the jejunum, ileum and colon. Since P-gp is the major efflux transporter in the 
intestinal permeation of ranitidine and PEG 400 is known to inhibit P-gp (Hugger 
et al., 2002, Shen et al., 2006b), we come to the hypothesis that the intestinal P-gp 
was the main reason behind this sex-related phenomenon. Thus, to further 
investigate the role of P-gp, a P-gp inhibitor (CsA) was used, as discussed in the 
following section. 
3.3.5 The effect of PEG 400 on the intestinal permeability 
of ranitidine in the presence of CsA 
The effect of PEG 400 on the absorptive transport of ranitidine in the CsA pre-
treated rat intestine is shown in Figure 3.11. Following the pre-incubation period 
with CsA, ranitidine absorption in the male and female rats was significantly higher 
(p<0.05). However, this effect was notably larger in males compared to female rats 
in all intestinal divisions. For example, in the jejunum, the absorptive permeability 
of ranitidine increased by 99% in male rats and in females by 13%. In the ileum, 
the presence of CsA enhanced the absorption of ranitidine by 74% in males, but 
only 14% in female rats.  
Where vigorously supported, Table 3.3 shows that a marked decrease of ranitidine 
secretion was obtained with CsA in male intestines only. Additionally, the sex 
differences of PEG 400’s impact on the transport of ranitidine were eliminated once 
the intestinal tissues were pre-incubated with CsA.  
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A 
 
 
 
B 
Figure 3.10 Secretive permeability of ranitidine in the absence and presence of PEG 
400 in male (A) and female (B) Wistar rats (Mean ± S.D., n=6). * Values are 
statistically different between the control and PEG group at p<0.05. 
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A 
 
B 
Figure 3.11 Absorptive permeability of ranitidine in the absence and presence of 
PEG 400 or CsA in male (A) and female (B) Wistar rats (Mean ± S.D., n=6). * 
Values are statistically different between the control and tested groups at p<0.05.
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Table 3.3 Efflux ratio of ranitidine in the absence and presence of PEG 400 or CsA in the duodenum, jejunum, ileum and colon of male and 
female rats (Mean ± S.D., n=6). Ranitidine 3mM, PEG 400 0.5%, CsA 8μM. * Values are statistically different between the control and tested 
groups at p<0.5. 
  duodenum jejunum ileum Colon 
Males Ranitidine 1.01±0.36 2.20±0.70 1.96±0.58 3.29±0.83 
 Ranitidine + PEG  0.64±0.03 * 1.14±0.22 * 1.05±0.15 * 1.75±0.13 * 
 Ranitidine + CsA 0.56±0.11 * 0.64±0.16 * 0.65±0.13 * 1.30±0.12 * 
 Ranitidine + PEG + CsA 0.61±0.09 * 0.60±0.11 * 0.67±0.21 * 1.33±0.25 * 
Females Ranitidine 0.55±0.18 0.92±0.25 0.98±0.18 1.36±0.48 
 Ranitidine + PEG  0.49±0.14 0.84±0.19 0.88±0.13 1.06±0.09 
 Ranitidine + CsA 0.47±0.09 0.71±0.09 0.76±0.17 0.95±0.09 
 Ranitidine + PEG + CsA 0.5±0.12 0.73±0.12 0.73±0.15 0.98±0.14 
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All the results in this study reflect previously published in vivo work, which 
proposed that there was a higher P-gp activity in males compared to females in 
Chapter 2. The study herein showed that PEG 400 dose-dependently modified the 
activity of P-gp, which was also shown by Shen et al., who demonstrated that the 
inhibitory effect on P-gp was concentration-dependent across the range of 0.1 to 20% 
(w/v) (Shen et al., 2006b). Furthermore, the region-related transport of ranitidine in 
the intestine of rats could also be explained by the reportedly constant increase in 
the P-gp expression along the small intestine from proximal to distal parts (Yumoto 
et al., 1999, Tian et al., 2002, Dahan and Amidon, 2009, Kagan et al., 2010). 
Additionally, sex differences in the P-gp activity might be influencing the effect of 
PEG 400 on the bioavailability of ranitidine. For example, a study by Ballent et al., 
provided results that corroborated with a study conducted by Mariana et al., 
whereby a greater P-gp activity was found in male rats compared to females 
(Ballent et al., 2012, Mariana et al., 2011). The reason for greater P-gp activity in 
males compared to females is likely attributed to the sex differences in its own 
modifying-mechanisms, such as higher P-gp ATPase or ATP levels in the cells of 
males, and also due to the higher P-gp expression in males’ intestine (Gerrard et al., 
2004).  
The importance of studying sex-based differences has been supported by an 
increasing body of evidence demonstrating that sex can alter drug efficacy and 
toxicity profiles (Gandhi et al., 2004); this phenomenon was recently further 
reported to be influenced by formerly regarded “inert” pharmaceutical excipients. 
It has been stated that “every cell in our bodies has a sex” (Wizemann and Pardue, 
2001), and this was currently endorsed in the study herein. Higher P-gp activity in 
males was exhibited, which highlights the influence of sex within clinical research 
and the selection of excipients in the development of oral formulation for drugs, 
particularly for P-gp substrates. As some excipients are thought to alter the 
expression of membrane transporters, further work is required to clarify whether 
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this effect is the same in males and females, and which may have considerable 
pharmacological and clinical relevance.  
3.4 CONCLUSION 
In this chapter, the influence of PEG 400 on P-gp-mediated ranitidine transport at 
the intestinal level showed a sex-dependent manner, in line with the findings in the 
in vivo study.  
Low amounts of PEG 400 increased the intestinal uptake of ranitidine in the 
jejunum, ileum, and colon in male rats, but not in females using an Ussing chamber. 
However, no sex-based differences were found in the duodenum, which suggests 
that this sex-related phenomenon is region-related and dose-dependent. Hence, the 
PEG 400-mediated modulation of P-gp activity accounted for changes in ranitidine 
intestinal transport and in the marked differences between male and female subjects, 
which was also observed in the CsA inhibitory effect. Furthermore, pre-treatment 
with CsA on rat tissues were shown to inhibit this sex-based effect of PEG 400 on 
ranitidine intestinal transport. These findings highlight that sex differences should 
be considered in the use of these excipients, given the aforementioned studies of 
PEG 400 influencing oral drug bioavailability. Better efficacy and safety outcomes 
for the use of pharmaceutical excipients could also be potentially obtained with 
further research on this topic. 
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CHAPTER 4: Differences in Expression: How 
does PEG 400 modify the intestinal efflux 
transporter P-glycoprotein in males and 
females?  
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4.1 INTRODUCTION 
Our previous studies proposed there is a sex-dependent manner in the interaction 
between PEG 400 and intestinal P-gp, thus, it was the aim of the work reported here 
was to investigate the influence of PEG 400 on the intestinal P-gp expression, with 
the purpose of ascertaining the reason behind the aforementioned sex differences in 
the effect of PEG 400 on the bioavailability of ranitidine and ampicillin (Ashiru et 
al., 2008). 
In details, the following questions were addressed in this chapter: the protein 
abundance and mRNA expression of P-gp were studied in four segments of intestine 
in both male and female rats; and the effect of PEG 400 on the expression of P-gp 
during a 3-hour period was characterized with Western blotting and real-time 
reverse-transcription polymerase chain reaction (real time RT-PCR), respectively. 
4.1.1 Western blotting 
Western blotting (also called protein immunoblotting as an antibody is used to 
specifically detect its antigen) is a widely accepted analytical technique used to 
detect specific proteins in the given sample. It uses SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) to separate various proteins contained in the given 
sample. The separated proteins are then transferred or blotted onto a matrix 
(generally nitrocellulose or PVDF membrane), where they are stained with 
antibodies (used as a probe) specific to the target protein. By analyzing the location 
and intensity of the specific reaction, expression details of the target proteins in the 
given cells or tissue homogenate could be obtained. A schematic representation of 
Western blotting was shown in Figure 4.1. 
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Figure 4.1 The final detection for indirect Western blotting, (derived from 
LeincoTech). 
 
This method is used in the fields of molecular biology, biochemistry, 
immunogenetics and other molecular biology disciplines. However, Western 
blotting is not an exact science, particularly in a methodological sense, and 
obtaining perfect, publication-ready results immediately is not the norm. There are 
several steps to refine the experimental method and procedures to establish to 
ensure better results. Details of which are outlined in Table 4.1. 
Table 4.1 Factors affecting Western blotting experiment. 
Factors Variable Characteristic 
Gel Material, percentage, purity. 
Membrane Toughness, stability, resistance to acids and alkalis. 
Transferring Voltage, time 
Primary antibody  Affinity, concentration, incubation time, temperature, pH 
Secondary antibody Cross-reactivity, concentration, incubation time, 
temperature, pH 
Blocking  Concentration, composition, incubation time 
Washing Concentration, composition, volume, number of washes 
Detection Exposure time, sensitivity 
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Moreover, compared with other targeted protein quantification techniques such as 
the enzyme-linked immunosorbent assay (ELISA) and liquid chromatography-
tandem mass spectrometry (LC-MS/MS), Western blotting has its own advantages 
and disadvantages (shown in Table 4.2).  
Table 4.2 The advantages and disadvantages of Western blotting. 
Advantages Disadvantages 
 Immunogenic responses from 
infectious agents (ex. viruses, 
bacteria) are hard to find since 
they are difficult to isolate from 
patient sample. However, it can 
be detected by western blotting. 
 Western blotting utilizes not 
only antigens, but also antisera 
as a diagnostic tool. Antisera is 
widely used in the test for HIV 
presence. 
 Compared to ELISA, western 
blotting has higher specificity. 
 Since the polyvinylidene 
difluoride (PVDF) used as 
membrane in western blotting 
has a high protein-binding 
capacity and chemical stability. 
Some small and unstable protein 
groups can even be measured. 
 Among three common enzyme 
substrates, fluorescent and 
chemiluminescent create light 
detectable through X-ray or 
scanners. This ability enables 
high levels of sensitivity and 
quicker processing time. 
 A non-intended protein has a 
slight chance of reacting with 
the secondary anti-body, 
resulting in the labeling of an 
incorrect protein. 
 Western Blotting is a very 
delicate process requiring the 
correct amounts of each 
component in order for 
successful identification of 
the presence of proteins. An 
imbalance in any step of the 
procedure may skew the 
entire process  
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4.1.2 Real-time qPCR 
PCR (reverse transcription-polymerase chain reaction) is the most sensitive 
technique for mRNA detection and quantitation currently available. Compared to 
the two other commonly used techniques for quantifying mRNA levels, Northern 
blot analysis and RNase protection assay, PCR can be used to quantify mRNA levels 
from much smaller samples. The principle and process of PCR was shown in Figure 
4.2. 
 
Figure 4.2 The principle and process of PCR. 
 
PCR is conducted on an automated cycler which can heat and cool the tubes with 
the reaction mixture in a very short time. There are three major steps in a PCR: 
1. Denaturation: The double strand melts open to single stranded DNA, all 
enzymatic reactions stop.  
2. Annealing: During this period, the primers are jiggling around. Ionic bonds are 
constantly formed and broken between the single stranded primer and the single 
stranded template. The more stable bonds last for a longer period of time and 
on the piece of double stranded DNA, the polymerase can attach and start to 
copy the template. Once there are a few bases built in, the ionic bond is strong 
between the template and the primer, that it does not break anymore.  
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3. Elongation: The DNA polymerase synthesizes a new DNA strand 
complementary to the DNA template strand by adding free dNTPs from the 
reaction mixture that are complementary to the template in the 5'-to-3' direction. 
The bases (complementary to the template) are coupled to the primer on the 3' 
side (the polymerase adds dNTP's from 5' to 3', reading the template from 3' to 
5' side, bases are added complementary to the template). 
Real-time qPCR is a reliable detection and measurement technique of products 
generated during each cycle of the PCR process. This is directly proportional to the 
amount of template prior to the start of the PCR process. 
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4.2 MATERIALS AND METHODS 
4.2.1 Materials  
Polyethylene glycol 400 (PEG 400) was purchased from Sigma-Aldrich (Poole, 
UK). Krebs-Bicarbonate Ringer’s solution (KBR), pH 7.4, composed of 10mM D-
glucose, 1.2mM CaCl2, 1.2mM MgCl2, 115mM NaCl, 25mM NaHCO3, 0.4Mm 
KH2PO4 and 2.4mM K2HPO4 (Clarke, 2009). Lysis buffer (details described in 
Table 4.3) was freshly prepared with 50mM Tris, 250mM NaCl, 5mM EDTA, 1mM 
Na3VO4, 1mM PMSF, 1% Nonidet P40 and protease inhibitor cocktail in PBS 
(phosphate-buffered saline). All other chemicals and kits are noted individually in 
the following methods. 
Table 4.3 Components of the tissue protein extraction and cell lysis buffer, (adapted 
from Dr Vipul Yadav’s PhD work). 
Ingredient Function Quantity for 10mL Buffer 
Tris buffer (10x solution) Buffering agent 2mL 
Sodium chloride Maintaining ionic strength 146mg 
EDTA Matrix metalloprotease 
inhibitor 
18mg 
NonidetTM P40 substitute Lysis of the cell membrane 100L 
Sodium azide Bacterial growth inhibitor 2mg 
Sodium orthovanadate Tyrosine and alkaline 
phosphatase inhibitor 
2mg 
Phenylmethane sulfonyl 
fluoride 
Serine protease inhibitor 1.8mg 
Protease inhibitor cocktail 
(Sigma Aldrich) 
Mixture of protease 
inhibitors 
8mL PBS in 1 bottle 
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4.2.2 Animals 
All the animal work was approved by the UCL School of Pharmacy’s ethical review 
committee and was conducted in accordance with the Home Office standards under 
the Animals (Scientific Procedures) Act, 1986. Healthy 8-13 week old male and 
female Wistar rats (Harlan UK Ltd, Oxfordshire, UK) weighing 150-250g were 
used for excised rat intestine. The rats were housed at controlled temperatures (25℃) 
and humidity (50-60%) with a constant light-dark cycle of 12h, were provided with 
food and water and were acclimatized for 7 days. One day before the experiments, 
the rats were fasted overnight and housed individually in metabolic cages.  
On the day of the experiment, each rat was dosed with 26mg/kg PEG 400 using an 
oral gavage syringe. Subsequently, rats were killed after 15min, 30min, 60min, 
90min, 120min or 180min using a CO2 euthanasia chamber, and their intestines 
were immediately collected and kept in ice-cold KBR solution.  
4.2.3 Mucosal tissue preparation 
The intestines were cut into 4 segments: the duodenum (1cm from the ligament of 
Treitz); the jejunum (10cm from the ligament of Treitz); the ileum (1cm from the 
cecum) and the colon, which were then washed with ice-cold KBR solution. 
Roughly 2cm pieces in length from the mid part of the duodenum, proximal part of 
the jejunum, the distal to mid part of ileum and the descending colon were opened 
along their mesenteric border. The tissues were washed gently with KBR solution 
to remove the intestinal contents. To obtain the mucosal tissue, tissue pieces were 
placed on an ice-cold glass plate and the serosa layer was gently squeezed out and 
divided into aliquots for determination of P-gp protein content and mRNA 
expression in detail below. 
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4.2.4 Detection of P-gp protein level in intestinal segments 
by Western blotting 
4.2.4.1 Sample preparation 
The mucosal tissues (about 60mg) were cut into small pieces and homogenized in 
3mL lysis buffer at 10,00rpm for 20s on ice with a T18 digital ULTRA-TURRAX® 
(IKA, Wilmington, USA). The tissue homogenates were incubated at 4°C for 2h, 
then centrifuged at 10,000rpm for 10min. The supernatants were collected and 
stored in aliquots at -20°C. 
4.2.4.2 Sample preparation 
The mucosal tissues (about 60mg) were cut into small pieces and homogenized in 
3mL lysis buffer at 10,00rpm for 20s on ice with a T18 digital ULTRA-TURRAX® 
(IKA, Wilmington, USA). The tissue homogenates were incubated at 4°C for 2h, 
then centrifuged at 10,000rpm for 10min. The supernatants were collected and 
stored in aliquots at -20°C. 
4.2.4.3 P-gp Protein Level Analysis 
25μg of total protein of each sample was suspended in LDS (lithium dodecyl sulfate) 
sample loading buffer (Invitrogen, Carlsbad, CA) and denatured for 10min at 70°C. 
As a molecular weight marker, 5μL Sharp Pre-Stained protein standard (Invitrogen) 
was loaded on each gel. 
Protein in the samples were separated by electrophoresis in a NuPAGETM NovexTM 
4–12% Bis-Tris gel (Invitrogen) and transferred to a nitrocellulose membrane with 
XCell SureLock™ Mini-Cell Electrophoresis System (Invitrogen) according to the 
manufacturer’s instructions. Nitrocellulose membranes were blocked with 3% BSA 
(bovine serum albumin) in TBS-T (0.1% Tween 20 in tris-buffered saline) and 
incubated for 1h at room temperature. For detection of P-glycoprotein (P-gp) and 
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reference protein, blots were incubated for 1h at room temperature with the 
respective primary antibodies diluted in 3% BSA in TBS-T: mouse monoclonal 
anti-P-gp (C-219 3:200; Enzo Life Science, Exeter, UK) and anti-β-actin mouse 
monoclonal antibody (1:2000; Sigma-Aldrich, Poole, UK). Bound antibodies were 
detected with affinity-purified rabbit anti-mouse IgG coupled to horseradish 
peroxidase (secondary antibody; Sigma) diluted 1:5000 in 3% BSA in TBS-T. 
After 1h incubation with the secondary antibody conjugated with horseradish 
peroxidase, protein bands were visualized by chemiluminescence detection with 
Pierce™ ECL Western Blotting Substrate (ThermoFisher), subsequently were  
photographed with a ChemiDoc XRS camera (Bio-Rad, Hertfordshire, UK). 
Detection of bands of P-gp and reference protein was performed using the Image 
Lab™ software (Bio-Rad). For a calculation of the relative P-gp contents in the 
different samples, the reference protein was individually set to 1, and the intensity 
of P-gp was set relative to it. 
4.2.5 Measurement of P-gp mRNA expression in intestinal 
divisions by real-time reverse-transcription 
polymerase chain reaction 
4.2.5.1 RNA isolation 
All pieces of mucosal tissue (for segment definitions, please refer to Tissue 
Preparation) were cut and kept in RNA later® Stabilization Solution (Thermofisher). 
Total RNA of each piece was isolated with The TRIzol® (Table 4.4) and purified 
with PureLink® RNA Mini Kit (Thermofisher) according to the manufacturer’s 
instructions (briefly described in Figure 4.3). RNA concentration was measured 
with Nanodrop 2000 (Thermofisher).  
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Table 4.4 TRIzol reagent composition, function and optimized concentrations. 
Ingredient Function Concentration 
Phenol Extraction and purification of 
nucleic acid 
38% 
Guanidine thiocyanate Denaturation of proteins (such as 
those that strongly bind nucleic 
acids or those that degrade RNA) 
0.8M 
Ammonium thiocyanate Denaturation of proteins 0.4M 
Sodium acetate Maintain pH and provides the salt 
necessary for RNA precipitation. 
0.1M 
Glycerol Carrier for nucleic acids 5% 
 
Figure 4.3 The process of RNA isolation with TRIzol-chloroform method. 
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4.2.5.2 RNA level analysis 
Subsequently, the quantification of the target RNA was conducted as followed: 1 
mg total RNA of each sample was reverse transcribed using the iScriptTM cDNA 
Sythesis Kit (Bio-Rad). To quantify the amount of P-gp mRNA (mdr1a and mdr1b), 
real-time PCR was performed on the 7500 Real Time PCR System (Applied 
Biosystems, Thermofisher) using the method described in MacLean’s study 
(MacLean et al., 2008). Briefly, 50μL PCR reaction contained 25μL of PowerUpTM 
SYBR Green PCR Master Mix (Thermofisher), 500nM each of forward and reverse 
primers, and 1μg of cDNA. Anti-beta actin was used for normalization and 
amplification of 1μg cDNA, respectively. Real-time PCR was carried out in 96 well 
PCR plates (Thermofisher). The amplification program for all genes consisted of 
one pre-incubation cycle at 95°C with a 10min hold, followed by 45 amplification 
cycles with denaturation at 95°C with a 10s hold, an annealing temperature of 50°C 
with a 10s hold, and an extension at 72°C with a 10s hold. Amplification was 
followed by a melting curve analysis, which ran for one cycle with denaturation at 
95°C with a 1s hold, annealing at 65°C with a 15s hold, and melting at 95°C with a 
1s hold. Distilled water was included as a negative control in each run to access 
specificity of primers and possible contaminants. 
Primers (shown in Table 4.5) were designed by primer-BLAST searching with 
publicly available sequence information of the GeneBank of the National Center 
for Biotechnology Information (NCBI) and purchased from Eurofins (Eurofins 
Genomics, Germany).  
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Table 4.5 Primers used for the analysis of P-gp gene expression by real-time qPCR 
Gene Primer (5’ – 3’) Amplicon (bp) Genebank Accession 
mdr1a Forward CACCATCCAGAACGCAGACT 139 NM_133401 
Reverse ACATCTCGCATGGTCACAGTT 
mdr1b Forward AACGCAGACTTGATCGTGGT 144 NM_012623 
Reverse AGCACCTCAAATACTCCCAGC 
anti-beta actin Forward GCAGGAGTACGATGAGTCCG 74 NM_031144 
Reverse ACGCAGCTCAGTAACAGTCC 
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4.2.5.3 Data analysis 
Relative expression of mdr1a and mdr1b mRNA in different intestinal segments 
were calculated using 7500 software (version 2.0.6, Thermofisher). The average of 
the threshold cycle (Ct) values for tested genes (mdr1a and mdr1b) and the internal 
control (anti-beta actin) was taken, and then the differences between Ct values for 
tested genes and internal control (∆Ct) were calculated for all the experimental 
samples.  
4.2.6 Statistical analysis 
The experiments were performed at least six times and data were expressed as mean 
± standard deviation (S.D.). Significant differences among groups were analysed 
by one-way ANOVA and three-way ANOVA using IBM SPSS Statistics 19 (SPSS 
Inc., Illinois, USA). A minimum p value of 0.05 was used as a significance level 
for the tests. Also, the relationship between P-gp protein levels and mRNA 
expression (both mdr1a and mdr1b) was investigated using Pearson product-
moment correlation coefficient (r). 
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4.3 RESULTS AND DISCUSSION 
4.3.1 P-gp protein abundance in different intestinal 
segments 
To obtain a general picture of the expression profile of P-gp along the intestinal 
tract, the amount of P-gp protein was quantified in the duodenum, jejunum, ileum 
and colon in male and female rats. As can be seen from Figure 4.4, there is a 
constant increase in the P-gp content along the intestine from proximal to distal 
parts (duodenum < jejunum < ileum < colon), with the trend being more obvious in 
males compared to female rats.  
A progressive increase in P-gp protein abundance and activity from the proximal to 
the distal small intestine (Yumoto et al., 1999, Tian et al., 2002, Dahan and Amidon, 
2009, Kagan et al., 2010), with the highest P-gp levels appearing in the colon (Fojo 
et al., 1987, Fricker et al., 1996) has previously been reported in rodents. In contrast 
to rodents, the P-gp contents in the intestine of human subjects is different. A recent 
study where the absolute P-gp content from six organ donors was quantified using 
LC-MC/MS (Drozdzik et al., 2014) showed a 3-fold higher P-gp level in the distal 
ileum compared to the duodenum or the proximal jejunum, alongside notably lower 
P-gp levels in the colon. Regardless of the different techniques used in the above 
studies, the influence of location on the protein content was similar in rats and 
humans for the small intestine, but not the colon. The lower P-gp level and related 
efflux in the proximal (in contrast to the distal) small intestine explains why the 
proximal end is the ideal absorption site for drugs which are P-gp substrates. It also 
explains how compounds which reduce the gastrointestinal motility, such as sodium 
acid pyrophosphate, mannitol and sorbitol, can significantly increase the oral 
absorption of concomitantly administered P-gp substrate drugs (Adkin et al., 1995a, 
Chen et al., 2007).  
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Figure 4.4 Relative quantitation of P-gp protein abundance in selected intestinal 
segments (duodenum, jejunum, ileum and colon). The levels of protein are 
normalized to anti-β actin. * Values are statistically different between the male and 
female groups at p<0.05. 
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Figure 4.4 also shows a considerable influence of an animal’s sex on the intestinal 
P-gp level. While the P-gp abundance was similar in male and female duodenums 
(p>0.05), it differed markedly in other intestinal segments. Specifically, abundance 
was about 40% higher in the male jejunum, ileum and colon (p<0.05). This reflects 
previous reports of higher enterocyte P-gp content in men’s small intestine 
compared to women’s (Schuetz et al., 1995a, Potter et al., 2004), and a lack of 
difference in the upper duodenum (Ungell et al., 1992, Tozaki et al., 1997). As far 
as the colon is concerned, there is limited literature on sex-related P-gp protein 
abundance or mRNA expression in rodents and humans. In contrast to our studies, 
MacLean et al (2008) reported no significant sex-related difference in the intestinal 
P-gp expression along the whole intestine of male and female rats (MacLean et al., 
2008). Such a difference between our studies and those of MacLean et al could have 
been due to the fasted/fed status of the rats, which were fasted in our studies but fed 
in MacLean’s study, as well as high inter- and intra-variability.  
The presence of food was indeed reported to modify the P-gp expression in the 
intestine. Grapefruit juice, as an example, was reportedly prohibited in the clinical 
studies due to its inhibition on P-gp, increasing the cyclosporine (P-gp substrate) 
AUC ranging from 20% to 60% (Huang et al., 2004). The ingredient 
furanocoumarins in grapefruit juice was later confirmed to be the main reason for 
its P-gp inhibition, as conducted on Caco-2 cells (Paine et al., 2008). Aside from 
the inhibitory effects, P-gp expression could also be induced in the presence of food. 
For example, garlic extracts have been demonstrated to decrease drug exposure for 
saquinavir (P-gp substrate), owing to its induction of P-gp expression in the human 
intestine and liver (Hajda et al., 2010). 
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4.3.2 Influence of PEG 400 on the P-gp protein contents 
The influence of orally administered PEG 400 on P-gp protein level in the jejunum 
is shown in Figure 4.7. Similar results are found in duodenum, ileum and colon 
(Figure 4.6, Figure 4.8 and Figure 4.9). It can be seen that PEG 400 administration 
reduced P-gp protein levels in a time- and sex- dependent manner. In male rats, the 
reduction in P-gp protein levels peaked at 60 min post PEG dosing, after which, P-
gp levels seem to recover to their original values. In contrast, in female rats, P-gp 
levels decreased to a much lower extent compared to the control values (when PEG 
was not administered), such that no statistical differences were found. There was a 
general trend of decreasing P-gp levels, however, this trend continued for a longer 
time, i.e. until the end measurement at 180 min. 
Reduction of P-gp levels by PEG 400 in the rats reflects a previous report where 
PEG 400 reduced P-gp protein abundance and enhanced the uptake of Rho-123 (a 
P-gp substrate) into Caco-2 cells (Hodaei et al., 2015). The mechanisms underlying 
the reduction in P-gp levels was unclear, and the authors suggested that the 
alteration of fluidity of the epithelial membranes by PEG 400 was regarded as the 
principal reason for the inhibition of P-gp activity and enhancement in the Rho-123 
uptake. An earlier report showed that PEG 400 and other excipients such as Tween-
80 and F-68 blocked the binding sites of P-gp and altered the membrane fluidity (Li 
et al., 2011). Although, there is still controversy over whether P-gp-inhibiting 
excipients increase or decrease the fluidity of the epithelial membranes (Dudeja et 
al., 1995, Rege et al., 2002), it is known that P-gp is highly sensitive to the lipid 
environment of the cell membrane (Regev et al., 1999, Ferte, 2000). Therefore, any 
disturbance in this environment by excipients can possibly result in changes in the 
secondary and tertiary structures of the P-gp protein. It is feasible that PEG 400, 
containing oxyethylene groups, can intercalate in the lipid phase of the membrane, 
thereby changing the latter’s fluidity (Hugger et al., 2002). It has also been 
suggested that the alkyl and unsaturated C-C bonds in the chemical structure of 
PEG derivatives may influence the function of P-gp (Shen et al., 2006a). On the 
other hand, the modulation of excipients on the nuclear receptors was also 
considered as another main reason behind the phenomenon, given that transporter 
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protein abundance is generally regulated by these nuclear receptors, such as 
pregnane receptor in rodents (PXR), retinoic acid receptor (RAR) and farnesoid 
receptor (FXR) (Yoshikawa et al., 2002, Lee et al., 2006a). For instance, mRNA 
expression of P-gp was strongly predicted by the mRNA levels of PXR, whose 
signaling pathway for intestinal efflux transporter was likely in a constantly 
activated physiological state (Drozdzik et al., 2014). All the hypothesis are 
summarized in Figure 4.5. 
Figure 4.5 The mechanisms on the interaction between PEG 400 and intestinal P-
glycoprotein. 
While the above studies shows that P-gp modulation by excipients is well-known, 
we report, for the first time, an influence of animal’s sex. The influence of PEG 400 
on the P-gp abundance in female rats was quite different to that in the males. Firstly, 
PEG 400 administration had a longer-lasting effect such that the P-gp protein 
content continuously decreased over the 3hr duration. Secondly, the magnitude of 
reduction in P-gp levels was lower in females. The reason behind this sex-based 
phenomenon is unknown, but the rat intestinal P-gp seems to be less sensitive to 
PEG 400 in females than in males. It is possible that the intestinal membrane was 
more stable to changes in fluidity and for that the epithelial renewal was slower in 
females compared to males. To further understand the time- and sex- dependent 
influence of PEG 400 on P-gp levels, P-gp related mRNA expression was measured 
and is discussed below. 
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Male-Jejunum                                               Female-Jejunum 
 
Figure 4.6 The effect of PEG 400 on relative quantitation of P-gp protein expression in jejunum over 3h.  
The levels of protein are normalized to anti-β actin. * Values are statistically different between the control and PEG groups at p<0.05. 
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Male-Duodenum                                                 Female-Duodenum 
Figure 4.7 The effect of PEG 400 on relative quantitation of P-gp protein expression in duodenum over 3h. 
The levels of protein are normalized to anti-β actin. * Values are statistically different between the control and PEG groups at p<0.05. 
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Male-Ileum                                                  Female-Ileum 
 
Figure 4.8 The effect of PEG 400 on relative quantitation of P-gp protein expression in ileum over 3h. 
The levels of protein are normalized to anti-β actin. * Values are statistically different between the control and PEG groups at p<0.05. 
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Male-Colon                                               Female-Colon 
 
Figure 4.9 The effect of PEG 400 on relative quantitation of P-gp protein expression in colon over 3 hours. 
The levels of protein are normalized to anti-β actin. * Values are statistically different between the control and PEG groups at p<0.05
0
0.5
1
1.5
2
Control 15 30 60 90 120 180
P
ro
te
in
 E
x
p
re
ss
io
n
 o
f 
P
-g
ly
co
p
ro
te
in
  
  
  
  
  
  
o
n
 C
o
lo
n
Male Female
*
*
*
*
*
   Chapter 4 
158 
 
4.3.3 P-gp mRNA (mdr1a and mdr1b) expression in the 
absence and presence of PEG 400.  
The control (i.e. without PEG administration) gene expression of P-gp, namely 
mdr1a and mdr1b, is shown in Figure 4.10. In both male and female rats, the mdr1a 
expression of P-gp increased from the proximal to the distal end of the intestinal 
tract, whereas no obvious trend was observed for the mdr1b expression along the 
intestine. When an animal’s sex was considered, mdr1a expression consistently 
lower in females except the duodenal segment, while any trend in mdr1b expression 
was once more lacking (shown in Figure 4.11).  
Following oral administration of PEG 400, the mdr1a expression in the male rat 
intestine decreased in the first 1 to 2 h and then constantly increased returning to 
the control within 3h of PEG administration. In contrast, mdr1a expression in 
female jejunum kept decreasing followed the PEG 400 PEG 400 administration and 
mdr1a contents had not return to control levels by the end of the study (shown in 
Figure 4.13 for the jejunum). Similar results were found in the duodenum, ileum 
and colon (graphed in Figure 4.12, Figure 4.14 and Figure 4.15). The jejunal mdr1b 
expression in both males and females fluctuated with time after PEG 400 dosing, 
and no trend could be seen. 
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A 
B 
 
Figure 4.10 Comparison of mdr1a (A) and mdr1b (B) mRNA expression in different 
intestinal segments of rats. The level of mRNA is normalized to anti-βactin. 
Expression intensities of duodenum were individually set to 1 and the intensities of 
jejunum, ileum and colon were relative to it. 
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Figure 4.11 Comparison of mdr1a (A) and mdr1b (B) mRNA expression in the male 
and female rats. The level of mRNA is normalized to anti-βactin. Expression 
intensities in male rats were individually set to 1 and the intensities in females were 
relative to it. 
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B  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Fold changes in mdr1a (A) and mdr1b (B) mRNA expression in jejunum of rats after 3h administration with PEG 400.  
* Values are statistically different between the control and PEG groups at p<0.05. 
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Figure 4.13 Fold changes in mdr1a (A) and mdr1b (B) mRNA expression in duodenum of rats after 3h administration with PEG 400.     
* Values are statistically different between the control and PEG groups at p<0.05. 
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B  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Fold changes in mdr1a (A) and mdr1b (B) mRNA expression in ileum of rats after 3h administration with PEG 400. 
* Values are statistically different between the control and PEG groups at p<0.05. 
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B  
Figure 4.15 Fold changes in mdr1a (A) and mdr1b (B) mRNA expression in colon of rats after 3h administration with PEG 400. 
* Values are statistically different between the control and PEG groups at p<0.05. 
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It can be seen from Figure 4.16 and Table 4.6, there is a strong positive correlation 
between mdr1a (but not mdr1b) expression and P-gp protein abundance, r=0.78, 
n=336, r<0.001, with high levels of P-gp protein associated with high levels of 
mdr1a expression. 
 
A 
 
B 
 
Figure 4.16 Correlation coefficients between P-gp protein levels and its related 
mdr1a (A) and mdr1b (B) mRNA expression.  
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This positive correlation in mdr1a expression and P-gp protein level in the rats 
reflects similar positive correlation between gene expression and absolute intestinal 
P-gp protein level in humans (Drozdzik et al., 2014). Having said that, the literature 
about the relationship P-gp and its mRNA levels is contradictory. It has been 
suggested that the predictive power of transcript analysis must be investigated on a 
gene-by-gene and/or a case-by-case basis, and that mRNA expression data should 
only be used as supportive information regarding protein levels. Nevertheless, from 
our work, we can conclude a greater usefulness of mdr1a compared to mdr1b for 
predicting P-gp protein levels. 
 
Table 4.6 Correlation coefficient (r) from Pearson correlation analysis between P-
gp protein levels and its related mRNA expression (mdr1a and mdr1b). 
Groups P-gp protein level mdr1a 
expression 
mdr1b 
expression 
P-gp protein level —— 0.785 ** 0.095 
mdr1a expression  —— 0.083 
mdr1b expression   —— 
** p < 0.001 (2-tailed). 
 
This work also raises several new aspects that could be discussed. To begin with, 
the colonic P-gp protein abundance differed from rodents and human subjects, 
possibly due to different protein quantification techniques used in these studies. It 
may be worth confirming the absolute protein level of P-gp in rodents with the same 
method LC-MC/MS, and aid in the characteristic of membrane transporters in 
animal models related to human. Also, it could help to elucidate the semi-
quantitative methods, such as Western blotting, applied in this study. A second 
consideration is that fast-release dosage forms would be a better choice in the oral 
formulation development of P-gp substrates, owing to lower P-gp content in the 
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proximal small intestine disregarding both species and sex of the subjects. 
Furthermore, inclusion of “active” pharmaceutical excipients, such as PEG 400, are 
likely to benefit oral formulations containing P-gp substrates that are BCS Class IV 
drugs (poor solubility and poor permeability), as PEG 400 could both improve the 
solubility and permeability of co-formulated drugs. Finally, the unexpected sex 
differences demonstrated in this study highlights a potential safety concern, 
requiring a greater consideration in the selection and use of pharmaceutical 
excipients for oral formulation development. These findings further underline the 
role of sex in the drug pharmacokinetics and clinical studies. 
 
4.4 CONCLUSION 
The work in this chapter further elaborates on the sex-related influence of the 
purportedly inactive excipient PEG 400 on the absorption of drug which are P-gp 
substrates. This influence can now be attributed to sex differences in the intestinal 
P-gp protein levels and its related mRNA expression. We confirmed female had 
lower levels of P-gp protein as well as mRNA expression. In addition, female 
intestinal P-gp levels seem to be less sensitive (in terms of extent and timing) to 
oral administration of PEG 400. The reason for and mechanism underlying this sex-
related difference is still unknown, but needs to be clarified in future work. 
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CHAPTER 5: Exploring Excipients: Are there 
other excipients that exhibit differences in 
drug absorption due to our sex? 
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5.1 INTRODUCTION 
In the previous study, we have thoroughly investigated the reason behind the 
unexpected sex-dependent influence of PEG 400 on the bioavailability of ranitidine. 
The results showed that this effect was attributed to its sex-specific reduction on the 
P-gp activity, protein level and mRNA expression. Pharmaceutical excipients are 
assumed to be safe for long-term therapy as they have been used for many years in 
pharmaceutical formulations and are approved for use by responsible government 
bodies. Thus, our findings precisely highlight the importance of excipient selection 
in formulation strategy.  
Apart from PEG 400, other solubilizing agents, such as Cremophor RH 40, 
Poloxamer 188, Tween 80 and Span 20 (chemical structures shown in Figure 5.1), 
were also reported to interact with membrane transporters, however, knowledge 
about whether their influences were sex-specific is very limited. Moreover, the 
transport inhibitory activity has been found to be below the critical micelle 
concentration (CMC) of the surfactant. Not only does the transport inhibitory 
activity relate to the hydrophile-lipophile balance (HLB) of surfactants, but also 
their concentrations (Varma and Panchagnula, 2005). In addition, the excipients 
Cremophor RH 40, Poloxamer 188, Tween 80 and Span 20 were commonly used 
in the commercial products at a wide range of concentrations.  
Consequently, the purpose on this chapter was to investigate the effect of these 
formerly considered “inert” excipients on the bioavailability of ranitidine in male 
and female rats, with the aim of exposing any sex-associated or dose-dependent or 
manners in the interplay between these excipients and drug absorption. The work 
herein was conducted in two phases. 
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Poloxamer 188 (a=80; b=27) 
 
 
 
Cremophor RH 40 
 
 
Tween 80 
 
 
Span 20 
 
 
 
 
 
Figure 5.1 Chemical structures of tested excipients. 
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Phase I: Screening the influence of other excipients (Cremophor RH 40, Poloxamer 
188, Tween 80 and Span 20) on the drug absorption in male and female rats, with 
the aim of establishing if these impacts are sex-dependent as the effect of PEG 400. 
Ranitidine was selected as the model drug in this study. Also, only one dose of each 
excipient was selected based on the ratio of their molecular weight to PEG 400, 
which was calculated using the format as followed: 
Concentration (Excipient) = 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛(𝑃𝐸𝐺 400)×𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑊𝑒𝑖𝑔ℎ𝑡(𝐸𝑥𝑐𝑖𝑝𝑖𝑒𝑛𝑡)
𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑊𝑒𝑖𝑔ℎ𝑡 (𝑃𝐸𝐺 400)
 
The study was designed as followed:  
 The influence of Cremophor RH 40, Poloxamer 188, Tween 80 and Span 
20 on the in vivo bioavailability of ranitidine in rats. 
 The effect of Cremophor RH 40, Poloxamer 188, Tween 80 and Span 20 
on the in vitro intestinal transport of ranitidine in rats, using Ussing 
chamber system. 
 The impact of Cremophor RH 40, Poloxamer 188, Tween 80 and Span 20 
on the P-gp protein abundance and mRNA expression, with Western 
blotting and real-time RT-PCR respectively. 
If sex differences were shown in the influence of the tested excipients on ranitidine 
bioavailability in Phase I, we will proceed to Phase II.  
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Phase II: Evaluation on the bioavailability of ranitidine in male and female rats in 
the presence of Cremophor RH 40, Poloxamer 188, Tween 80 and Span 20 at a 
series of doses utilized in the commercial formulations. The concentrations were 
shown in Table 5.1. 
Table 5.1 Concentrations and applications of excipients in pharmaceutical 
formulation. 
Excipients 
Concentration 
(%) 
Use 
Cremophor RH 40 
0.1 
used to solubilise ethereal oils, perfume 
compositions, vitamins and hydrophobic active 
substances in aqueous- alcoholic and purely 
aqueous solutions. 
1 
5 
10 
20 
Poloxamer 188 
0.1 fat emulsifier; flavor solubilizer;  
1 spreading agent; wetting agent 
5 stabilizing agent; suppository agent;  
10 tablet coating; tablet excipient 
20 gelling agent 
Tween 80 
0.1 
nonionic surfactant in ophthalmic preparations 
1 
5 nonionic surfactant in lipophilic bases 
10 used in combination with plasticizing agents 
15 
solubilizing agent in lipophilic bases; 
emollient in topical formulations; 
emulsifying agent in oil-in-water emulsions 
Span 20 
0.5 
nonionic surfactant and solubilizing agent for 
insoluble, active constituents in lipophilic bases 
1 emulsifying agent used in combination with 
hydrophilic emulsifiers in oil-in-water 
emulsions and to increase the water-holding 
properties of ointments; 
solubilizing agent for poorly soluble, active 
constituents in lipophilic bases 
5 
10 
15 
emulsifying agents used alone in water-in-oil 
emulsions 
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Phase I 
5.2 MATERIALS AND METHODS 
5.2.1 Materials  
Ranitidine hydrochloride, glacial acetic acid and sodium acetate trihydrate were 
obtained from Sigma Aldrich (Dorset, UK). Span 20 and Tween 80 were purchased 
from Fluka (Dietikon, Switzerland). Poloxamer 188 and Cremophor RH 40 were 
from Agenda (Bradford, UK) and BASF (Cheadle, Germany), respectively. Water 
and acetonitrile were purchased from Fisher Scientific (Loughborough, UK), and 
were of HPLC grade. 
5.2.2 Animals 
Animals used for the experiments were male and female Wistar rats (8 weeks old), 
purchased from Harlan UK Ltd (Oxfordshire, UK). Male and female Wistar rats 
weighed approximately 250g and 200g, respectively.  
All the animal work was conducted in accordance with the Home Office standards 
under the Animals (Scientific Procedures) Act, 1986. The rats were housed at room 
temperature (25℃) and in a light-dark cycle of 12h. They were caged in groups of 
six, allowed to move freely and provided with food and water before the experiment. 
The day before the experiment, they were fasted overnight and individually housed 
in metabolic cages. 
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5.2.3 Effect of excipients on the intestinal transport of 
ranitidine 
5.2.3.1 Tissue preparation 
On the day of the experiment, rats were sacrificed with a CO2 euthanasia chamber 
(Schedule 1 method) and the intestine was rapidly removed. The jejunum (10cm 
from the ligament of Treitz) was cut from the whole intestine, washed with cold 
KBR solution and put into beakers with KBR solution on ice. The tissue was then 
allowed to rest for approximately 20 minutes for lowing the tissue temperature to 
minimize tissue damage during preparation. About 2-3 cm long pieces from the 
proximal part of the jejunum were opened along their mesenteric border.  
5.2.3.2 Ussing chamber set-up 
When the preparation was finished, tissues were mounted in the vertical Ussing 
Chamber (Harvard Apparatus Inc., Holliston, MA, USA) as flat sheets on a 0.32cm2 
segment holder with needles to stabilize it. A 5mL KBR solution was added to each 
compartment of the Ussing Chamber and the solutions were gassed with an O2/CO2 
(95%/5%) gas mixture. The chambers were screwed tight and the entire assembly 
was kept at 37℃.  
To evaluate tissue integrity during experiments, tissue transepithelial electrical 
resistance (TEER) was measured using an EVOMX meter (World Precision 
Instruments Inc., WPI, Hertfordshire, UK). Any jejunum tissue presented a value 
of TEER lower than 40Ω•cm2 at the beginning of experiment was regarded as 
poorly viable and excluded immediately. When TEER values decreased more than 
15% from the value measured at the end of equilibration period, the tissue was 
considered not viable. 
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5.2.3.3 Transport study 
After an equilibrium period of 20-30 minutes, the experiment was initiated by 
replacing the blank KBR solution with pre-warmed ranitidine solution in the 
absence and presence of pharmaceutical excipients in the donor compartment. The 
appropriate concentrations were shown in Table 5.2. 
Table 5.2 Concentrations of excipients used in the in vitro studies. 
Excipients Mean Molecular Weights 
(g/mol) 
Concentration (%) 
Poloxamer 188 4600 5.5 
Cremophor RH 40 2500 3 
Tween 80 1310 1.6 
Span 20 346 0.4 
The permeation experiment lasted 3h and 100μL of receiver solution was taken for 
measuring the drug amount with HPLC method every 30min. An equal volume of 
heated blank KBR solution was added immediately after each sample was 
withdrawn.  
5.2.3.4 Calculation 
The Papp of each experiment, in cm/s, was computed using the equation followed: 
𝑃𝑎𝑝𝑝 =
𝑄
𝐶 ▪ 𝐴 ▪ 𝑡
 
where Q (μmol) is the total amount of drug that permeated to the receiver 
compartment throughout the incubation time, C (μmol/mL) is the initial drug 
concentration in the donor side, A (cm2) is the diffusion area of the Ussing Chamber, 
and t (s) is the time of experiment. 
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5.2.4 Influence of excipients on the bioavailability of 
ranitidine 
Each rat was weighed on the day of the experiment and administered ranitidine 
solution in the absence and presence of pharmaceutical excipients using an oral 
gavage syringe. Doses were showed in Table 5.3.  
Table 5.3 Concentrations of excipients used in the in vivo studies. 
Excipients Mean Molecular Weights 
(g/mol) 
Concentration 
(mg/kg) 
Poloxamer 188 4600 295 
Cremophor RH 40 2500 160 
Tween 80 1310 84 
Span 20 346 22 
Then, approximately 250μL-300μL of blood was collected from the tail vein of rats 
into anticoagulant centrifuge tubes (BD Microtainer® K2E Becton, Dickinson and 
Company, USA) at 0.5, 1.25, 2, 3, 4 and 6h. At 8h post-administration, the rats were 
sacrificed with a CO2 euthanasia chamber (Schedule 1 method) and about 1mL of 
blood was taken via cardiac puncture immediately. All blood samples were 
centrifuged at 10000rpm (930g) for 10 min on a Centrifuge 5804R (Eppendorf AG, 
22331 Hamburg, Germany) within 8h of sampling. 50µL of the supernatant was 
collected and placed into a 1.5mL Eppendorf tube, the same volume of acetonitrile 
was added to precipitate the plasma proteins. After 1min of vortex-mixing, 100µL 
HPLC grade water was added to the mixture and after subsequent vortex-mixing, 
the samples were centrifuged at 4℃ for 10 min at 10000rpm. The supernatant was 
collected and kept at 4℃ until analysis.  
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5.2.5 Methods of analysis 
The samples were stored in freezer at 4℃ until use and allowed to thaw at room 
temperature before processing. The sample was subjected to HPLC-UV analysis 
using a previously validated method. The column used was a 5µm Luna SCX 
(Phenomenex, UK); the mobile phase was a mixture of 20:80 (acetonitrile):(0.1M 
sodium acetate pH=5.0) with a flow rate of 2ml/min and 40µL of injection volume. 
5.2.6 Pharmacokinetic analysis 
Pharmacokinetic parameters, involving Cmax, tmax, AUC0-480, AUC∞, CL, Vd and t1/2 
were calculated by non-compartmental analyses using a free Microsoft Excel add-
in, “PKSolver.” (Zhang et al., 2010). 
5.2.7 Detection of P-gp protein level by Western blotting 
5.2.7.1 Animal treatment 
On the day of the experiment, each rat was weighed and orally administered 
with/without the pharmaceutical excipient solutions (doses were the same as what 
used in Table 5.3). 15min later, rats were sacrificed in a CO2 euthanasia chamber 
and the intestine was rapidly removed. The jejunal intestinal pieces were prepared 
as described in Session 5.5.3.1.  
5.2.7.2 Sample preparation 
The mucosa (about 60mg) were cut into some small pieces and homogenized in 
3mL lysis buffer at 10,00rpm 20s with a T18 digital ULTRA-TURRAX® (IKA). 
The tissue homogenates were incubated at 4°C for 2h and centrifuged at 10,000rpm 
for 10min. The supernatants were collected and stored in aliquots at -20°C until use. 
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5.2.7.3 Protein analysis 
Protein concentration of each homogenate was determined with the PierceTM BCA 
Assay Protein kit (ThermoFisher, Loughborough, UK) according to the 
manufacturer’s instructions. 
For gel electrophoresis, 25μg of total protein of each sample was suspended in LDS 
sample loading buffer (Invitrogen, Carlsbad, CA) and denatured for 10 min at 70°C. 
As a molecular weight marker, 5μL Sharp Pre-Stained protein standard (Invitrogen) 
was loaded on each gel. Samples were separated by electrophoresis in a NuPAGETM 
NovexTM 4–12% Bis-Tris gel (Invitrogen) and transferred to a nitrocellulose 
membrane with XCell SureLock™ Mini-Cell Electrophoresis System (Invitrogen) 
according to the manufacturer’s instructions. Membranes were blocked with 3% 
bovine serum albumin (BSA) in TBS-T and incubated for 1h at room temperature. 
For detection of P-glycoprotein and reference protein, blots were incubated 1h at 
room temperature with the respective primary antibodies diluted in 3% BSA in 
TBS-T: mouse monoclonal anti-Pgp (C-219 3:200; Enzo Life Science, Exeter, UK) 
and anti-β-actin mouse monoclonal antibody (1:2000; Sigma-Aldrich, Poole, UK). 
Detection of bound antibodies was done with affinity-purified rabbit anti-mouse 
IgG coupled to peroxidase (secondary antibody; Sigma) diluted 1:5000 in 3% BSA 
in TBS-T. 
After 1h of incubation with secondary antibody conjugated with horseradish 
peroxidase, protein bands were visualized by chemiluminescence detection method 
with Pierce™ ECL Western Blotting Substrate (ThermoFisher) and blots were 
photographed with a ChemiDoc XRS camera (Bio-Rad). Detection for bands of P-
gp and reference protein weas performed with the Image Lab™ software (Bio-Rad). 
For a calculation of the relative P-gp expression in selected groups, the reference 
protein was individually set to 1 and the intensity of P-gp was set relative to it. 
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5.2.8 Measurement of P-gp mRNA expression by real-time 
reverse-transcription polymerase chain reaction 
5.2.8.1 RNA isolation 
Rats were pre-treated as described in Section 7.2.7.1. All pieces of mucosal tissue 
were cut and kept in RNA later® Stabilization Solution (Thermofisher). Total RNA 
of each piece was isolated and purified with PureLink® RNA Mini Kit 
(Thermofisher) according to the manufacturer’s instructions. RNA concentration 
was measured with Nanodrop 2000 (Thermofisher).  
5.2.8.2 RNA level analysis 
1mg total RNA of each sample was reverse transcribed using the iScriptTM cDNA 
Sythesis Kit (Bio-Rad). To quantify the amount of mdr1a and mdr1b mRNA, real-
time PCR was performed on the 7500 Real Time PCR System (Applied Biosystems, 
Thermofisher) using the method described by MacLean (MacLean et al., 2008). 
Briefly, 50μL PCR reaction contained 25μL of PowerUpTM SYBR Green PCR 
Master Mix (Thermofisher), 500nM each of forward and reverse primers, and 1μg 
of cDNA. Anti-beta actin was used for normalization and amplified of 1μg cDNA, 
respectively. Real-time PCR was carried out in 96 well PCR plates (Thermofisher). 
The amplification program for all genes consisted of one pre-incubation cycle at 
95°C with a 10min hold, followed by 45 amplification cycles with denaturation at 
95°C with a 10s hold, an annealing temperature of 50°C with a 10s hold and an 
extension at 72°C with a 10s hold. Amplification was followed by a melting curve 
analysis which ran for one cycle with denaturation at 95°C with a 1s hold, annealing 
at 65°C with a 15s hold and melting at 95°C with a 1s hold. Water was included as 
a negative control in each run to access specificity of primers and possible 
contaminations. Primers (shown in Table 4.5 in Chapter 4) were designed by 
primer-BLAST searching using publicly available sequence information of the 
GeneBank of the National Center for Biotechnology Information (NCBI) and 
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purchased from Eurofins (Eurofins Genomics, Germany).  
5.2.8.3 Data analysis 
Relative expression of mdr1a and mdr1b mRNA in different intestinal divisions 
were calculated using 7500 software (version 2.0.6, Thermofisher). The average of 
the Ct values for tested genes (mdr1a and mdr1b) and the internal control (anti-beta 
actin) were taken, and then the differences between Ct values for target genes and 
internal control (∆Ct) were calculated for all the experimental samples. ∆∆Ct was 
used to present the relative quantification of tested samples according to the control.  
5.2.9 Statistical analysis 
The experiments were performed at least six times and data were expressed as 
mean±standard deviation (SD). Significant differences between groups were 
analyzed by one-way ANOVA, followed by a Tukey post-hoc analysis with a 95 % 
confidence interval using IBM SPSS Statistics 19 (SPSS Inc., Illinois, USA). 
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5.3 RESULTS AND DISCUSSION 
The solubilizing agents evaluated in this study were by no means inert regarding 
relevant interactions with the function of P-gp, thereby altering the absorption of P-
gp-mediated drug ranitidine (shown in Figure 5.2-5.6).  
In detail, the presence of Poloxamer 188 increased the bioavailability and uptake 
transport of ranitidine by 10% and 46% in male rats respectively, whilst there were 
no changes demonstrated in the female (p>0.05). In addition, Poloxamer 188 
reduced the P-gp protein and the corresponding mdr1a mRNA expression in male 
rats only. Mdr1b mRNA, however, was relatively evenly expressed and effected 
compared with the mdr1a isoform.  
Correspondingly, Tween 80 was a potent excipient to modulate the activity and 
expression of efflux transporter P-gp, in that enhancing the absorption of ranitidine 
in male rats but not in female ones. In the male rats, the bioavailability and uptake 
transport of ranitidine increased by 29% and 24% respectively with Tween 80. 
Consonantly, there were 0.6-fold decreases in the P-gp protein abundance in the 
presence of Poloxamer 188.  
Cremophor RH 40 also showed a sex-related impact on the absorption of ranitidine 
via the inhibition on the P-gp protein and gene expression. The bioavailability and 
uptake of ranitidine in male rats was increased by 30% and 33% respectively, with 
a 0.6-fold decrease in the P-gp protein content and mdr1a mRNA expression in the 
presence of Cremophor RH 40. Interestingly, with regard to the female rats, 
Cremophor RH 40 decreased the intestinal uptake of ranitidine by 25% compared 
to the control, however, no impacts were found in the bioavailability and P-gp 
expression (p>0.05).  
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Span 20, on the contrary, reduced the P-gp protein level by 41% and 59%, thereby 
increasing the uptake of P-gp substrate ranitidine by 21% and 23% in both male and 
female rats. Additionally, the presence of Span 20 enhanced the bioavailability of 
ranitidine in 37% and 20% in male and female rats respectively (p<0.05), which led 
to no sex differences in the effect of Span 20 on either ranitidine absorption or P-
gp expression.  
We could clearly demonstrate that Cremophor RH 40, Poloxamer 188, Tween 80 
and Span 20 are able to significantly modulate the function and expression of efflux 
transporter P-gp. However, Span 20 is the only solubilizing agent studied here 
showed its interaction with membrane transporter to alter the drug bioavailability 
in both sexes, whilst the others exhibit their impacts only in male rats but not the 
female ones. Since these excipients are frequently used in the formulation for poor-
soluble drugs, and P-gp is shown to be a major efflux transporter in the absorption 
and disposition of many drugs, sex-specific influences of these excipients on the 
pharmacokinetic of P-gp-mediated drugs were expected.
   Chapter 5 
183 
 
Figure 5.2 Mean AUC0-480 of ranitidine in the presence and absence of excipients in male and female Wistar rats (Mean ± S.D., n=6).  
* Values are statistically different between the control and tested groups at p<0.05. 
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Figure 5.3 Permeability of ranitidine in the absence and presence of excipients in male and female Wistar rats (Mean ± S.D., n=6). 
* Values are statistically different between the control and PEG group at p<0.05. 
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Figure 5.4 Fold changes in P-gp protein expression in jejunum of rats after 1h administration with excipients.  
* Values are statistically different between the control and PEG groups at p<0.05. 
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Figure 5.5 Fold changes in mdr1a expression in jejunum of rats after 1h administration with excipients.  
* Values are statistically different between the control and PEG groups at p<0.05. 
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Figure 5.6 Fold changes in mdr1b expression in duodenum of rats after 1h administration with excipients.  
* Values are statistically different between the control and PEG groups at p<0.05.
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5.3.1 Cremophor RH40 
Cremophor RH40 (polyoxyl 40 hydrogenated castor oil) is used as a solubilizer for 
various hydrophobic drug moieties. It was suggested to be a useful excipient 
particularly for enhancing bioavailability of P-gp substrates, considering its effects 
on efflux transporter, P-gp. However, interaction of Cremophor RH 40 with P-gp 
was sex-dependent in our study, where Cremophor RH40 inhibited the function of 
P-gp in male rats but not in females.  
This finding in the males was in line with the previously published data. In details, 
Cremophor RH40 was found to increase the absorption of a P-gp substrate digoxin 
resulting in its increased bioavailability by up to 22% in a clinical trial on male 
individuals, and this in vivo human data supports the validity of in vitro observations 
on P-gp (Tayrouz et al., 2003). Taking this inhibitory effect on P-gp, Cremophor 
RH40 has also been used as a surfactant to increase bioavailability of tacrolimus (a 
poorly water soluble P-gp substrate) in male rats by formulating self-
microemulsifying drug delivery system (SMEDDS) (Wei et al., 2005). After all, 
sex-related effect of Cremophor RH 40 on the P-gp function observed in this study 
highlights the safety on the application of Cremophor RH 40 as solubility and 
permeability enhancer in the oral drug formulations, if they are P-gp substrates. 
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5.3.2 Poloxamer 188 (Pluronics F68) 
Poloxamers (poly (ethylene oxide) – blockpoly (propylene oxide) – block – poly 
(ethylene oxide)), also known as Pluronic, were widely used as O/W type 
emulsifying agents, viscosity increasing excipients and for surfactant gels.  
Pluronics P85 was found to inhibit both MRP-1 and MRP-2 in a study performed 
on MDCK cells resulting into increased intracellular accumulation of vinblastine 
and doxorubicin (MRP substrates) (Batrakova et al., 2003). Apart from MRPs, 
Pluronics P85 showed its inhibitory action on P-gp present on the Caco-2 cells 
(Batrakova et al., 1998).  
Other Poloxamers, like Poloxamer 188 (Pluronics F68), also displayed its impact 
on the P-gp-mediated transport of celiprolol and CYP3A4-mediated formation of 
midazolam metabolite 1'-hydroxymidazolam in Caco-2 cell monolayer, indicating 
that it is a potent in vitro inhibitor of both P-gp and CYP3A4 (Huang et al., 2008). 
Poloxamers are incorporated into membranes followed by subsequent translocation 
into the cells and affecting various cellular functions, such as mitochondrial 
respiration, ATP synthesis, activity of drug efflux transporters, apoptotic signal 
transduction and gene expression. This enhances drug transport across the blood 
brain and intestinal barriers, and causes transcriptional activation of gene 
expression both in vitro and in vivo. (Kabanov et al., 2002, Batrakova and Kabanov, 
2008). Frustratingly, different activity of Poloxamers were observed between males 
and females in this study, resulting in differential influences on the function of P-
gp and absorption of a P-gp substrate ranitidine in male and female rats. This 
information emphasizes sex differences in the bioavailability of drugs with flooding 
active pharmaceutical excipients.  
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5.3.3 Tween 80 
Another widely-used nonionic surfactant, Tween 80 (polyoxyethylene 20 sorbitan 
monooleate), was also pharmacologically-active. Clearly, it was found to increase 
apical-to-basolateral permeability and decrease basolateral-to-apical permeability 
of Rhodamine 123 (a P-gp substrate) in Caco-2 cell monolayers at concentrations 
ranging from 0.01mM to 1mM in a dose-dependent manner (Rege et al., 2002). In 
another study, P-gp inhibition by Tween 80 was found for a model peptide drug 
(Acf (NMef)2NH2) in Caco-2 cell lines, where basolateral-to-apical permeability of 
the drug was decreased mostly with Tween 80 whose CMC was below 50 μM, 
indicating that monomers of this surfactant were responsible for its activity and not 
its micellar forms (Nerurkar et al., 1997). Subsequently, Tween 80 was reported to 
inhibit the activity of MRP2 slightly (Hanke et al., 2010). Recently, Tween 80 at 
concentrations below 0.01% (w/v) was able to decrease the expression of P-gp, 
resulting in an enhanced uptake of P-gp-mediated Rhodamine 123 (Hodaee et al., 
2013). Although no in vivo and clinical studies have been carried out to describe 
the effects of Tween 80 on the function of P-gp, in vitro results strongly prove its 
affects. Multiple effects like P-gp alteration and enhanced solubility render it a 
valuable excipient for bioavailability improvement of poor water soluble P-gp 
substrates. However, Tween 80 herein was not only proved its active interaction 
with efflux transporter P-gp, but also reported its sex-dependent manner in the 
impact on the P-gp function.  
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5.3.4 Span 20 
Span 20 (sorbitan monolaurate) significantly increases the absorption of ranitidine 
via the reduction on the intestinal P-gp expression in both male and female rats in 
this study. This result was in an agreement with the published information that Span 
20 showed an inhibitory effect on the efflux transporters P-gp and BCRP in Caco-
2 cell monolayers (Yamagata et al., 2007).  
Judging from our data, lipid-based solubilizing excipients Cremophor RH 40, 
Poloxamer 188, Tween 80 and Span 20 all exhibited their inhibitory influences on 
the activity and expression of efflux transporter P-gp. Some mechanisms by which 
excipients non-specifically inhibit P-gp activity have been proposed and carefully 
investigated. For example, surfactants have been shown to modulate P-gp activity 
through altered fluidity of the lipid membrane environment of P-gp, leading to a 
reduction of ATPase activity, as well as decreased the affinity of P-gp for ATP with 
depletion of intracellular ATP (Cornaire et al., 2004). On the other hand, the 
expression of P-gp was recently reported to be linked to a group of nuclear receptors, 
which have lipid ligands providing interplay between lipids and transcriptional 
control of P-gp (Lee et al., 2006b, Chawla et al., 2001, Bookout et al., 2006). Such 
as the nuclear receptor proteins retinoic acid receptor (RAR), farnesoid receptor 
(FXR), steroid-activated receptor (SXR) and pregnane receptor in rodents (PXR) 
(Denson et al., 2002, Freedman, 1999, Yoshikawa et al., 2002). Therefore, lipid 
excipients studied in this paper may interact with the receptor pathways, resulting 
in the observed decreases in P-gp expression, similar to a previously reported lipid 
agent Peceol® and Gelucire® 44/14 (Sachs-Barrable et al., 2007). 
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However, these excipients, excluding Span 20, altered the P-gp function only in 
male rats but not in females. Sex difference is rarely reported on the influence of 
excipients on the function of membrane transporters. According to the data in this 
study, the surprising sex-related effect of excipients on the drug bioavailability may 
be related to the chemical structure of excipients, considering Cremophor RH 40, 
Poloxamer 188 and Tween 80 are all polyethoxylated surfactants. Taking PEG 400 
into account, excipients are found to bind to P-gp in a substrate-like manner. 
Specifically, the interaction between excipients and P-gp in the lipid membrane is 
due to transient hydrogen bond formation of EO groups with hydrogen bond donor 
groups of the transmembrane domains of P-gp (Li-Blatter et al., 2009). Thus, more 
polyethoxylated agents widely-used in the formulations need to be studied their 
impacts on the function of membrane transporters in both males and females in the 
future. 
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5.4 SUMMARY 
In Phase I, the influence of four excipients (Cremophor RH 40, Poloxamer 188, 
Tween 80 and Span 20) which are commonly used as solubilizing agents in 
formulations were investigated on their effects on the absorption of P-gp-mediated 
drug ranitidine, and the reason behind these influences was also studied. We 
identified that Cremophor RH 40, Poloxamer 188 and Tween 80 were capable of 
reducing the activity and expression of intestinal P-gp. This resulted in the 
enhancement of ranitidine bioavailability in male rats but not in females. No sex 
differences were found in the case of Span 20. Span 20, however, is not an example 
of a polyethoxylated agents when compared with the former four excipients. The 
mechanism underlying the sex-related influence of excipients on transporters may 
be related to the chemical structure of excipients.  
However, only one dose of each tested excipients was investigated. Considering the 
aforementioned influence of PEG 400 on drug bioavailability was not only sex-
related but dose-dependent. More concentrations of these tested excipients will be 
studied in Phase II. 
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Phase II 
5.5 MATERIALS AND METHODS 
5.5.1 Materials  
Ranitidine hydrochloride, glacial acetic acid and sodium acetate trihydrate were 
obtained from Sigma Aldrich (Dorset, UK). Span 20 and Tween 80 were purchased 
from Fluka (Dietikon, Switzerland). Poloxamer 188 and Cremophor RH 40 were 
from Agenda (Bradford, UK) and BASF (Cheadle, Germany), respectively. Water 
and acetonitrile were purchased from Fisher Scientific (Loughborough, UK), and 
were of HPLC grade. 
5.5.2 Animals 
All the animal work was approved by the UCL School of Pharmacy’s ethical review 
committee and was conducted in accordance with the home office standards under 
the Animals (Scientific Procedures) Act, 1986. Healthy male and female, 8-13 week 
old Wistar rats (Harlan UK Ltd, Oxfordshire, UK) weighing 150-250 g were used 
for excised rat intestine. The rats were housed at controlled temperatures (25℃) 
and humidity (50-60%) with a constant light-dark cycle of 12h, were provided with 
food and water and were acclimatized for 7 days before being studied. One day 
before the experiments, the rats were fasted overnight and housed individually in 
the metabolic cages.  
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5.5.3 Pharmacokinetic study 
On the day of the experiment, each rat was weighed and administered 50mg/kg 
ranitidine in the absence or presence of excipients (doses of excipients were shown 
in Table 5.1) by oral gavage. Subsequently, approximately 250μL-300μL of blood 
was collected from the tail vein of the rat into anticoagulant centrifuge tubes (BD 
Microtainer® K2E Becton, Dickinson and Company, USA) at 0.5, 1.25, 2, 3, 4 and 
6h. At 8h post-administration, the rats were killed in a CO2 euthanasia chamber and 
about 1mL of blood was taken by cardiac puncture.  
5.5.4 Samples preparation 
Blood samples were centrifuged at 10,000rpm for 10min and the supernatants 
(plasma samples) were collected into 1.5mL Eppendorf tubes. The samples were 
prepared using a reported method (Afonso-Pereira et al., 2016). Briefly, 50µL of 
the supernatant was placed into a 1.5mL Eppendorf tube and the same volume of 
acetonitrile was added to precipitate the plasma proteins. After 1min of vortex-
mixing, 100µL HPLC grade water was added to the mixture, which was vortex-
mixed again for 30s, and centrifuged at 4ºC for 10min at 10000rpm. The 
supernatant was collected and 40µL aqueous was analyzed by HPLC.  
5.5.5 Chromatographic analysis 
Chromatographic analysis was performed with a high performance liquid 
chromatography (HPLC) system (Agilent Technologies, 1260 Infinity) equipped 
with pump (model G1311C), an autosampler (model G1329B) and a diodearray UV 
detector (model G1314B).  
The sample was subjected to HPLC-UV analysis using a previously validated 
method (Ashiru et al., 2007). The column used was a 5µm Luna SCX (Phenomenex, 
UK); the mobile phase was a mixture of 20:80 (acetonitrile):(0.1M sodium acetate 
pH=5.0) with a flow rate of 2mL/min.  
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5.5.6 Pharmacokinetic analysis 
Pharmacokinetic parameters, (Cmax, tmax, AUC0-480, AUC∞, CL, Vd and t1/2) were 
calculated by non-compartmental analyses using a free Microsoft Excel add-in, 
“PKSolver.” (Zhang et al., 2010).  
5.5.7 Statistical analysis 
All results are expressed as mean ± SD (n = 6). The control and test group data were 
analyzed by one-way ANOVA, followed by post-hoc Tukey analysis with a 95 % 
confidence interval using IBM SPSS Statistics 16 (SPSS Inc., Illinois, USA).  
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5.6 RESULTS AND DISCUSSION 
The bioavailability of ranitidine in the absence of excipients presented by the 
cumulative area under the plasma concentration versus time curve (AUC0-480) in 
male and female rats was 338±27μg.min/mL and 451±53μg.min/mL, respectively, 
which was consistent with the value reported in previous study(Afonso-Pereira et 
al., 2016), where the bioavailability of ranitidine was comparable in male and 
female rats.  
The enhancement on ranitidine bioavailability with excipients was in a dose-
dependent and sex-dependent manner. Also, the bioavailability of a drug is 
influenced by many factors, including the solubility of drug. The solubility of 
ranitidine was measured and was in agreement with literature values. In this study, 
different concentrations of these solubilizing agents (Cremophor RH 40, Poloxamer 
188, Tween 80 and Span 20) had no statistically significant effect (p>0.05) on the 
solubility of ranitidine, thereby eliminating it as a reason for any observed increases 
in drug bioavailability.  
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5.6.1 Cremophor RH 40 
Cremophor RH 40 ranging from 0.001% to 20% was usually used in oral 
formulations as a solubilizer for fat soluble vitamins, essential oils and other 
hydrophobic pharmaceuticals, and also proved to have inhibitory effect on 
membrane transporters to enhance the drug permeability. The presence of 0.1%, 1%, 
5% and 10% Cremophor RH 40 increased the bioavailability of ranitidine in male 
rats by 55%, 69%, 33% and 12% respectively (p<0.05). Pronounced bioavailability 
enhancement was observed with 1% Cremophor RH 40 dose, a 69% increase over 
the control (p<0.05) (shown in Figure 5.7).  
The low doses Cremophor results in male rats reflect the findings in the previous 
literatures. In a study, the effects of a range of low concentrations of Cremophor 
RH 40 (0.001% to 3%) as potential inhibitors of P-gp were tested with the use of 
digoxin transport in Caco-2 cells. The results showed the inhibitory influence of 
Cremophor RH 40 on P-gp enhanced with the increase of its concentration, with 
100% blocking of P-gp by 3% Cremophor RH 40 (Wandel et al., 2003). Moreover, 
in a clinical study, 600mg Cremophor RH 40 (corresponding to the concentration 
of 3% in this study) was reported to increase the bioavailability of digoxin by 22% 
in twelve male individuals via P-gp inhibition and prolongation of the dissolution 
time (Tayrouz et al., 2003).  
When it comes to the high doses of Cremophor RH 40, it was usually used as 
surfactants in the emulsion formulations. The enhancement on the absorption of a 
P-gp substrate daidzein in the presence of 20% Cremophor RH 40 and 10% PEGs 
in male rats were demonstrated without explaining the underlying reason (Shen et 
al., 2011). In contrast, our data clearly show that a high dose of Cremophor RH 40 
(20%) has a reduced influence on the bioavailability of P-gp-mediated ranitidine in 
male rats, thereby suggesting the influence of high doses of Cremophor RH 40 on 
the uptake transport of ranitidine and/or the pronounced prolongation of the 
dissolution time. 
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Figure 5.7 Mean AUC0-480 of ranitidine in the presence and absence of Cremophor RH 40 ranging from 0.1% to 20% in male and female 
rats (Mean ± S.D., n=6). * Values are statistically different between the control and tested groups at p<0.05. 
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In contrast to the male rats, no significant changes were found in the bioavailability 
of ranitidine with 0.1%, 1%, 5% and 10% Cremophor RH 40 in female rats (p>0.05). 
Moreover, the ranitidine bioavailability with high concentration of Cremophor RH 
40 (20%) in male and female rats was 255±29μg.min/mL and 381±31μg.min/mL 
respectively, corresponding to decreases by 25% and 16% compared with the 
control (p<0.05) (Figure 5.7). 
The knowledge about the effect of Cremophor RH 40 on drug bioavailability in 
females was limited based on the previous reports. It however showed a clear 
statistical contrast to that seen in male rats (p<0.05) in our study. To be specific, in 
the females, the bioavailability of ranitidine was not influenced in the presence of 
Cremophor RH 40 in low concentrations, while the high dose of Cremophor RH 40 
reduced the ranitidine absorption.  
 
5.6.2 Poloxamer 188 (Pluronics F68) 
Likewise, low concentrations of Poloxamer 188 (0.1%, 1%, 5% and 10%) enhanced 
the bioavailability of ranitidine in male rats, with the greatest enhancement by 55% 
found with 0.1% Poloxamer 188 compared to the control (p<0.05). In the female 
rats, only 10% Poloxamer 188 has a significant impact on the bioavailability of 
ranitidine with a 14% increase over the control (p<0.05). Additionally, alteration 
was not found in the ranitidine bioavailability in either male or female rats with 
high concentration Poloxamer (20%) (shown in Figure 5.8). 
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Figure 5.8 Mean AUC0-480 of ranitidine in the presence and absence of Poloxamer 188 ranging from 0.1% to 20% in male and female rats 
(Mean ± S.D., n=6). * Values are statistically different between the control and tested groups at p<0.05. 
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Poloxamers (Pluronics) are nonionic polyoxyethylene-polyoxypropylene 
copolymer surfactants used primarily in formulations as emulsifying or solubilizing 
agents (Lee et al., 2003, Mata et al., 2005). Low doses of Poloxamers are usually 
used as emulsifying and solubilizing excipients used to maintain the clarity of 
elixirs and syrups whist high doses of Poloxamers are utilized as wetting agent in 
ointments, gelling agent, tablet binders and coatings.  
Poloxamers mediate drug enhancement through efflux pump inhibition, often 
exhibited for blood-brain-barrier (BBB) drug delivery. The concentration-
dependent efflux pump (P-gp) inhibitory effect of Pluronic 85 in brain microvessel 
endothelial cell monolayers was revealed. Furthermore it has been demonstrated 
that the efflux pump inhibitory effect of Poloxamers is reduced when its 
concentration reaches toward critical micelle concentration (CMC) (Miller et al., 
1997).  
Subsequently, an early study has successfully demonstrated larger gastrointestinal 
absorption of the aminoglycoside amikacin (P-gp substrate) following oral 
administration to mice in the presence of Poloxamer CRL-1605 (Jagannath et al., 
1999). It also stands that dose-dependent influence of Poloxamers on the efflux 
transporters on the intestine. Although 0.8% Poloxamer 188 was reported not to 
inhibit intestinal P-gp to effect the transport of talinolol on male volunteers 
(Bogman et al., 2005), a significant (p<0.05) difference was later found in the 
transport of P-gp substrate diltiazem from the intestinal sacs of male rats pretreated 
with 0.25%, 0.5% and 1% Poloxamer 188 and control, indicating the inhibition of 
P-gp transporter and CYP3A enzyme respectively (Hafsa et al., 2015).  
Apart from the inhibitory effect on membrane efflux transporters, Poloxamers can 
also be used to restore the membrane integrity attributed to its ability of interacting 
with the lipid bilayers and sealing the structurally damaged membranes. Based on 
this, several researchers have demonstrated the application of Poloxamer 188 as 
membrane sealing agent for therapeutic purposes due to its medical safety record 
(Lee et al., 1992, Padanilam et al., 1994, Merchant et al., 1998, Hannig et al., 2000, 
Frim et al., 2004).  
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5.6.3 Tween 80 
It becomes apparent from Figure 5.9 that 0.1% Tween 80 was capable in increasing 
the bioavailability of ranitidine by 14% in male rats. The ranitidine AUC0-480 in the 
presence of 1% and 5% Tween 80 was 517±70μg.min/mL and 548±98μg.min/mL 
respectively, corresponding to 32% and 49% increases in bioavailability when 
compared with the control. On the contrary, low doses of Tween 80 have no 
influences on ranitidine bioavailability in female rats (p>0.05). However, ranitidine 
AUC0-480 in females could be enhanced with higher dose of Tween 80, for example, 
15% Tween 80 almost doubled the bioavailability of ranitidine in females (p<0.05). 
In pharmaceutical applications, Tween 80 is the most commonly used surfactant in 
FDA-approved parenteral products (Nema et al., 1997). It can be used as 
solubilizing agents for a variety of substances and also used to improve the chemical 
stability of solution formulation (Haque et al., 1999). Higher concentrations of 
Tween 80 were also used as plasticizing agents to reduce the melting temperature 
of drug molecules and the glass transition temperature of solid dispersion 
formulation (Ghebremeskel et al., 2007), while lower concentrations are used as 
emollients to increase the water holding capacity of the formulation in topical 
applications.  
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Figure 5.9 Mean AUC0-480 of ranitidine in the presence and absence of Tween 80 ranging from 0.5% to 15% in male and female rats (Mean 
± S.D., n=6). * Values are statistically different between the control and tested groups at p<0.05. 
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Tween 80 has been found to be useful in improving the oral bioavailability of drug 
molecules which are substrate for P-gp (Nerurkar et al., 1996). Firstly, Tween 80 
was shown to enhance apical‑to‑basolateral permeability and decrease 
basolateral‑to‑apical permeability of a P-gp substrate Rhodamine 123 in Caco‑2 cell 
monolayers at concentrations ranging from 0.01mM to 1mM in a dose‑dependent 
manner due to Tween 80’s inhibitory influence on efflux transporter P-gp (Rege et 
al., 2002). Secondly, the extent of P-gp inhibition on the cell line by Tween 80 was 
reported to depend logarithmically on excipient concentration, ranging from 0.5% 
to 3% (Sun et al., 2004). Thirdly, in the in vivo study, 10% Tween 80 showed a 
greater impact on the bioavailability of digoxin in a 61% increase in male rats 
(p<0.05), compared with 1% Tween which enhanced the drug bioavailability by 
only 30% (Zhang et al., 2003).  
The advanced influence of Tween 80 at high doses on drug bioavailability was 
previously investigated as well: the application of 40% Tween 80 in a developed 
SEDDS (self-emulsifying drug delivery system) formulation for carvedilol 
increased its bioavailability in beagle dogs (males) up to 413% compared with 
commercially available tablets (Luode®). It indicated high concentrations of Tween 
80 may induce the bioavailability of drugs via solubility enhancement and/or 
transporter modulation, however, the advantage of a new delivery system cannot be 
ignored (Wei et al., 2005).  
Furthermore, a dose-dependent effect of Tween 80 on the function of P-gp could be 
explained by a clear inhibitory effect of Tween 80 on P-gp ATPase is observed at 
low concentrations which is lost at high concentrations. This is most likely due to a 
membrane loosening effect at high concentration of Tween 80 (Li-Blatter et al., 
2009). However, it was not the same as what obtained in the female rats in study 
herein, where the bioavailability of ranitidine was increased in the presence of 
higher dose of Tween 80 but not low doses, suggesting sex differences in the 
membrane fluidity and/or response to excipients.   
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5.6.4 Span 20 
Comparable data were shown in the case of Span 20 (shown in Figure 5.10). The 
presence of 15% Span 20 exhibited a 155% enhancement on the bioavailability of 
ranitidine in females (p<0.05), whereas lower doses of Span 20 did not alter the 
ranitidine AUC0-480 (p>0.05). In the male rats, the bioavailability of ranitidine with 
0.5%, 1%, 5%, 10% and 15% Span 20 was 562 ± 157μg.min/mL, 504 ±
51μg.min/mL, 390±87μg.min/mL, 433±30μg.min/mL and 437±47μg.min/mL, 
respectively. These correspond to 66%, 49%, 15%, 28% and 29% increase 
compared to the control treatment. Pronounced bioavailability enhancement was 
observed with 0.5% Span 20 which was a 66% increase over the control. 
Span 20 are widely incorporated into cosmetics, food products and pharmaceutical 
formulations as lipophilic nonionic surfactants, mainly used as emulsifying agents 
and used at a low concentration of 0.1-3% in the preparation of a solubilizing agent 
for insoluble compounds in lipophilic bases (Fatouros et al., 2007).  
Low doses of Span 20 (50M and 100M) were reported to increase the uptake of 
mitoxantrone in P-gp/MDCK-II and BCRP/MDCK-II cells significantly (p<0.05), 
suggesting that it could inhibit efflux transporters P-gp and BCRP. Also, it 
demonstrated that the Span 20 did not reduce the intercellular ATP in the cells, 
thereby indicating intercellular ATP levels played a minor role in the influence of 
Span 20 on membrane transporters (Yamagata et al., 2007).  
Our data demonstrated Span 20 lower than 0.5% enhanced the bioavailability of 
ranitidine in males but not in females, while 1% Span 20 increased the drug 
bioavailability in both male and female rats, supporting the previous studies in some 
cases. In a similar manner as the high doses of Tween 80, Span 20 at high 
concentration (15%) enhanced the bioavailability of ranitidine in male and female 
rats with a five-time stronger response in females compared to the males. 
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Figure 5.10 Mean AUC0-480 of ranitidine in the presence and absence of Span 20 ranging from 0.5% to 15% in male and female rats (Mean 
± S.D., n=6). * Values are statistically different between the control and tested groups at p<0.05.
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5.7 CONCLUSION 
Great progress has been made in the application of excipients in formulation 
development, not only for predetermined purposes but to also increase the drug 
bioavailability via effects on efflux transporters according to the work in this 
chapter. Briefly, commonly used excipients are emerging as a different class of P-
gp inhibitors owing to advantages of being safe, not being absorbed from gut and 
pharmaceutically acceptable. However, some excipients showed different impacts 
on the function of transporters in males and females. For example, Cremophor RH 
40, Poloxamer 188 and Tween 80 can modify the intestinal P-gp protein and mRNA 
expression to induce the bioavailability of ranitidine in male rats, but not in females. 
These influences were also dose-dependent. Within the tested concentration range 
for all drug-excipient combinations, low doses of excipients caused increases in the 
bioavailability of ranitidine in male rats but not in females, while high doses of 
excipients enhanced the drug bioavailability in both male and female rats. 
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CHAPTER 6: Conclusion and future work 
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6.1 CONCLUSION 
To clarify the reasoning behind the unexpected sex-associated influence of PEG 
400 on the bioavailability of ranitidine in humans and rodents, we established that 
PEG 400 also had a sex-dependent impact on the absorption of ampicillin. This 
resulted to a marked increase in male rats but no alteration in females. Taking their 
absorptive mechanisms into consideration, we noticed both ranitidine and 
ampicillin are substrates for the efflux transporter P-gp, hereby estimating that this 
sex-based phenomenon only occur with P-gp-mediated drugs. Indeed, the presence 
of PEG 400 showed no effects on the bioavailability of metformin (a non-P-gp 
substrate) in neither males nor female rats, highly supporting our hypothesis. 
Further investigations into the role of P-gp in the effect of PEG 400 on the 
bioavailability of P-gp substrates were conducted in the P-gp blocking animal 
models, who were pre-administrated with the P-gp inhibitor, CsA, for P-gp 
blockage. Interestingly, PEG 400 did not enhance the bioavailability of ranitidine 
or ampicillin when the P-gp of rats were pre-blocked. This data may suggest two 
aspects: firstly, PEG 400 has an inhibitory effect on efflux transporter P-gp to 
induce the absorption of drugs in male rats; secondly, sex differences may be 
observed in the interaction between PEG 400 and P-gp. CsA was then found to 
make a greater enhancement on the ranitidine bioavailability in male rats compared 
to the females, thus, a higher P-gp activity and/or larger P-gp expression may be 
obtained in males. 
Subsequently, an in vitro model was established to characterize the influence of 
PEG 400 on intestinal transport of a P-gp substrate ranitidine in the intestine of male 
and female rats, with the aim to study the effect of PEG 400 on the P-gp activity 
and determine the in vivo-in vitro relationship of this sex-related phenomenon. The 
data showed that low concentrations of PEG 400 was capable of increasing the 
intestinal uptake of ranitidine in the jejunum, ileum and the colon in male rats, 
  Chapter 6 
211 
 
although this was not observed in female rats when using the Ussing chamber 
system. However, no sex-based difference was found in the duodenum, suggesting 
that the sex-related phenomenon was region-related and dose-dependent. Moreover, 
the PEG 400-mediated modulation of P-gp activity accounted for changes in 
ranitidine intestinal transport and in marked differences between males and females. 
This was also observed in the CsA inhibitory effect which exhibited a higher P-gp 
activity in male rats when compared with females. Additionally, pre-treatment with 
CsA on rat tissues could eliminate this sex-based effect of PEG 400 on ranitidine 
intestinal transport. This further supports our hypothesis that in in vivo study, sex-
related effect of PEG 400 on the drug bioavailability is mediated by the influence 
of PEG 400 on the efflux transporter P-gp. We speculate that sex-related differences 
in the variations in P-gp ATPase or ATP level in cells could cause sex differences 
in the interaction between CsA/PEG and P-gp. CsA was reported to alter the P-gp 
activity by inhibiting both the substrate stimulated and the basal P-gp ATPase, while 
PEG was found to influence the function of P-gp by producing mitochondrial 
toxicity and depleting the amount of intracellular ATP. 
To better understand the sex differences from the influence of PEG 400 on the P-gp 
expression, we demonstrated that the presence of PEG 400 could alter the P-gp 
protein content and mRNA expression in the adult rat intestine from the jejunum to 
colon. This alteration was studied within 3hrs which then showed a sex-based 
difference. In the male rats, the intestinal P-gp protein abundance was reduced in 
the first hour and then increased slowly in the next two hours. On the contrary, P-
gp protein levels were continuously decreased in female rats. The aforementioned 
data suggested that the intestinal membrane fluidity was more stable whilst the 
epithelial renewal in the intestinal epithelium was slower in females when 
compared with males. Also, sex differences were observed in the P-gp protein 
abundance in the absence of PEG 400, with a higher P-gp content in the jejunum, 
ileum and colon of male rats compared to females. In addition, the relative P-gp 
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protein content was highly correlated to the mdr1a expression, but not mdr1b gene 
expression, in both male and female rats.  
Mechanistic investigation in the effects of more commonly-used solubilizing 
reagents Cremophor RH 40, Poloxamer 188, Tween 80 alongside Span 20 at one 
concentration on the bioavailability of ranitidine in male and female rodents 
(regarding their influence on the intestinal transport of ranitidine and P-gp 
expression) were conducted using the formerly developed methodologies. 
Surprisingly, Cremophor RH 40, Poloxamer 188 and Tween 80 showed a sex-
dependent manner similar to PEG 400, in which an increase of bioavailability and 
permeation of ranitidine via the reduction on the P-gp activity and expression in 
male rats was identified, but not in female rats. On the contrary, the presence of 
Span 20 decreased the P-gp expression to induce the absorption of ranitidine in both 
male and female rats, which led to no sex differences. This finding illustrated that 
the mechanism underlying this sex-related influence of excipients on transporters 
may be related to the chemical structure of excipients as Span 20 is the only 
excipient which is not polyethoxylated among the tested excipients.  
Extensive investigation on the influence of the bioavailability of ranitidine with the 
aforementioned “active” excipients was carried out at a wide range of 
concentrations. The results showed that Cremophor RH 40, Poloxamer 188, Tween 
80 and Span 20 have a sex-associated and dose-dependent impact on the ranitidine 
absorption in rats. In detail, low concentrations of these four pharmaceutical 
excipients caused an increase in the bioavailability of ranitidine in male rats but not 
in females, whilst high concentrations of excipients enhanced the drug 
bioavailability in both male and female rats.  
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Overall, formerly regarded “inert” pharmaceutical excipients PEG 400, Cremophor 
RH 40, Poloxamer 188 and Tween 80 reduced the activity and expression of efflux 
transporter P-gp to enhance the intestinal absorption of P-gp-mediated drug 
ranitidine in male rats, but not in females. Based on these finding, we can provide 
suggestions. Firstly, pharmaceutical excipients used for specific predetermined 
purposes in formulation like solubility enhancement, taste masking and controlled 
release are also able to be enhance therapeutic efficacy of the drug by modulation 
of transporter activity and expression, therefore, two purposes can be simply 
achieved with the use of only one excipient in the formulation development.  
Secondly, the function of transporters are altered depending on the sex of the 
organism. This emphasizes the selection of excipients during formulation 
development to prevent different therapeutic efficacy and side effects between 
males and females. 
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6.2 FUTURE WORK 
The findings in this study highlight the need of pharmaceutical companies or 
research groups to acknowledge that excipients selected during formulation 
development are capable to alter therapeutic efficacy and side effects between male 
and female participants. This work further raises several new aspects that could be 
investigated in the future. 
Firstly, only five excipients were investigated of their potential sex-related 
influences on the efflux transporter P-gp. It is of vital importance to explore and 
identify more “active” excipients which may show sex-related effect on P-gp.  
Lipophilic compounds and suspending agents reportedly interact with some 
membrane transporters. For instance, lipophilic compound cholesterol can 
influence the fluidity of the membrane (Baggetto and Testa-Parussini, 1990) and 
reduce the activity of efflux transporters such as P-gp and MRP (Ferte, 2000). It 
was first observed that the ATPase activity of MRP-1 was decreased by 
approximately 40% when the level of cholesterol in the proteoliposomes increased 
from 0 to 20–40%. On the other hand, it also demonstrated that cholesterol could 
improve the toxicity of some cytotoxic agents by affecting the ATPase activity of 
P-gp in the plasma membrane (Shu and Liu, 2007). Besides cholesterol, sodium 
taurocholate (NaTC) was used in orally administered liposomes to increase 
intestinal permeation of insulin, due to its enhancement on paracellular absorption 
by opening tight junctions (Johansson et al., 2002, Degim et al., 2004). Further 
experiments showed that NaTC could also increase the transcellular absorption of 
certain APIs by affecting P-gp mediated efflux (Ingels et al., 2004), when the effect 
of simulated intestinal fluid was investigated on drug permeability across Caco-2 
monolayers (Ingels et al., 2002). 
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On other hand, Hydroxypropyl-β-cyclodextrin (HPCD) as one of the cellulose 
derivates, was reported to be a strong inhibitor of OATP1B3, OATP1A2 and 
OATP1B1 (Yan et al., 2008, Frijlink et al., 1991). Furthermore, HPCD and other 
cyclodextrins are known to form stable complexes with cholesterol, which can 
affect the fluidity of the membrane (Baggetto and Testa-Parussini, 1990) and 
decrease the activity of efflux transporters such as P-gp and MRP (Ferte, 2000).   
It would be interesting to evaluate the influence of these active excipients on the 
bioavailability of ranitidine in male and female rats, following investigation on the 
reason behind the phenomenon if sex-related differences are shown. 
Secondly, since an increasing number of pharmacologically active excipients were 
found to interact with various efflux transporters, uptake transporters and enzymes, 
sex differences in the interaction between these excipients and transporters need to 
be acknowledged.  
Thirdly, the tested excipients were prepared with the model drugs in a water solution. 
It would be appropriate to explore if the sex-associated effect of excipients on the 
P-gp substrates still exist when excipients are co-formulated with P-gp-mediated 
drugs.  
Taking Cremophor RH 40 as an example, it has been widely used as a surfactant to 
increase the solubility of poorly water soluble drugs in self-microemulsifying drug 
delivery system (SMEDDS). It would be of worth to establish a new formulation 
for poor-soluble drugs which are modified by P-gp using SMEDDS. Consequently, 
an investigation into its impact on the bioavailability of these drugs in male and 
female rats could be conducted. 
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Fourthly, novel formulations can be developed to enhance the bioavailability of 
drugs, and avoid the sex differences, based on our findings in this study.  
Fast-releasing dosage forms would be an optimal choice in the oral formulation 
development of P-gp substrates, owing to lower P-gp content in the proximal small 
intestine disregarding both species and sex of the subjects. In addition, inclusion of 
“active” pharmaceutical excipients, such as PEG 400, are likely to benefit oral 
formulations containing P-gp substrates that are BCS Class IV drugs (poor 
solubility and poor permeability) as PEG 400 could both improve the solubility and 
permeability of co-formulated drugs.  
Taking these two ideas into consideration, a proximal small intestine targeted 
formulation could be developed for BCS Class IV drugs with the application of 
active excipients. For example, testicular cancer is one of the cancers known to only 
affect men. Vinblastine is a typical chemotherapy medication to treat this cancer 
which is a BCS Class IV drug mediated by P-gp. Therefore, a fast-releasing oral 
formulation could be established for vinblastine. The addition of PEG 400, 
Cremophor RH 40, Poloxamer 188 or Tween 80 in the formulation would be 
beneficial to increase its solubility and permeability.  
Last but not least, it would be useful to test the influence of other excipients on drug 
bioavailability in human, since all the studies in this thesis were conducted in rats. 
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